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 Abstract 
 
Epstein-Barr virus (EBV) has been etiologically associated with Burkitt lymphoma (BL) since its 
discovery 50 years ago, but despite this long-standing association the precise role of the virus 
in the pathogenesis of BL remains enigmatic.  
EBV can be lost spontaneously from EBV-positive BL cell lines, and these EBV-loss clones have 
been reported to exhibit increased sensitivity to apoptosis. We have confirmed and extended 
those observations and report that sporadic loss of EBV from BL cells is consistently associated 
with enhanced sensitivity to apoptosis-inducing agents and conversely, reduced tumorigenicity 
in vivo. Importantly, reinfection of EBV-loss clones with EBV can restore apoptosis protection, 
although surprisingly, individual Latency I genes cannot.  
We also used inducible pro-apoptotic BH3 ligands to investigate Bcl-2-family dependence in BL 
clones as well as profiling gene expression changes in response to apoptosis induction in EBV-
positive versus EBV-loss clones. We found that EBV-loss was consistently associated with 
enhanced sensitivity to BH3-ligand-induced death and increased activation of apoptosis 
signalling pathways, although no individual apoptosis-related gene was responsible. Instead 
we find that Latency I EBV genes co-operate to co-ordinately repress the BH3-only proteins 
Bim, Puma and Noxa to inhibit apoptosis in BL. 
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1. Introduction 
1.1 The early history of EBV research 
The discovery of the Epstein-Barr virus (EBV), in an unusual yet common paediatric cancer in 
sub-Saharan Africa, has become something of legend within the cancer research community. 
Not only because it is a remarkable story, but also because it was in the research fields of EBV 
and Burkitt lymphoma (BL), as the African cancer came to be called, in which many of the 
paradigms of cancer biology were first demonstrated [1, 2].  
1.1.1 ‘More than a curiosity’ 
In 1958, Denis Parsons Burkitt, a missionary bush surgeon working in Uganda, published the 
first detailed clinical study of 38 children with tumours of the jaw, in a paper that is now a 
citation classic [3]. Although the disease had been described before, Burkitt was the first to 
realise that the additional swellings in the abdomen and elsewhere, which were seen in almost 
every patient, were part of the same disease, and that these related tumours, which could 
arise at the same time or even before those in the jaw, were not simply metastases [4, 5].   
Burkitt, with the help of several colleagues, went on to show that the all of the tumour cells 
were lymphocytes, regardless of the site of the tumour, and that these often rapidly fatal 
lymphomas accounted for up to 50% of all malignancies of African children [6-8]. This careful 
cataloguing of the incidence of the ‘lymphoma syndrome’ alerted Burkitt to another 
peculiarity; its occurrence appeared to be geographically restricted. BL was only ever recorded 
in low-lying tropical areas with high rainfall, distributed across a swathe of Africa he referred 
to as the ‘lymphoma belt’; a distribution exactly coincident with that of holoendemic malaria 
and other arthropod-borne infections [9-11]. 
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1.1.2 ‘A cell filled with herpesvirus!’ 
During visits back to the UK, Burkitt would give lectures about the ‘African lymphoma 
syndrome’ and it was after one such lecture, at Middlesex Hospital in 1961, that Burkitt first 
met Anthony Epstein. Epstein, who was working on animal viruses, was enthralled by the 
prospect of searching for a virus that might be relevant to human cancer. Burkitt agreed to 
send biopsies to Epstein and eventually, after three disheartening years of failure, during 
which Epstein and his colleagues, Bert Achong and Yvonne Barr, tried all of the then known 
methods to propagate malignant cells and prove the presence of any virus therein, there was a 
breakthrough. The EB1 cell line, which grew out from the 26th biopsy sample, was one of the 
first human lymphoid cell lines to be grown in culture [12, 13]. Soon after the technique of 
culturing the cells was mastered came the remarkable images of the previously undescribed 
virus contained within them, and so EBV became the first virus to be identified by electron 
microscopy alone, without experimental demonstration of viral activity [14].  
1.1.3 A ‘stalking horse’ 
In the decades that followed, discoveries about this seemingly rather inert virus and the 
disease in which it was discovered came thick and fast. Respected virologists, Gertrude and 
Werner Henle confirmed the presence, experimental inertness, and therefore uniqueness of 
the virus in the EB1 cell line [15], and showed that EBV is widespread in all populations, with 
over 90% of all adults and all African Burkitt lymphoma patients being seropositive [16].  
Soon afterwards, two groups showed that human lymphocytes could be transformed into 
continuously growing lymphoblastoid cell lines (LCLs) using BL cell lines as a source of virus [17, 
18]. This provided the first evidence of EBV’s growth transforming capabilities. Furthermore, 
epidemiological studies and detailed analysis of virus load in children living in areas where BL is 
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endemic showed that the disease tended to arise in individuals who were infected very young 
and had high levels of circulating virus, directly implicating EBV as the causative agent [19].  
Apart from the virological discoveries, Burkitt lymphoma was also the first cancer shown to 
respond effectively to chemotherapy [20-22], and was one of the first cancers shown to carry a 
characteristic chromosomal translocation in every cell [23, 24]. This genomic aberration, which 
turned out to be the critical cellular determinant of BL, causes constitutive expression of the 
potent oncogene MYC, a transcription factor capable of reprogramming the cell for maximum 
proliferative capacity [25-28]. Oncogenes were initially discovered in RNA viruses and so the 
demonstration that these growth transforming viral factors had cellular homologues, of which 
MYC was one of the first identified, was a landmark in cancer research [29-31].  
 
1.2 EBV 
1.2.1 Taxonomy 
Due to a recent restructure of virus taxonomy, Human herpesvirus 4 (EBV), now resides in the 
order Herpesvirales which encompasses 3 families, 3 sub-families, 17 genera and more than 90 
species and has been reviewed in detail by Davison [32]. EBV is a gammaherpesvirus of the 
genus lymphocryptovirus (LCV) and is the only known human virus of this genus; the remaining 
members of the LCV genus infect Old World and New World primates [33]. The use of primate 
models of herpesvirus infection using LCVs has provided important insights into the behaviour 
of the virus in vivo [34].  
1.2.2 Structure 
Characteristic of Herpesvirilae, EBV has a complex structure comprised of multiple layers 
enveloped by a host-derived lipid-bilayer [35]. The envelope is studded with viral glycoproteins 
which mediate plasma membrane binding, fusion, and entry of the virus into the cytoplasm 
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[36, 37]. Beneath the viral envelope lies the tegument layer, components of which are likely to 
direct virus trafficking to the nucleus and egress of newly formed virus particles, although this 
is not well understood [38, 39]. Recently it has been reported that EBV virions also contain 
viral RNAs which may function immediately following host cell entry to enhance infection [40].  
Inside the tegument layer the viral DNA is contained within a nucleocapsid comprised of 162 
capsomer proteins arranged in a T=16 icosahedral lattice [41], inside which the EBV genome is 
encoded within approximately 170-180 kilobase pairs (kbp) of double-stranded DNA; the exact 
size varying by strain.  
1.2.3 Viral genome 
The EBV genome is often described in terms of BamHI regions, a reference to the molecular 
cloning studies which used libraries of restriction fragments to obtain the first complete EBV 
genome sequence [42-46]. When linearised, the viral genome is flanked by a variable number 
of terminal repeat (TR) regions which mediate circular episome formation. The number of 
terminal repeats in a given virus isolate can also be used to give an indication of the clonality of 
EBV in cells [47, 48]. A schematic of the viral genome is shown in Figure 1.1, which is adapted 
from Kalla and Hammerschmidt [49]. The majority of the approximately 85 open reading 
frames (ORFs) of EBV are only expressed during the productive lytic cycle and are not shown, 
apart from the lytic cycle initiator, BZLF1. The highly spliced latent genes of EBV that are 
expressed in LCLs and confer the growth transforming abilities of the virus are shown, as are 
the promoters that drive their expression. The non-coding RNAs; the EBERs, the BART 
microRNAs and the BHRF1 microRNAs are also indicated.  
1.2.4 Strain variation 
EBV genomes are classified as either type 1 or type 2 (previously type A and B) and then 
further sub-divided into a number of strains [50, 51]. Since variability is most common within 
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Figure 1.1 Schematic of EBV genome and position of transcripts 
 
BamHI A regions indicated by single letter code around circular genome 
: EBNA-LP, EBNA2, BHRF1, EBNA3A, B and C, EBNA1. Driven from Latent transcripts
promoters; Cp, Wp and Qp 
: LMP1 and LMP2A/B driven from terminal repeats (TR) Latent membrane proteins
: BART microRNAs, BHRF1 microRNAs and EBERs 1 and 2  Non-coding RNAs
BZLF Lytic cycle initiator: 
: origin of lytic replication, : origin of plasmid replication, the characteristic oriLyt oriP
12kb deletion harboured by the prototype B95.8 strain is also indicated 
 
Adapted from Kalla and Hammerschmidt, 2012 [49]. 
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the latent genes which govern cellular transformation, it is possible that strain type may affect 
the pathogenicity of EBV [52-55]. Interestingly, type 2 EBV is less efficient at transforming 
lymphocytes [56], a feature that was recently found to be conferred by a single amino acid 
polymorphism of EBNA2 [57]. Type 2 EBV is more prevalent in regions where BL is endemic 
[58], although it has been suggested that this association may reflect altered immune 
recognition of EBV between different populations [59, 60].  
Many attempts have been made to correlate disease risk and prevalence with virus strain, 
particularly where risk varies geographically as in BL and Nasopharyngeal carcinoma (NPC) [61, 
62], or where an aetiological role for EBV is not proven or poorly understood, for example; in 
multiple sclerosis (MS) or rheumatoid arthritis [63, 64]. The revolution in Next Generation 
Sequencing (NGS) has allowed whole virus genomes to be sequenced, annotated and analysed, 
more quickly, cheaply and accurately than previously possible [65-67], and large scale efforts 
to sequence dozens of complete virus isolates are now underway (Paul Farrell, Oral 
Presentation, Oxford, March 2014. Alan Chiang, Oral Presentation, Brisbane, July 2014). If 
these projects are able to conclusively show correlations between viral strains and disease 
prevalence or outcome there may be significant implications for immunotherapy and vaccine 
development.  
1.2.5 EBV infection and growth transformation in vitro 
The ability of EBV to cause growth transformation of B cells was first reported in 1967, when 
Henle et al. demonstrated that co-cultivation of peripheral leukocytes with lethally irradiated 
BL cells leads to the outgrowth of a continuously proliferating cell line [17]. The establishment 
of EBV-transformed lymphoblastoid cell lines or LCLs has since provided a useful model of EBV 
infection and latency away from host immune responses. The efficiency of B cell infection in 
vitro is dependent on the multiplicity of infection (MOI) as this dictates the number of virus 
particles that are likely to bind at the B cell surface [68]. EBV binding to B cells is mediated by 
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the viral envelope glycoproteins, gp350 and gp42, interacting with the cellular CD21 
complement receptor (alternatively called CR2) and human leukocyte antigen (HLA) class II 
molecules, respectively [69-71]. Once bound, the virus undergoes membrane fusion and 
endocytosis of the viral capsid into the cytoplasm [72, 73], followed by tegument-mediated 
delivery of the virus to the nucleus [74]. Once in the nucleus, the viral DNA particle becomes 
circularised and is maintained as an episome by ‘piggy backing’ onto the host replication 
machinery during mitosis [75] although, in rare instances, viral DNA may become integrated 
into the host chromosomal DNA [76, 77].  
Viral gene expression during transformation of B cells 
The first detectable de novo transcripts are driven rightwards from the Wp promoter, which is 
present in multiple copies within the BamHI W region. These long transcripts are differentially 
spliced to encode the Epstein-Barr Nuclear Antigens; Leader Protein (EBNA-LP), and EBNA-2 
[78], which then go on to transactivate the Cp and LMP1 promoters [79-81]. Transcription 
from the activated Cp promoter gives rise to heavily spliced mRNAs from which EBNA3A, 3B, 
3C and EBNA1 are generated in addition to EBNA-2 and EBNA-LP [82-84].  EBNA2 also induces 
expression of the three Latent Membrane Proteins; LMP1, LMP2A and LMP2B [85, 86] and 
these, along with the 6 previously mentioned viral antigens make up the so called ‘growth’, or 
Latency III programme of gene expression that is evident in all LCLs [87].  
More recently, BHRF1, a viral Bcl-2 homologue (v-Bcl-2), previously thought to be expressed 
exclusively in lytic phase has also been shown to be important in growth transformation, 
although it is only essential for transformation when BALF1, which may be a functional 
homologue of BHRF1, is also deleted [88]. In primary infection in vitro, BHRF1 is initially 
expressed from the Wp promoter and like other Wp-transcribed genes, reaches maximal 
expression at around 12 hours post infection. In LCLs BHRF1 is expressed continuously at low 
levels [89].   
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Viral non-coding RNAs in transformation 
Viral non-coding RNAs are also expressed during early infection, although their role(s) in 
transformation are less well understood. The non-coding EBER RNAs are abundantly expressed 
in LCLs but are not-detectable until around 72 hours after infection [90], and there have been 
conflicting reports about the effect their deletion from the viral genome has on the 
transformation of B cells [91-93].  
The EBV-encoded microRNAs (miRs/miRNAs) are divided into two families, according to their 
location within the viral genome. The BHRF1 miRNAs, which reside either side of the BHRF1 
ORF, are detectable within 24 hours of infection, peaking at 72-120 hours [94] and have been 
found to enhance transformation in vitro [95-97], although they did not affect tumorigenicity 
in a humanised mouse model [98]. The second family of EBV miRNAs are derived from the 
BamHI A rightward transcripts (BARTs). Despite abundant primary BART transcript expression 
at early time points, the BART miRNAs are not detectable until at least 72 hours post infection 
[94], and their role in transformation is unclear. One group found that a recombinant EBV 
lacking both BART and BHRF1 miRs was equally as efficient in transformation assays as a virus 
lacking only BHRF1 miRs, indirectly suggesting that BART miRs are not necessary for this 
function [95]. Whilst a second group showed more efficient outgrowth of B cells infected with 
recombinant viruses expressing all known BART miRs compared to the 2089 recombinant, 
which is deleted for the majority of the miR-BARTs. Interestingly however, there was greater 
variation between two different miR-BART repaired recombinant virus strains than between 
the B95.8 strain and the less efficient repaired strain [99].  
Morphological consequences of transformation 
Transformation was first described in terms of the striking changes that occur in the 
morphology and antigenic properties of the B cells and is synonymous to antigenic or 
mitogenic B cell stimulation during normal B cell maturation and differentiation. Within 24-48 
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hours of infection, cells enlarge and become blast-like in their appearance before rapid DNA 
synthesis and EBV-driven proliferation begin [100]. Blasts upregulate HLA and adhesion 
molecules, secrete immunoglobulin and are able to efficiently process antigen [101-103]. By 5 
days post infection the cells have adhered to one another and become part of tightly packed 
clumps which are visible to the naked eye.  
Once transformed, Latency III LCLs proliferate in culture for up to approximately 200 
population doublings, at which point the cells appear to reach a crisis. The number of 
doublings the cells can undergo before crisis is dictated by telomere length in progenitor cells. 
If cells within an LCL culture mutate to acquire a permanently activated telomerase this crisis 
can be overcome leading to the outgrowth of a truly immortalised cell line [104, 105]. 
1.2.6 EBV infection and persistence in vivo 
In the developing world, primary infection with EBV occurs early in childhood; >90% of infants 
seroconvert by 3 years of age, and infection is usually asymptomatic. Conversely, in developed 
countries, infection is delayed; around 50% of children are still seronegative at ten years of age 
[106]. Half to three quarters of those who are infected during late childhood or adolescence 
develop the self-limiting lymphoproliferative disease infectious mononucleosis (IM). Despite 
the age of seroconversion tending to be delayed in Western countries, by adulthood, infection 
is ubiquitous worldwide, although interestingly, around 5% of adults remain uninfected long 
term [107].  
EBV is transmitted in the saliva [108], though it may also be transmissible via other bodily 
fluids [109]. In one widely accepted model of in vivo infection, the virus infects naïve B cells in 
the tonsillar crypts after passing through the oropharyngeal epithelium [110-112]. Although it 
is not yet known whether passage of the virus through the oropharynx involves infection of the 
epithelium or whether the epithelial cells play a strictly passive role. Once infected, naïve B 
cells are thought to be activated into growth and proliferation by Latency III EBV gene 
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expression mimicking normal B cell activation and differentiation caused by cognate antigen 
stimulation. EBV-activated B cells, which may or may not have undergone clonal expansion, 
then pass into germinal centres where they are subjected to selection and maturation [110].   
In the germinal centre, B cells undergo affinity maturation during which somatic 
hypermutation (SHM) and selection leads to the retention of only those B cells with receptors 
which display a high affinity for antigen [113]. Once all low-affinity antigen-presenting B cells 
have been eliminated, the remaining cells are subject to isotype switching and differentiate 
into either antibody-secreting plasma cells, or resting memory B cells [114].  By subversion of 
this normal maturation pathway, EBV is thought to enter and persist benignly within the 
circulating memory B cell population at a frequency of <50 cells per million lymphocytes [115, 
116]. It has been noted however, that X-linked agammaglobulinaemia (XLA) patients, who lack 
naïve B cells, show no evidence of EBV infection or immunity, suggesting that the lack of 
mature B lymphocytes renders them refractory to infection [117]. Additionally, that patients 
suffering from X-link proliferative disease (XLP) who lack functional germinal centres are still 
persistently infected with EBV, implying that EBV can exploit additional mechanisms in order to 
persist [118].  
In healthy carriers EBV resides as a latent infection in resting memory B cells, where the virus 
remains largely quiescent, although detection of non-coding RNAs, LMP2A and periodic 
expression of EBNA1 to maintain the viral genome has been reported [119-122]. This 
immunologically silent gene expression pattern is referred to as Latency 0 [1]. 
1.2.7 Reactivation and lytic cycle 
In vitro, a large number of stimuli have been reported to induce latently-infected B cells to 
reactivate into lytic cycle and produce infectious virus. Many studies have investigated 
chemical means of inducing reactivation including; 12-0-tetradecanoyl phorbol-13-acetate 
(TPA), sodium butyrate, phorbol ester, calcium ionophore and chemotherapeutic agents [123-
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127], although more physiologically relevant inducers such as TGF-β, interaction with CD4+ T 
cells and immunoglobulin (Ig) crosslinking have also been reported [128-131].  
In vivo, reactivation is thought to be induced when infected cells undergo differentiation. 
When infected memory B cells bind antigen causing crosslinking of the B cell receptor (BCR), 
the cells differentiate into antibody-producing plasma cells, whilst simultaneously homing to 
mucosa [132, 133]. Therefore, when the viral lytic cycle is completed and the cell lyses, the 
infectious virions that are released are able to easily access body fluids from which they can be 
transmitted to other individuals. It seems likely that EBV infects epithelial cells when entering 
and/or leaving the body, although finding such infected epithelial cells in healthy individuals 
has proved difficult. Interestingly, there is some evidence that infection of epithelial cells is 
directional; EBV can only infect polarised epithelium via the basolateral surface, implying that 
infection occurs when the virus is leaving the body [134]. Additionally, since differentiated 
epithelial cells can support high levels of lytic viral replication, they may also release infectious 
virus if they become infected by EBV as it transits out of the body [135]. 
Lytic cycle is initiated by expression of the immediate early lytic genes, BZLF1 and BRLF1, and 
then proceeds in phases of early gene expression followed by late gene expression. BZLF1 
binds and activates promoters containing Z-response elements (ZREs) [136, 137], and seems to 
preferentially bind ZREs that are highly methylated [138, 139].  BRLF1 can enhance 
transcription directly, by binding DNA at GC-rich promoter sequences to activate transcription 
[140], or indirectly, where DNA-binding is not necessary [141, 142]. These transcription factors 
then go on to stimulate the expression of a second wave of lytic-associated viral genes, known 
as the early lytic genes. Early genes include; those required for viral DNA synthesis, inhibitors 
of apoptosis and immune evasion genes. Together these viral genes function to replicate the 
viral DNA whilst ensuring the survival of the reactivated cell long enough for the complete 
virions to be assembled. Once the DNA has replicated, the late lytic genes are expressed, many 
of which are structural or packaging elements of the virus. A single EBV-infected cell may 
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produce as many as a thousand virions before the cell lyses, releasing the newly synthesised 
infectious virus [143]. 
1.2.8 Tissue tropism 
In vitro, EBV readily infects B cells derived from a number of sources, including peripheral 
blood, lymphoid tissues and cord blood, and at different stages of maturation (naïve, switched 
memory and non-switched memory) [144-147]. In contrast to B cells, epithelial cells are 
relatively refractory to infection with EBV using cell-free virus in vitro however, the virus can 
infect epithelial cells when transferred from a B cell, via the formation of a virological synapse 
[134]. Some NK and T cell tumours are known to carry EBV, yet there is little reliable evidence 
that primary T and NK cells can be infected in vitro [148-151]. It is possible that the conditions 
required for NK and T cell infection only occur in rare circumstances, such as during chronic 
inflammation and thus entry into these cell types represents an unusual biological accident 
[152]. Or it may be that EBV entry into these cell types is restricted by surface receptors that 
are transiently expressed, and may require a sequential and directional passage through other 
cell types. This scenario appears to be the case for the murine Kaposi’s sarcoma-associated 
herpes virus (KSHV) homologue, MuHV-4, which must first pass through neuroepithelium and 
myeloid cells before gaining entry to the B cell compartment [153, 154]. There has also been 
suggestion that viral strain may influence the tropism of EBV, as was recently reported by 
Delecluse and colleagues who isolated a previously undescribed virus strain, M-81, which 
appears to show enhanced tropism for epithelial cells compared to the prototype B95.8 strain 
[66].  
1.2.9 Viral latency  
The majority of the genes encoded by EBV function during the viral lytic cycle and so are 
generally not expressed in EBV-associated malignancies, where most, if not all, of the tumour 
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cells necessarily support a non-productive infection. Several different programmes of latent 
infection have been described, known as Latency I, Latency II, Latency III, Latency 0 and       
Wp-restricted Latency, which vary by cell type and disease setting. A schematic of the known 
Latency patterns is shown in Figure 1.2. Since many of the EBV latent genes are immunogenic, 
generally fewer viral antigens are expressed in malignancies where patients tend to be more 
immunocompetent, whereas a greater repertoire of viral genes may be expressed in the 
immunocompromised. 
Latency III 
In Latency III, the profile of gene expression characteristic of LCLs, all of the essential growth 
transforming proteins; EBNA1, EBNA2, EBNA-LP, EBNA3A, 3B, 3C, and LMP1 are expressed as 
well as LMP2A, 2B, and low levels of BHRF1 [89, 107]. Additionally, a number of non-coding 
RNAs are present including; the EBER RNAs, all three BHRF1 miRNAs and the BART microRNAs 
[94, 155, 156]. LCLs created by infecting B cells in vitro express Latency III, but this gene 
expression pattern is also found in lymphoproliferations and lymphomas of the T-cell 
immunocompromised, such as transplant patients receiving immunosuppression, or in late 
stage AIDS [157-159].  
Latency II 
EBV exhibits a Latency II pattern of gene expression in which the EBER RNAs, EBNA1, LMP-1,     
-2A, and -2B proteins and high levels of BART microRNAs are expressed in several types of 
malignancy including; Nasopharyngeal carcinoma (NPC), Hodgkin lymphoma (HL), and 
extranodal NK/T cell lymphoma [160-163]. In these diseases the immunodominant EBNA2 and  
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Figure 1.2 Viral Latency programmes found in EBV infected cells 
 
EBV Genome - shows the relative positions of relevant genes 
Latency III - also called the growth transforming programme, found in LCLs and PTLDs 
Wp-restricted Latency - found in a subset of 15% of BLs, gene expression imposed by 
deletion in viral genome 
Latency II - also called the default programme, found in a number of epithelial and 
lymphoid malignancies (see Section 1.2.10) 
Latency I - found in 85% of EBV-positive BLs 
Latency 0 - in resting B cells EBV has been reported to express Latency I genes, 
possibly periodically and at very low levels as there are no reports of finding all 
Latency I-associated genes in a single healthy donor 
 
Adapted from Rowe, Fitzsimmons, and Bell, 2014 [280] 
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EBNA3 proteins are not expressed, although the latent membrane proteins, which can also be 
recognised by cytotoxic CD8+ lymphocytes (CTLs) are present [164, 165]. The LMP proteins are 
thought to modulate NF-κB signalling and inhibit apoptosis [166, 167], whilst the high level of 
BART miRNAs may contribute to immune evasion [168, 169]. 
Latency I 
Latency I is the most restricted form of viral gene expression found in EBV-associated diseases, 
where only the EBNA1 protein, the EBER RNAs and the BART miRNAs are expressed. The virus 
exhibits Latency I in around 85% of all EBV-positive BL as well as in EBV-associated cases of 
gastric carcinoma [170-173]. Recent studies have also suggested that additional transcripts 
may be present in Latency I BL cell lines however; it is currently unclear whether these 
transcripts are present in every cell or what function they may have [174, 175].  
Wp-restricted Latency 
In a small sub-set of BLs, comprising around 15% of the biopsies we have had the opportunity 
to examine, the pattern of EBV gene expression is more extensive than that seen in the 
Latency I tumours and includes EBNAs 3A, B, and C, a truncated form of EBNA-LP (t-EBNA-LP) 
and the BHRF1 protein, in addition to EBNA1, EBERs and BARTs [89, 176]. More recently we 
have also found that two of the three BHRF1 miRNAs are also expressed in these tumours [94]. 
This pattern of gene expression, known as Wp-restricted Latency (Wp-BL) appears to occur 
uniquely in BL, and is imposed by a large deletion within the transcriptionally active viral 
genome in the cell. The exact size of the deletion varies between tumour samples, but always 
encompasses the coding region of the EBNA2 gene, placing BHRF1 adjacent to the      
promoter-encoding Wp repeat region [176]. This promoter, which is silent in Latency I BL, 
drives high levels of BHRF1 expression and also transcribes the EBNA proteins [89]. 
Interestingly, wild-type genomes can also be isolated from cells expressing Wp-restricted 
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Latency, but they appear to be transcriptionally silent [176]. Presumably, the deletion of 
EBNA2 arises as a rare, random event however; the observation that EBNA2 expression is 
incompatible with c-myc [177], suggests that Wp-BLs may arise from a Latency III lymphoblast 
that has acquired an Ig/MYC translocation, which then selects against expression of EBNA2. 
Once the deletion has occurred it is likely to be strongly selected for as BHRF1, t-EBNA-LP, 
EBNA3s all confer apoptosis resistance to BL cells [178-181]. 
In addition to several examples of Wp-BL where every cell exhibits this pattern of viral gene 
expression, we also identified a tumour in which multiple forms of Latency were evident. From 
this single biopsy we were able to isolate single cell clones exhibiting Latency I, a novel form of 
EBNA2+/LMP1- Latency or Wp-restricted Latency as well as cells that had apparently lost the 
viral genome entirely. Compellingly, these viral gene expression programmes were also shown 
to confer varying degrees of apoptosis resistance, with the EBV-loss cells exhibiting the most 
sensitive phenotype [178, 182].  
Latency 0  
As mentioned in Section 1.2.5, EBV is found to be almost entirely quiescent in circulating 
memory B cells, in a state known as Latency 0. No viral proteins are expressed in Latency 0, but 
EBER RNAs and BART miRNAs have been detected in blood from healthy donors [119, 121, 
183, 184]. Additionally, EBNA1 transcripts driven from the Qp promoter have been detected in 
replicating cells and LMP2A transcripts have also been reported [119, 122].  
 
 
1.2.10 Disease associations 
Outside of its long-held association with Burkitt lymphoma, EBV has also long been associated 
with a variety of other malignant and non-malignant diseases. Previous estimates suggested 
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that EBV contributes to around 2% of the global cancer burden [185, 186], and a recent 
evaluation of current data has calculated that annually, there are around 200,000 cases of 
EBV-associated cancer globally and 120,000 cases of infectious mononucleosis in the US alone 
[187]. Therefore, despite the fact that a relatively small percentage of carriers will go on to 
develop an EBV-associated disease, the vast number of individuals that are infected worldwide 
means that the virus poses a significant challenge to global health. A detailed discussion of 
EBV-associated disease is outside of the scope of this review; however Table 1.1 contains a 
summary of the principle features of several cancers and diseases that are commonly 
associated with the virus. In addition to those listed, it has been suggested that EBV may also 
play an aetiological role in a number of other cancers including; certain epithelial tumours of 
the salivary gland, lung, oesophagus, cervix and breast [188]. Although since case reports of 
EBV-positive tumours of almost every type can be found in the literature, further investigation 
is required to determine whether the virus genuinely contributes to the pathogenesis of these 
cancers. EBV has also long been implicated in a range of autoimmune diseases including; 
multiple sclerosis (MS), Sjögrens syndrome, rheumatoid arthritis and systemic lupus 
erythematosus. It is difficult to prove a role for EBV in inflammatory diseases, as EBV is 
recruited in infected B cells to sites of inflammation. However, recent meta analyses have 
shown that the association of EBV with MS is extremely robust [189, 190] .  
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Table 1.1 Features of EBV-associated diseases.  
 
All characteristics as described in Rickinson and Kieff, 2007 [107]. 
 
HLH – haemophagocytic lymphohistiocytosis 
 
Page | 19  
 
1.3 Burkitt lymphoma  
1.3.1 Incidence and clinical characteristics 
BL tends to be referred to as three sub-types; endemic (eBL), sporadic (sBL) and HIV-associated 
(HIV-BL), defined on the basis of epidemiology, as outlined in Table 1.2 [191]. It has also been 
reported that subtypes of BL differ in terms of their primary site of tumour presentation, with 
endemic BL tending to occur as a tumour of the jaw, and other subtypes tending to present as 
an abdominal swelling. However, there have recently been reports of a shift in primary tumour 
site in endemic regions which raises the possibility that earlier data may have been misleading  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2 Features of BL that are known to vary by sub-type 
Adapted from Kelly and Rickinson, 2007 [190], with additional data from 
sources as cited within the main text 
 
Page | 20  
 
[192, 193]. After all, in rural Africa abdominal swelling may be misdiagnosed, and it can be 
hard to tell from hospital records whether abdominal swellings may have been attributable to 
BL. Interestingly, although the differences between the BL subtypes may suggest differences in 
the route to pathogenesis, there is little evidence for histologic or molecular differences 
between the subtypes [194, 195].  
Histology 
Histologically, BL appears as rapidly growing (>95% Ki67 positive), small to medium sized, 
regular-shaped B cells with prominent nucleoli, as a diffuse infiltrate interspersed with 
macrophages giving the tumours a characteristic ‘starry sky’ appearance. Immunochemically, 
BL cells are defined by their expression of centroblastic or germinal centre markers CD10, 
CD77, CD38 and Bcl-6 and the absence of Bcl-2 expression [196, 197]. In-keeping with a 
germinal centre or post-germinal centre cell phenotype, BL cells also harbour Ig V 
rearrangements; this phenotype has also been confirmed by transcriptional microarrays [198]. 
Ig rearrangements are monoclonal within individual tumours and most BLs express surface 
IgM, although other phenotypes have also been reported. 
Endemic BL  
In endemic regions of sub-Saharan Africa and New Guinea BL is common, probably accounting 
for 30-50% of all childhood lymphomas [199]. Incidence of eBL peaks in children aged 5-9 and 
tends to occur earlier in life and more commonly in boys than girls, although estimates vary. 
Furthermore, recent studies have brought attention to misdiagnosis of BL leading both to 
under-reporting and over-reporting in different centres [200, 201]. Malaria is likely to be a 
cofactor in the pathogenesis of eBL, although this is poorly understood (see Section 1.3.2). 
Intriguingly, eBL patients appear to be immunocompetent and yet this is the only subtype with 
which EBV is 100% associated. Additionally, there are areas, such as Northern Brazil, where BL 
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incidence is described as intermediate, as it is less common than eBL, but >50 times more 
common than sBL and 75-90% of cases are EBV-positive [202-204], which implicates a role for 
other geographically-restricted cofactors in these areas. 
Sporadic BL 
Outside of ‘intermediate’ areas, the sporadic form of BL (sBL) is rare at around 1-3 cases per 
million as a worldwide average [199]. The peak age of incidence is also slightly delayed in 
comparison to eBL and tumour cells are EBV-positive in only 15-30% of cases [205, 206]. 
Patients diagnosed with sBL appear to be immunocompetent and as yet no other contributory 
cofactors have been identified, although there may be some differences in cellular mutations 
or miRNA expression between eBL and sBL [207, 208].  
HIV-associated BL 
HIV-associated BL (HIV-BL) became of clinical importance in the early 1980’s when there was 
an ‘outbreak’ of BL in the US, predominantly presenting in homosexual males [209, 210]. It was 
soon realised that these patients were also infected with HIV, although at the time of BL 
diagnosis, T cell counts were not depleted and there was no other suggestion of immune 
deficiency; in fact BL was often the first indication of their HIV status. BL remains a common 
early complication of HIV infection, accounting for <40% of AIDS-associated non-Hodgkin 
lymphoma (NHL) and EBV is found in the tumour cells of 30-40% of HIV-BL cases [211]. The 
peak age of HIV-BL is reported as 10-19, although the data that was gained during the HIV 
epidemic in the US, on which this statistic is based, actually shows that the actual number of 
HIV-BL cases within this age group was very small (14 cases versus 496 in those aged 19-50 and 
80 cases in those aged over 50) [212].  
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1.3.2 The role of cofactors in BL pathogenesis 
The reasons for variation in EBV-association between different forms may well be explainable 
in terms of the cofactors associated with each subtype. Malaria and HIV are known cofactors 
for developing BL, yet the interactions of these infections with EBV are not well described.  
Malaria 
BL is endemic in Africa and Papua New Guinea where malaria is holoendemic, meaning that 
the population is chronically exposed to the Plasmodium parasite from birth [213]. Since 
children with greater exposure to malaria exposure tend to have higher EBV viral loads [214, 
215], it was hypothesised that malaria might cause polyclonal B cell expansion [216]. However, 
it has also been proposed that malaria may instead inhibit T cell function and therefore lead to 
poor control of primary EBV infection, which may also result in elevated viral loads [217]. 
The T-cell hypothesis was given early support by findings that PBMCs from malaria-infected 
children could not inhibit the growth of autologous LCLs [218, 219], unlike those from healthy 
donors [220]. There is now a good deal more data concerning how T cells might control EBV, 
although we still have little idea of exactly what dictates the balance in otherwise healthy 
individuals in vivo. Recent publications have found that CD8+ T cells from children in 
holoendemic malaria regions are deficient in IFN-γ production and that EBV latent gene 
specific T cells exhibit a more differentiated phenotype then those specific for lytic genes, and 
than the T cells of non-malarial individuals [221-223]. Additionally, it has recently been 
hypothesised that EBV may alternatively induce SHM in infected B cells, leading to a greater 
risk of MYC-translocation occurring [224].  
Co-infection with HIV 
HIV vastly increases the risk of an individual developing NHL, although the risk of developing 
several subtypes that are also associated with non-HIV immune deficiencies, such as PTLD, 
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DLBCL and Kaposi’s sarcoma, has decreased significantly since the introduction of highly active 
anti-retroviral therapy (HAART). Surprisingly, there has been no such decrease in the incidence 
of HIV-BL [225, 226], and diagnosis of the infection and the malignancy are still often 
coincident (800 of 1,100 HIV-BLs in one recent study). Curiously, this study also showed that 
those with impaired CD4+ T cell counts due to AIDS were at a significantly decreased risk of 
developing BL [227]. It may be that CD8+ T cell activation status may explain the predisposition 
of immunocompetent HIV-positive individuals to develop BL; one study recently showed that 
CD8+ cell activation was significantly increased in 13 HIV-BLs versus controls, but more data is 
needed to support this finding [228].   
Another hypothesis, and one that has also been posited to be a consequence of malaria 
infection, is that the presence of HIV increases expression of activation-induced (cytidine) 
deaminase (AID) in the B cell compartment and that the concomitant increase in SHM 
increases the risk of a MYC translocation [224]. However, although increased AID expression 
has been described in HIV-positive individuals [229], a different study found that detection of 
MYC translocations in the blood was not predictive of HIV-BL [230]. It is noteworthy that many 
HIV-infected individuals in the US are undiagnosed and also that some cancer registry entries 
fail to record patients’ HIV-status, meaning that comparisons of HIV-BL to non HIV-BL may be 
skewed [231].  
Other cofactors 
There have also been a number of studies investigating the role of other possible 
environmental cofactors in the pathogenesis of BL. Ever since the ‘lymphoma belt’ was first 
mapped out there has been suspicion that infections other than malaria may play a role in BL. 
However, despite several studies, there is still little evidence to implicate those suggested 
which include; Chikungunya virus, O’Nyong-nyong virus, and sexually transmitted infections 
[227, 232, 233]. Lifestyle factors such as selenium deficiency, gum damage, use of some 
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traditional or Western medicines and exposure to known carcinogens have been the focus of 
other studies, but these are mainly stand-alone publications which often rely on retrospective 
self-reporting [234-240]. There is evidence to suggest that additional cofactors may play a role 
in BL; BL ‘outbreaks’ do not always correlate with malaria exposure [234, 241] and age-
distribution curves of BL in the US indicates non-cumulative risk factors [242]. However, larger 
and more detailed studies are needed to fully understand and interpret these observations.  
1.3.3 Genetic factors 
MYC translocation 
Common to all cases of BL is the hallmark reciprocal translocation between the MYC oncogene, 
which lies on the long arm of chromosome 8 (8q24), and one of the immunoglobulin (Ig) loci 
positioned on chromosomes 2, 14 and 22. In the majority of cases (80%), MYC is expressed 
from the Ig heavy chain locus 14q32, whereas the variant translocations; to either the kappa 
(2p12) or lambda (22q11) light chain locus, each occur at a frequency of around 10% [2, 243-
245]. Interestingly, several papers have described differences in the position of the breakpoint, 
with respect to both the Ig gene and MYC, which vary between endemic and sporadic BL. In 
endemic cases the Ig breakpoint tends to occur in the VDJ region of the heavy chain, 
juxtaposing MYC at the 5’ end, proximal to its start site. Whilst in sporadic cases the light chain 
switch region is more frequently the site of translocation and intersects MYC within its ORF 
[206, 246, 247]. These findings may reflect different routes of pathogenesis for the different BL 
subtypes.  
MYC function 
Regardless of the breakpoint, MYC translocation leads to constitutive overexpression of c-myc, 
a global transcription factor capable of binding and regulating around 15% of cellular genes in 
BL cells [248]. In normal cells, MYC is expressed transiently in order to stimulate proliferation 
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in resting cells and its expression is strictly regulated. Unsurprisingly, unchecked expression of 
c-myc has a dramatic effect on the cellular phenotype and has been shown to deregulate many 
genes and pathways (reviewed in [249]). For some time the mechanisms behind these 
pleiotropic effects were not understood, but recently, two groups reported that c-myc binds 
to, and enhances expression from, only those loci that are already transcriptionally active [250, 
251]. Thus, MYC acts as a ‘megaphone’ for whatever signalling pathways and processes are 
already active in a particular cell [252]. In immature B cells, which are poised to undergo clonal 
expansion, this leads to rapid proliferation through upregulation of cyclin D and derepression 
of cyclin E, whilst concomitantly reinforcing a centroblastic differentiation state by inhibiting 
NF-kB and interferon signalling [253-257].  
MYC and apoptosis 
In many cell types, c-myc over-expression is a double-edged sword as it also amplifies 
apoptosis-regulating genes, which serve to protect against inappropriate cell growth and are 
normally restrained in healthy cells [258]. Therefore, overcoming apoptosis is a prerequisite 
step in MYC-driven lymphomagenesis. One well-characterised pro-apoptotic pathway 
activated by c-myc is the p53-ARF-MDM2 axis and around 30% of BL biopsies [259], and 
around 70% of BL cell lines have mutated p53 sequences [260-262]. Furthermore, in BLs where 
p53 has a wild type sequence, p14ARF, p16INK4a or MDM2 are altered in their expression or 
function in order to circumvent p53-dependent cell death [263, 264]. It appears that 
suppression of p53 signalling is necessary, yet insufficient to overcome c-myc [265, 266]. 
Accordingly, several members of a second important family of apoptosis regulators; the Bcl-2 
homologues, are also commonly deregulated in MYC-driven lymphomas [267-273]. 
Additionally, deletion of the pro-apoptotic Bcl-2 family members Bim, Puma and Noxa have 
been found to synergistically contribute to lymphomagenesis in the Eμ-myc mouse model, 
where MYC is constitutively expressed from the IgM heavy chain enhancer [266, 274]. 
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Interestingly, MYC itself is frequently found to be mutated in BL [275], and this is also thought 
to reflect a need to avoid apoptosis activation whilst retaining or enhancing its proliferative 
capability [276, 277]. Indeed, one common MYC mutation abolishes upregulation of Bim [269]. 
Outside of the p53 and Bcl-2 pathways, mutations in other signalling pathways may also play a 
role in BL. Recent genome-wide studies have identified ID3, the transcription factor E2A and 
cyclin D3 as frequently mutated in BL biopsies and cell lines [277-279]. Interestingly, these 
targets all contribute to a third survival axis, which is ultimately co-ordinated by PI3K; hence 
several different diversion mechanisms may contribute to apoptosis escape in BL [280]. 
1.3.4 Treatment and prognosis 
Early chemotherapeutics showed great promise in treating BL, with Burkitt himself reporting 
that even one dose of methotrexate can cause tumours to completely regress [281, 282]. 
Indeed, the current recommended treatment in Europe, known as COPAD, where only two 
cycles of cyclophosphamide, vincristine, prednisolone and doxorubicin are given, achieves 99% 
5 year survival in children and adolescents with NHL (40% of the cohort had BL) [283]. 
Additionally, even 90% of those with central nervous system or significant bone marrow 
involvement have been shown to survive at least 5 years when treated with COPAD plus the 
anti-CD20 antibody, rituximab [284], but sadly, these impressive survival rates are not 
achieved in all BL patient cohorts. 
In the developing world, where intensive patient support is not available and 
chemotherapeutic options are limited, survival is greatly reduced. One study evaluated a      
28-day treatment with cyclophosphamide, methotrexate and hydrocortisone, which cost just 
$50 per patient to administer. Whilst the treatment was affordable and well tolerated, only 
48% of patients survived more than 5 years [285]. There is also poor survival worldwide in 
elderly patients; two recent studies carried out in the US report 5-year survival rates of only 
29-33% in patients over 60, this is a remarkable contrast to the almost complete cure rate in 
Page | 27  
 
younger patients [242, 286]. Additionally, patients who respond poorly, relapse, or have 
refractory disease have an extremely poor prognosis and very few of these patients respond to 
further treatment [287].  
1.3.5 The role of EBV in BL 
EBV infection is known to induce cellular genomic instability in a number of settings [288-290], 
possibly via upregulation of AID and SHM [147, 291], which direct hypermutation and class 
switching in B cells. Therefore it has been hypothesised that the major role for EBV in BL occurs 
prior to tumour formation by increasing the likelihood of the c-myc translocation however, 
there are several lines of evidence which suggest that the virus makes an ongoing contribution 
to the tumour cells [292, 293].  
In EBV-positive BLs, the virus is present in every tumour cell at around 20-100 episomal copies 
per cell [294], and in contrast to cell lines derived from other EBV-positive lymphomas, is 
efficiently maintained in cultured BL cells long term. Yet, virus episome replication and 
segregation to daughter cells is imperfect; around 16% of plasmids are not replicated per cycle 
and, despite episomal pairing at sister chromatids, they are unevenly distributed during 
mitosis [295-297]. Therefore, it appears that there is strong selection against loss of the virus. 
Additionally, treating BL cells with a dominant negative EBNA1 (dnEBNA1), which enforces the 
loss of viral genomes, also induces apoptosis, suggesting that EBV is essential to these cells 
[298, 299]. Interestingly, there are differences between the number of somatic mutations and 
in the frequency of chromosomal copy number changes in EBV-positive versus EBV-negative 
tumours [208, 300]. This suggests that EBV-negative BLs appear to arise via a slightly different 
pathogenic route, independently of EBV. 
Given that subversion of apoptosis is an essential step in MYC-driven lymphomagenesis, and 
that inactivation of p53 alone is insufficient in this regard [265, 301, 302], it has long been 
suggested that EBV may provide additional protection against apoptosis in the established 
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tumour. In the 15% of eBLs that exhibit Wp-restricted Latency the evidence for this is clear; 
BHRF1 provides a strong survival advantage via binding to pro-apoptotic members of the 
intrinsic apoptosis pathway [89, 303-305], whilst the EBNA3 proteins have been shown to 
epigenetically silence expression of a protein from the same family [181, 306]. In fact, the anti-
apoptotic phenotype of Wp-restricted BL cells is so pronounced in comparison to Latency I 
counterparts that we suspect that these tumours may be resistant to chemotherapy, although 
this has yet to be fully investigated.  
In classical Latency I BL, the nature of the ongoing contribution of EBV has been much 
discussed, but remains controversial (reviewed in [1, 307, 308]). In 1994, a report that 
spontaneous loss of EBV from a sporadic BL cell line increased the sensitivity of the cells to 
apoptosis, impaired their growth and rendered them non-tumorigenic in a mouse model 
provided compelling evidence and for the first time, demonstrated a system in which isogenic 
cells that contained or had ‘lost’ the virus could be directly compared [309]. This group later 
showed that the ‘EBV-loss’ phenotype could be reversed by restoring the virus genome; a key 
result which directly implicated the virus as a protective agent in BL [310]. However, since the 
Akata-BL cell line used in these studies had been passaged over 200 times before it gave rise to 
EBV loss cells and because eBL cell lines often retain EBV indefinitely in culture, several studies 
were initiated to determine the generality of these findings. 
The Sixbey group used hydroxyurea to eliminate the viral genome from Mutu-BL as well as 
Akata-BL, but found that only Akata-BL-derived EBV-loss cells showed an increase in apoptosis 
sensitivity [311]. An alternative strategy was used by the Sugden group, who treated BL cells 
with dnEBNA1 to evict EBV and found that loss of EBV genomes consistently induces apoptosis 
in both Latency I and Wp-restricted BL cells [99, 182, 298, 299, 312]. Although this approach 
convincingly demonstrates the addiction of BL cells to the presence of EBV, due to the toxicity 
of this treatment, it is difficult to isolate EBV-loss clones to allow for comparison to EBV-
positive cells in the same manner as the spontaneous loss method. Interestingly, the Awia-BL 
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cell line that was generated by our group from an endemic BL yielded spontaneous EBV-loss 
clones during early passage and also exhibited increased sensitivity to apoptosis compared to 
isogenic EBV-positive clones [178]. Since our group had amassed a collection of early passage 
eBL tumour cell lines, we therefore initiated a project to investigate the frequency and 
consequence of EBV-loss on a large panel of eBLs; the findings of which form the basis of this 
thesis.  
There has also been a significant amount of debate about the mechanisms by which EBV might 
subvert the cell death machinery. Since EBNA3s can epigenetically silence the tumour 
suppressor protein, Bim, it has been suggested that the viral gene(s) responsible might 
themselves be silenced after carrying out this modification and therefore, be absent from the 
resulting tumour. However, whilst Bim is irreversibly downregulated by EBV during primary 
infection [313], it is highly expressed in our panel of Latency I BLs [301]. Ectopic expression of 
LMP2A has also been shown to protect some BL cell lines from apoptosis [167, 314], and can 
enhance tumorigenicity in a mouse model [315, 316], but we find no evidence that LMP2A 
protein is expressed in our Latency I cell lines [317]. Therefore we have focussed our attention 
on the EBNA1 protein, EBER RNAs and BART microRNAs that are consistently present in 
Latency I BLs.  
EBNA1 
The critical function of EBNA1 in viral genome maintenance through tethering of the viral 
genome to sister chromatids and directing viral replication has been well characterised, but it 
has also been ascribed several other important functions [297, 318, 319]. Apart from its status 
as the only viral protein known to be expressed in BL, the first suggestion that EBNA1 might 
contribute to survival in BL was the finding that EBV-positive cells undergo apoptosis when 
treated with dnEBNA1, whereas EBV-negative cells are unaffected [298]. Whilst this does 
support an essential role for EBV in BL, since dnEBNA1 causes the virus to be rapidly lost from 
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the cells, it does not necessarily implicate EBNA1 as the protective factor. There are several 
other mechanisms by which EBNA1 has been suggested to inhibit apoptosis including 
modulation of p53 signalling and upregulation of Survivin [320-322]. However, no direct 
evidence exists to support these findings in a BL model. EBNA1 has also been reported to 
exhibit tumorigenic properties in mice [323, 324], but this finding could not be repeated in a 
different model, which implied that the increased tumorigenicity was an experimental artefact 
of transgene integration [325, 326]. Importantly, two groups who ectopically expressed EBNA1 
in EBV-loss clones could not demonstrate any effect on cell survival [310, 327]. 
EBER RNAs 
The highly abundant small non-coding EBER RNAs are also expressed in all recognised forms of 
EBV latency [78, 328] and several functions have been attributed to them. Principally, they are 
thought to be involved in the evasion of innate immunity and inhibition of apoptosis, although 
a varying number of differing, and sometimes conflicting, mechanisms have been proposed to 
govern these functions. The EBER RNAs share several features with the two small adenovirus 
RNAs, VAI and VAII, which suggested that these RNAs might also be functionally homologous. 
The VAs bind the host-protein shut-off regulator, RNA-dependent protein kinase (PKR), in 
order to maintain protein translation, which is critical to allow replication of adenovirus when 
the interferon signalling pathway is activated due to the presence of the viral genome [329, 
330]. Although EBERs can partially rescue the replication of an adenovirus lacking VAs [331, 
332], there are several lines of evidence that suggest it is unlikely that they inhibit PKR function 
during EBV infection. The location of the EBERs appears to be strictly nuclear, and they cannot 
shuttle to the cytoplasm unlike VAs [333, 334]. Additionally, the presence or absence of EBERs 
neither alter the activity of PKR as measured by interferon sensitivity in LCLs, nor do they 
affect the phosphorylation of PKR and its substrate eIF2 in EBV-loss Akata-BL clones or LCLs 
[335-337], although this second point is disputed [338]. 
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EBERs have been shown to confer apoptosis protection to EBV-loss cells [339], although other 
studies found that this protection was only partial when compared to EBV-positive cells [327, 
340], which was attributed to upregulation of Bcl-2 and IL-10 as well as PKR signalling [339-
342]. Importantly, all of these studies addressing a possible pro-survival role for EBERs in BL 
were carried out in EBV-loss clones of Akata-BL and, therefore, further studies are needed in 
other tumour backgrounds in order to reconcile these data and establish their generality.  
 The EBERs have also been subject to a number of detailed biochemical analyses, which have 
demonstrated that EBERs are able to bind the ribonucleoproteins (RNPs), La and L22 [343-
346], but the functional consequences of this binding have remained doggedly enigmatic. 
Although one group has proposed that EBERs are able to provide a growth advantage to L22-
positive cells, but not in its absence [347].   
BART microRNAs 
Although the BamHI A region, which is transcriptionally active in several malignancies, has long 
been known to give rise to a complex variety of transcripts driven from 2 promoters (known as 
P1 and P2) [348-351], it took until 2004 to discover that these transcripts give rise to tiny non-
coding RNAs, known as microRNAs [352]. A schematic of the primary transcripts and the 
microRNAs is shown in Figure 1.3. It had previously been proposed that these transcripts 
encoded proteins [353-355], but whilst they could be transcribed and investigated in vitro, 
there was little evidence for the existence of BamHI A-derived proteins in EBV-positive cell 
lines [356, 357]. 
The class of short (22-24nt), regulatory RNAs known as microRNAs (miRs) function as part of 
the RISC complex, which selectively binds to mRNAs causing them either to become unstable 
and be degraded, or inhibiting their translation, although the exact mechanisms governing this 
are unclear. Like many other miRs, the BARTs are encoded within introns and are initially 
transcribed as long primary transcripts (pri-miRNAs) which are then processed by Drosher and 
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Dicer and transported to the cytoplasm where the mature miR becomes incorporated into the 
RISC complex. This complex then goes on to bind its target transcript to which the miR confers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specificity by virtue of its short (6nt) ‘seed sequence’, which recognises a region or regions 
within the 3’ UTR of the mRNA with perfect or near perfect complementarity (reviewed in 
[358, 359]).  
The BART miRNAs are reported to play a role in the regulation of many processes including; 
virus replication and lytic cycle regulation, apoptosis (inhibition and activation), NF-κB 
signalling and cell growth via targeting of a number of cellular and EBV-encoded transcripts 
[360-371]. However, the majority of these studies were carried out in epithelial cells where the 
BART miRNAs are very highly expressed [156, 372, 373] and so may not be relevant to BL. The 
BART miRNAs are expressed at lower levels in B cells compared to epithelial cells, although 
Figure 1.3 Position of BART transcripts and microRNAs within the EBV genome 
Transcripts are driven from promoters, P1 and P2. Coding exons (grey) and microRNAs (red) 
are shown against a schematic of the linearised viral genome. The position of the deletion in 
the prototypic EBV strain, B95.8 is also indicated.  
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they still number thousands of copies per cell in total [168], and are consistently detected in all 
types of Latency [94, 171]. 
A number of in silico and in vitro methods have been used to identify possible targets of the 
miR-BARTs in B cells which include; CASP3, CLEC2D, LY75, SP100 (miR-BART 1), DAZAP2, IPO7, 
PDE7A, PELI1 (miR-BART 3), MICB, TOM22, DICER, CAPRIN2 and C1orf109 (miR-BARTs 2, 16, 6, 
and 13, respectively) [99, 168, 368, 371, 374]. Although several have been shown to interact 
with miR-BARTs in reporter assays, there is still notable variation between studies, cell lines, 
and different identification methods even within a single study [375]. Interestingly, one recent 
study from the Sugden group found that ectopic expression of miR BARTs in Latency I BL clones 
can inhibit apoptosis when the cells are treated with dnEBNA1 [99]. RISC complexes 
precipitated from the miR BART-supplemented cells were found to be enriched for Caspase-3 
after treatment with dnEBNA1. Therefore, inhibition of pro-apoptotic Caspase-3 is the 
proposed mechanism by which miR BARTs inhibit apoptosis in this model however, miR BARTs 
were not shown to directly target Caspase-3 in Sav-BL; reporter assays were instead carried 
out in miR BART-transfected 293 cells or EBV-positive and loss cells isolated from a Wp-
restricted BL.  
 
1.4 Apoptosis 
1.4.1 Overview of apoptosis  
Although the peculiar morphological changes associated with programmed cell death were 
first described over 170 years ago by Carl Vogt, it took until 1972 for apoptosis to be 
christened and properly recognised for its essential role in normal development and organism 
homeostasis as well as being a crucial method of clearing faulty or damaged cells [376]. In 
common with other essential cellular processes, loss of control or subversion of apoptosis can 
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have disastrous consequences and as such, evasion of apoptosis is recognised as one of the 
hallmarks of cancer [377]. Apoptosis is now an enormous area of research, which has grown 
almost exponentially in recent decades, and it is now known that the commitment to 
programmed cell death is governed by extremely complex and interweaving signalling 
pathways that are delicately and subtly maintained. This introduction therefore, will only 
provide a brief overview of some of the most critical and well understood processes; specific 
details about particular components will be discussed alongside the relevant data in the 
following chapters.  
The extrinsic pathway 
Apoptosis is divided into the intrinsic and the extrinsic pathways (see Figure 1.4), based on the 
nature of the initial stimulus and the ensuing signalling events [378]. The extrinsic, or death 
receptor pathway, is triggered by the ligation of death receptors at the plasma membrane. The 
death receptors are members of the Tumour Necrosis Factor Receptor superfamily (TNF-R) 
that contain death domains, and they include; TNFR-1, Fas/CD95, DR4 and DR5. Different    
TNF-Rs each recognise specific ligands which, in the case of those receptors previously 
mentioned are; TNFα, FasL, and TRAIL, respectively (reviewed in [379]). Following stimulation, 
the TNF-Rs are able to recruit the adaptor proteins, FADD and TRADD via their death domains, 
which initiate the formation of the death inducing signalling complex (DISC) and resulting in 
the activation of Caspase-8 and -10 [380]. 
Caspases 
Regardless of the pathway by which cell death is initiated, the caspase family of proteins are 
responsible for the ultimate demolition of the cell. Caspases are a family of cysteine-
dependent aspartate-specific proteases that lie dormant in the cell in the form of inactive 
zymogens until they are required. They are divided into two types by their structure and 
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function (reviewed in [381]). The initiators; Caspase-2, -8, -9 and -10, instigate the caspase 
cascade and contain binding domains such as CARDs (caspase activation and recruitment 
domains) or DEDs (death effector domains), which recruit downstream apoptosis regulators 
known as scaffold proteins [382]. Whereas the effector, or executioner, Caspases (-3, -6 and     
-7) orchestrate the destruction of the cellular contents. Initiator caspases are activated when 
they are cleaved by members of the extrinsic or intrinsic pathway, and then the cleaved 
fragments of the caspase assemble into functional multimers which go on to activate scaffold 
proteins such as, FADD and Apaf-1, as well as the executioner caspases [383]. The executioner 
caspases then begin to cleave their hundreds of substrates [384]; destroying the majority, but 
also activating other destructive enzymes like Caspase-Activated DNAse (CAD) [385], which 
then  co-operate in disintegrating the remaining components of the cell. Interestingly, caspase 
cleavage does not always necessarily induce cell death; both initiator and executioner caspases 
have been reported to play important non-apoptotic roles in immune function, cell 
proliferation, differentiation and migration and neurodegeneration [386]. For example, 
Caspase-1 is known to process IL-1β, IL-18 and IL-33 to their mature forms and is able to 
activate lipid metabolism and can thereby regulate pro-inflammatory, anti-inflammatory and 
innate immune responses as well as apoptosis [387-390].   
The intrinsic apoptosis pathway  
The intrinsic apoptosis pathway is principally governed by the Bcl-2 family of apoptosis 
mediators, which consists of at least 15 members in humans. Unlike the extrinsic pathway, the 
intrinsic pathway is triggered by a wide variety of intra- and extracellular stimuli including; DNA 
damage, oxidative stress, growth factor starvation and cytotoxic agents, all of which can be 
detected by the Bcl-2 family [391, 392]. Although Bcl-2 family members may be pro- or anti-
apoptotic, they all share homology in their BH3 binding domain, which allows them to interact 
and agonise or antagonise one another’s function. Therefore, when the intrinsic pathway is  
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Figure 1.4 Overview of the intrinsic and extrinsic apoptosis pathways 
 
Typical stimuli are shown for each pathway followed by generalised signal transduction 
pathways. For each pathway an example initiator caspase is shown (Caspase-8 and 
Caspase-9, respectively), rather than extensive list. Similarly, only a generalised BH3-only 
and pro-survival Bcl-2 protein is depicted.  
 
Extrinsic pathway – TNF receptors ( ) are engaged by their ligands (purple ). pale blue
Adaptors ( ) are then recruited to TNF receptor death domains, initiating bright blue
formation of the DISC. The DISC then activates initiator caspases (black), which feed 
forward to executioner caspases (black). 
 
Intrinsic pathway – the Bcl-2 family BH3-only sensor proteins ( ) sense pro-apoptotic orange
stimuli however, not all pro-apoptotic stimuli are disastrous for the cell (e.g., repairable 
DNA damage), so the pro-survival proteins ( ) keep the BH3-only proteins in check, by green
inhibiting both them and their downstream effectors ( ). If this inhibition is overcome, red
the effectors oligomerise and permeablise the mitochondria, releasing cytochrome C 
( ). Cytochrome C then activates scaffold proteins (cyan ), initiating formation of the grey
apoptosome. The apoptosome then activates initiator caspases (black), which feed 
forward to executioner caspases (black). 
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engaged, the fate of the cell is decided by the overall balance of pro-survival versus pro- 
apoptotic (BH3-only sensors and effectors) interactions. The cell is committed to undergoing 
apoptosis via the intrinsic pathway when the mitochondrial outer membrane becomes 
permeablised (MOMP), which occurs when the balance of Bcl-2 family signalling is tipped in 
favour of the Bcl-2 effector proteins. Once the mitochondrial membrane is breached, 
cytochrome C is able to leak out and further potentiate the pro-apoptotic signal. Cytochrome C 
goes on to activate the scaffold protein Apaf-1 which, as mentioned earlier, is able to activate 
and complex with cleaved initiator caspases, forming the apoptosome. Once the mitochondrial 
pores (from which cytochrome C escapes) are formed, they continue to enlarge, releasing 
additional mitochondrial contents into the cytoplasm, which further drive the caspase cascade 
or alleviate downstream apoptosis inhibition. For example, Smac/DIABLO and Omi/HtrA2 
promote apoptosis by binding and antagonising or causing cleavage of the IAP family of 
apoptosis inhibitors upon release into the cytoplasm [393-395], whereas AIF and Endonuclease 
G translocate to the nucleus where they are involved in DNA fragmentation and degradation 
[396, 397].  
Finally, the executioner caspases are activated and the cell is dismantled (reviewed in [398, 
399]). The careful orchestration of apoptosis leads to the maintenance of the plasma 
membrane until the majority of the cellular contents are destroyed [400] and in vivo, the 
cellular corpse is then rapidly engulfed by phagocytes [401]. This avoids the release of pro-
inflammatory molecules from the dying cell; rendering this form of cell death ‘immunologically 
silent’ [402]. Since oncogenes trigger the intrinsic apoptosis pathway and this study is 
concerned with the possibility that EBV might counteract c-myc in BL, a more detailed 
exploration of the precise interactions of the Bcl-2 family of intrinsic apoptosis regulators is 
warranted. 
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1.4.2 The Bcl-2 family 
The first Bcl-2 family member identified was Bcl-2 itself, in the context of a common B Cell 
Lymphoma mutation cloned from a tumour in 1984 [403]. Its function was discovered by David 
Vaux, along with Suzanne Cory and Jerry Adams at the Walter and Eliza Hall Institute (WEHI) 
[404], who found that it could rescue rat fibroblasts from c-myc-induced cell death, thus 
allowing c-myc to growth transform the cells. As previously mentioned, Bcl-2 family members 
are divided into three types, depending on their structure and function (see Figure 1.5). Bcl-2 
and the other pro-survival family members generally contain four helical Bcl-2 homology 
domains (BH1-4) as well as a C-terminal transmembrane domain and their overall structure is 
that of an 8 α-helical bundle. The pro-apoptotic effector proteins, Bak and Bax, contain three 
BH domains (BH1-3) and the transmembrane domain, but are composed of 9 α-helices in total 
[405]. In contrast, the pro-apoptotic sensor proteins generally contain only the BH3 domain 
(although Bim, Bik and Hrk also have a transmembrane domain); hence they are also referred 
to as the BH3-only proteins and, apart from Bid, which is also an α-helical bundle [406, 407], 
they are largely unstructured when not bound [408]. The BH3 domain is around 26 amino acids 
long and confers the specificity and affinity with which different Bcl-2 family members bind 
one another.  
Evading apoptosis 
Bcl-2 has a number of cellular anti-apoptotic homologues, most notably; Bcl-XL, Mcl-1, Bcl-w 
and A1 (or Bcl-2-A1). These Bcl-2-homologues interact with their pro-apoptotic counterparts 
via their hydrophobic BH3-binding groove [409] and their primary function appears to be to 
sequester the BH3 only sensor proteins, thus preventing them from activating the effector 
proteins. The pro-survival proteins also bind the activated forms of the effector proteins 
directly, which stops them from binding to one another and therefore initiating MOMP.  
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A number of viruses, including EBV, are known to encode homologues of cellular Bcl-2 in order 
to evade apoptosis triggered as part of the anti-viral response. Viral Bcl-2 proteins vary in their 
similarity to their cellular counterparts in sequence, structure and function and there are 
examples of v-Bcl-2s, such as some of those encoded by certain pox viruses, which only 
resemble their cellular counterparts in their three-dimensional fold and have no known anti-
apoptotic activity (reviewed in [410]).  
EBV encodes two v-Bcl-2s, BHRF1 and BALF1, which are thought to exhibit functional 
redundancy by inhibiting apoptosis during primary infection, since a virus deleted for both is 
Figure 1.5 Schematic of functional domains in Bcl-2 family proteins  
 
The pro-survival proteins range in size from 20-37kDa, with Bcl-w and A1 being the 
smallest and Mcl-1 the largest. All contain the transmembrane ™ domain except A1. 
 
The effector proteins lack the N-terminal BH4 domain compared to their pro-survival 
counterparts and both contain the transmembrane domain which allows them to insert 
into and form pores in the mitochondrial outer membrane (MOM). Bax is 21kDa and Bak 
is 24kDa.  
 
The BH3-only proteins range from 11-22kDa in size, with Noxa being the smallest and Bim 
and Bid being the largest. Only Bim, Bik and Hrk contain the transmembrane domain.   
 
Sizes quoted are based on most commonly expressed isoforms. 
Transmembrane domains insert into endoplasmic reticulum (ER) or MOM where the 
proteins may be permanently tethered Bak/Bax) or only insert into membrane upon 
stimulus [380]. 
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unable to transform resting B cells, yet viruses lacking either v-Bcl-2 transform B cells with the 
same efficiency as a wild-type virus [88]. BHRF1 is relatively well-characterised; it exhibits 38% 
C-terminus sequence similarity to Bcl-2 and structurally closely resembles Bcl-XL, binding BH3 
ligands in a hydrophobic groove formed by α-helices 2-5 of its 7-helix bundle [411, 412]. BHRF1 
has been shown to be potently anti-apoptotic in vitro and in an animal model and can confer 
protection to a wide variety of stimuli [89, 303-305, 411, 413-420]. Whilst it has long been 
thought to contribute primary infection and lytic cycle, it is now known that BHRF1 is also 
constitutively expressed in LCLs and highly over-expressed in the Wp-restricted subset of BLs, 
as previously mentioned [89]. The mechanism by which BHRF1 protects BL cells is thought to 
largely be via binding and sequestration of Bim and to a lesser extent Bak, Puma and Bid [304, 
305, 411].  In contrast to BHRF1, little is known about BALF1 which was identified as a v-Bcl-2 
on the basis of structural similarity to Bcl-2 and Bcl-XL, and though it has been shown to 
modulate apoptosis, it remains controversial as to whether it promotes or inhibits cell death 
[421, 422].  
Sensing apoptosis 
The pro-apoptotic BH3-only proteins vary greatly in their affinity and specificity for anti-
apoptotic Bcl-2 proteins due to differences in the sequence and structure of their amphipathic 
BH3 domain (see Figure 1.6). Bim, Puma and the truncated form of Bid (tBid) exhibit the least 
specificity and are able to bind all of the well-characterised Bcl-2 homologues (Bcl-2, Bcl-XL, 
Mcl-1, Bcl-w and A1) with varying affinities, whereas other BH3-only proteins are more 
selective. For example, Noxa is able to bind to Mcl-1 and A1, but not Bcl-2, Bcl-XL or Bcl-w, 
which are specifically engaged by Bad, Bmf and Hrk, as depicted in Figure 1.6 [423, 424]. 
Accordingly, Bim, Puma and tBid are all potent inducers of cell death, whereas the other BH3-
only proteins must act in combination. For instance, Noxa and Bad can efficiently induce 
apoptosis as together they are able to bind all pro-survival Bcl-2 proteins. 
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BH3-only proteins act as ‘sensors’ for cellular threats, damage, and stress and as such, are 
activated by a diverse range of stimuli. The precise mechanisms by which the balance between 
the Bcl-2 family proteins dictates the fate of the cell have not been fully elucidated however, 
two, not mutually exclusive models have been proposed [425, 426].  In the direct activation 
model, the promiscuous binders; Bim, Puma and tBid, directly activate Bak and Bax when they 
are not bound by pro-survival proteins [424, 427, 428]. In contrast, the other BH3-only 
proteins act as ‘sensitisers’, by displacing  Bim, tBid and Puma from pro-survivals, leading to 
activation of Bak and Bax. In the indirect activation model [425], Bak and Bax become 
activated spontaneously and therefore, the BH3-only proteins simply need to bind to and 
inactivate all of the pro-survival proteins, stopping them from blocking the oligomerisation of 
Bak and Bax. In vivo, it is clear that both of these models can occur [429] and so the 
physiological situation is likely to be a hybrid of these two models [399]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.6 Binding specificities of Bcl-2 family members 
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Executing apoptosis 
The primary function of the Bak and Bax effector proteins is to form pores in the mitochondrial 
membrane, allowing the release of cytochrome C and other proteins into the cytosol. The 
effector proteins exhibit functional redundancy, with either being sufficient for normal 
development in mice, whereas Bak-/-/Bax-/- mice exhibit gross abnormalities and Bak-/-/Bax-/- 
cell lines fail to undergo apoptosis [430, 431]. To carry out their function, Bak and Bax must be 
activated, which causes them to undergo a substantial conformational change and thereby 
exposing the BH3 domain as well as other functional domains [428, 432]. Pro-survival Bcl-2 
proteins bind to effector proteins in order to block this activation, with Bcl-XL, Mcl-1 and A1 
being able to restrain both Bak and Bax, but Bcl-2 and Bcl-w only able to bind Bax [425, 433].  
Interestingly, whilst Bak is permanently associated with the mitochondrial membrane, Bax may 
be only loosely associated with the membrane or free within the cytoplasm [434]. There is also 
a third effector protein homologue, Bok, which may reside in the ER rather than mitochondrial 
membrane. Despite being widely expressed, the function of Bok remains poorly understood 
[435].  
Once activated the effector proteins can oligomerise by linking together in a daisy-chain 
fashion (i.e., front-to-back) [436], or by reciprocal interactions of the BH3 domain (face-to-
face) to form dimers [437-439]. In the latter mechanism, pairs of dimers link to one another by 
a second reciprocal interaction (back-to-back). Bak and Bax then congregate in large numbers 
in homo- or hetero-oligomers to form proteinaceous pores that allow the escape of molecules 
of at least several hundred kilo-Daltons [440, 441]. The conformational change that occurs 
during effector activation also releases two α-helices across the inner leaflet of the 
mitochondrial membrane, which may also be critical to pore formation [442].  
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1.4.3 Regulation of the Bcl-2 family 
The varying specificities and affinities with which the Bcl-2 family bind to one another allow for 
a dynamic and intricate web of different interactions to be possible, reflecting the careful and 
complex regulation of apoptosis. However, many of the Bcl-2 family are also subject to 
regulation by a number of mechanisms other than binding and neutralisation by their 
counterparts.  
Puma and Noxa were first identified as transcriptional targets of p53 [443, 444], although both 
can also be transcriptionally regulated in p53-/- cells [445, 446]. Other Bcl-2 family members are 
also known to be transcriptionally activated, for example; the potent pro-apoptotic inducer, 
Bim, which is known to be upregulated by FoxO transcription factors in response to 
glucocorticoids [447-449]. Many of the Bcl-2 family may also exist as a number of functionally 
different isoforms, which may agonise or antagonise the function of any other isoforms 
present, providing a second level of transcriptional regulation. For instance, there are three 
well characterised protein-coding isoforms of Bim; BimEL, BimL and BimS, which vary in their 
potency, but there are also many other splice variants whose physiological function remains 
enigmatic [450, 451]. The pro-survival Bcl-2 homologues, Mcl-1 and Bcl-XL, can also exist in 
different isoforms, some of which have opposing functions to the common isoform [452, 453].  
The Bcl-2 family are also subject to complex post translational modifications (PTMs), which are 
known to affect their activity, availability, binding affinity, and cause inactivation by 
sequestration or degradation. Bad can be phosphorylated at serines 112 and 136, causing it to 
be sequestered to the cytoskeleton [454], as well as at serine 155, which confers lower binding 
affinity for pro-survival proteins [455]. In contrast, ubiquitination of Mcl-1 causes it be rapidly 
degraded by proteasome-dependent and independent mechanisms [456, 457]. Bim also 
undergoes PTM and can be phosphorylated by ERK1/2 to undergo ubiquitin-independent 
degradation [458-460]. Interestingly, Bim is also sequestered to microtubules through 
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interaction with LC8, although this is not thought to be regulated by PTM [461]. Recently, even 
more mechanisms of Bcl-2 family regulation have been described, including modulation by 
miRNAs and stearic regulation by membrane lipids. For example, the miR-17-92 cluster of 
microRNAs is able to decrease Bim expression [462] and the interaction of sphingolipids in the 
mitochondrial membrane with Bak and Bax is able to regulate MOMP directly [463]. The 
extremely complex and incompletely understood mechanisms of Bcl-2 family regulation 
protect the fidelity of this critical pathway however; it also makes it difficult to 
comprehensively study and therefore interpret the workings of the pathway as a whole. 
1.4.4 The Bcl-2 family and lymphomagenesis 
Following the finding that overexpression of Bcl-2 can rescue MYC-driven apoptosis in vitro 
[404], Bcl-2 has also been shown to accelerate lymphomagenesis in the Eμ-myc mouse model 
[464].  However, since Bcl-2 protein is usually undetectable in BLs, alternative mechanisms of 
c-myc rescue must occur in this setting. More recently, Bcl-2, Bcl-XL, Bcl-w, Bcl-B, Mcl-1 and 
Bfl-1 have all been shown to be able to individually co-operate with c-myc to cause leukaemia 
in mice [465]. Additionally, Bcl-XL and Mcl-1 can significantly accelerate lymphomagenesis in 
Eμ-myc mice [466, 467]. Concordantly, deletion of the pro-apoptotic Bcl-2 family members can 
also contribute to murine tumorigenesis; Bax, Bim, Puma and Bmf can all act as tumour 
suppressors in vivo [267, 268, 270, 468].  Furthermore, and consistent with human BL, Bax-/- 
Eμ-myc tumours often exhibit p53 inactivation via modulation of MDM2 or p14ARF [270]. 
Additionally, mice knocked out for both Bim and Puma can spontaneously develop lymphoma 
[469] and myc-driven tumours require the activity of Bim as well as Puma and Noxa to be 
efficiently induced to undergo apoptosis [274]. 
In human cancers, there is also evidence that the Bcl-2 family are frequently knocked out, 
mutated, or selected against. Pro-survival proteins have been found to be overexpressed or 
have their loci amplified in many lymphoid tumours [465, 470], which may be due to mutation 
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or activation of the gene, but in other cases they may be indirectly activated. For instance, 
deletion of E3 ligase components can enhance lymphomagenesis by stabilising Mcl-1 [471, 
472], whilst Puma and Bim are often absent in BL through both deletion and epigenetic 
silencing [267, 473]. Given the dependence of so many lymphoid tumours on the Bcl-2 family 
in vivo, there is currently optimism that specific targeting of the Bcl-2 family will prove a 
successful strategy for therapeutic intervention. 
1.4.5 Targeting the Bcl-2 family in human disease  
Since the BH3 domain confers binding specificity to Bcl-2 family proteins, small molecule 
inhibitors, known as BH3 mimetics, have been developed that can bind and inactivate pro-
survival Bcl-2 proteins. ABT-737 and ABT-199 are bone fide BH3 mimetics; specifically binding 
Bcl-2, Bcl-XL and Bcl-w (ABT-737) or Bcl-2 alone (ABT-199) with high affinity and are non-
functional in the absence of effector proteins [474, 475]. Both ABT-199 and the orally-available 
analogue or ABT-737, ABT-263, are currently included in clinical trials [476-478]. There is also a 
considerable work underway to develop BH3 mimetics that can bind and inactivate other pro-
survival Bcl-2 proteins, such as Mcl-1 [301, 479].  
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1.5 Aims and Objectives 
This project aimed to expand previous findings, regarding the role of EBV in maintaining BL 
tumours by isolating a panel of EBV-loss clones from a range of endemic BL cell lines; thereby 
allowing them to be compared phenotypically to isogenic clones that do contain the virus. We 
aimed to compare human BL cells that contain or have lost EBV, to profile their response to 
apoptosis-inducing agents and determine their tumorigenicity in vivo, in order to fully 
characterise the EBV-loss phenotype and assess the generality of previous findings. We also 
wanted to map any modulation of apoptosis by the virus by re-expressing viral genes both 
individually and in combination. Finally, we profiled cellular changes associated with apoptosis 
induction in EBV-positive and EBV-loss BL clones. Overall, we hoped to gain insights into the 
regulation of apoptosis by EBV in endemic Burkitt lymphoma in order to better understand 
viral modulation of apoptosis and therefore, to identify potential therapeutic targets for this 
aggressive disease.  
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2. Materials and Methods 
2.1 Cell culture 
2.1.1 Cell lines used in this study 
The basis of this work is the comparison of single cell clones of several BL cell lines which either 
contain EBV expressing the Latency I gene expression pattern, or have lost the virus. All cell 
lines used are described in Table 2.1. Akata-BL was obtained from the Takada group [480], 
Martin Rowe developed the AKBM GFP-reporter cell line [481], and all other BL cell lines were 
established by Alan Rickinson and colleagues [178, 179, 482]. Jurkat clone E6.1 was from the 
European Collection of Cell Cultures, HEK 293 cells we obtained from the American Tissue 
Culture Collection (product number: ATCC CRL-1573) and the 293FT cell line used for high titre 
lentivirus production were from Life Technologies (R700-07).  
In the results sections EBV positive clones are denoted by the prefix ‘P’, whereas EBV-loss 
clones are denoted by the prefix ‘n’. Clones are differentiated from one another numerically, 
so for example; Kem n1 always refers to a particular loss clone of Kem-BL, whilst Kem n2 refers 
to a different EBV-loss clone also derived from the Kem-BL tumour background. 
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2.1.2 Cell line maintenance 
Cell lines were maintained in RPMI 1640 supplemented with 10% foetal calf serum (FCS) 
(Gibco), 6mM glutamine, 1mM pyruvate, 50μM α-thioglycerol, 20nM bathocupronine 
disulphonic acid and 8μg/ml gentamycin (all Sigma). Lymphoid cultures were passaged every 
48-72 hours by resuspension in fresh medium to approximately 3x105cells/ml. Adherent cells 
were seeded at ~10x103/cm2 and were passaged twice weekly when the cells reached 80-90% 
confluence; cells were dissociated from tissue culture dishes using Gibco TrypLE at 37°C for 5 
minutes before resuspension in fresh FCS-containing medium to inactivate the trypsin.  
Table 2.1 Details of cell lines used in this thesis 
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All cell lines have been cryopreserved in liquid nitrogen. Briefly, this involved pelleting              
5-10x106 cells by centrifugation at 1,400rpm (~450g) for 5 minutes in a BIOliner™ Swinging 
Bucket Rotor (Thermo Scientific) before resuspending the cells in freezing medium, which 
comprised: 50% v/v RPMI 1640, 40% v/v FCS and 10% v/v dimethylsulphoxide (DMSO) (Sigma), 
in Nunc 1ml cryovials. Cryovials were then transferred to a Mr Frosty™ container (Nalgene) 
filled with isopropanol and transferred to -80°C overnight. Samples were then stored in the gas 
phase of a liquid nitrogen freezer. Cell lines were recovered from nitrogen by rapidly thawing 
vials in a 37°C water bath, followed by the drop-wise addition of the appropriate pre-warmed 
medium. Cells were then pelleted as previously described before being resuspended in fresh 
media and then cultured as described.  
All cells were routinely grown at 37°C in a humidified atmosphere containing 5% CO2, in 25cm
2 
flasks (suspension cells) or 10cm culture dishes (adherent cells).  
2.1.3 Single cell cloning of BL cell lines 
Subclones of BL tumour lines were isolated using a standard limiting dilution technique 
whereby cultures were diluted to 10 cells/ml and seeded at 100µl/well in round-bottomed   
96-well plates. Several hours after seeding wells were checked by eye to ascertain the number 
of cells on average per well. Plates were then fed weekly with fresh medium until cells were 
numerous enough to be harvested for genome load analysis (at least 1000 cells per well). In 
these experiments maintenance medium used was as described in 2.1.2, with the addition of 
200µM acycloguanosine (ACV), a nucleoside analogue which inhibits lytic virus genome 
replication.  
2.1.4 Preparation of lentivirus stocks  
Lentivirus stocks were produced using the 293FT packaging cell line (Life Technologies, R700-
07) using liposome-mediated delivery of lentiviral plasmid DNA and second generation 
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packaging vectors. On day 1 of the protocol, confluent, early passage (<20) 293FT cells were 
plated at ~5x104/ml in fresh media. The following day the cells were transfected with the 
vector containing the gene of interest, the modified HIV-derived packaging plasmid psPax2, 
and the VSV-G envelope glycoprotein-encoding pMD2.G, premixed with Lipofectamine 2000 
(Life Technologies) as a DNA delivery agent in serum-free Optimem medium (Life 
Technologies). The prepared transfection mix was added directly to the medium on the 293FTs 
and consisted of 3ml Optimem, 36µl Lipofectamine 2000, 6µg psPax2, 4µg lentivirus plasmid 
DNA and 2µg pMD2.G per 10cm plate. Plates were then returned to the incubator overnight. 
The following day (~16 hours post-transfection) the transfection medium was removed and 
replaced with fresh medium supplemented with 0.1mM pyruvate. On day 5 the lentivirus-
containing supernatant was harvested, briefly centrifuged and filtered at 0.45µm. Before use 
the lentiviral supernatant was concentrated ≥50-fold by ultracentrifugation in an SW40 Ti rotor 
at 19,000rpm (~64,000g) for 2 hours at 16°C. 
2.1.5 Generation of stable lentivirus-transduced cell lines 
For transduction of BL cells, 1x105 cells were placed in a 10ml centrifuge tube with 
concentrated lentivirus harvested from 1 x 10cm dish and supplemented with 10µg/ml 
Polybrene (Sigma) in a total volume of 400µl. Efficient transduction of the cells was achieved 
using a ‘spin-infection’ protocol, whereby tubes were transferred to an incubator at 37°C for 
30 minutes to allow the lentiviral particles to bind to the cells and then spun at 2,200rpm 
(~1,100g) in a BIOliner™ Swinging Bucket Rotor (Thermo Scientific) at 32°C for 2 hours. The 
supernatant was then discarded and the cells washed in fresh, warmed medium twice before 
transferring to 24-well plates. For transduction of the 293 cell line, 1x105 cells were plated in  
6-well plates 24 hours before infection to allow them to adhere to the culture dish and then 
the plates were incubated and spun as above. Following centrifugation the supernatant was 
discarded and fresh medium gently applied.  
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All of the lentivirus constructs used in this thesis were derivatives of FTGW [483], which 
contains a constitutively-expressed enhanced GFP (eGFP) driven from a ubiquitin promoter, 
allowing lentivirus-transduced cells to be selected for on the basis of GFP expression. At 7-10 
days following transduction cells were sorted on a MoFlo cell sorter (Becton Dickinson) and 
GFP-positive cells were collected and put back into culture. Cells were sorted for a second time 
7-10 days later and selected for high GFP expression, with the top 5-10% of GFP-positive cells 
of the gene-of-interest-transduced cells being collected. Identical gates were used for all lines 
within a set, including controls. Two rounds of sorting were carried out to normalise gene 
expression between constructs as we and others have found that GFP-expression correlates 
with both the number of integrated lentiviral genomes and expression of the gene of interest 
[484].  
All genes-of-interest were placed under the control of tet-inducible promoters and expression 
was induced by addition of doxycycline (DOX) to a final concentration of 1µg/ml (Sigma) to the 
cell culture medium. Cells were used for functional assays or gene expression experiments   
24-48 hours after induction, unless otherwise stated. In the case of the BimS variant constructs 
cells were supplemented with 25µM Q-VD-OPh (Quinoline-Val-Asp-
difluorophenoxymethylketone) (MP Biomedicals) to inhibit caspase activation and cell death 
during gene expression assays.  
2.1.6 Preparation of infectious stocks of recombinant EBV 
Infectious virus of the CpWp-KO strain [485], was produced from 293 cells stably transfected 
with recombinant EBV bacterial artificial chromosomes (BACs) which were induced into lytic 
cycle by transfection with BZLF1 and BALF4. Briefly, BAC-containing 293 cells were seeded in 6-
well plates and when ~70% confluent were co-transfected with 0.5µg each of plasmids p509 
(BZLF1) and p2670 (BALF4) [486, 487] using Lipofectamine reagent (Life Technologies) in 
Optimem reduced-serum medium (Gibco). Transfection medium was replaced with fresh 
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target cell medium 16 hours after transfection and the virus-containing supernatant collected 
72 hours later, spun down to remove any cells and filtered using a 0.45µm filter to remove cell 
debris and ensure sterility. Virus stocks were stored at -80°C until use.  
Stocks of infectious Akata-BAC-GFP2 virus [488] were produced from a stable EBV-loss Akata 
cell line which had been reinfected with the Akata virus BAC. Unusually for a BL cell line    
Akata-BL is induced into lytic replication by crosslinking of surface IgG [130]. Therefore, the 
stably reinfected line containing the Akata BAC was stimulated with 0.5%v/v Fab 2 α-IgG 
(1mg/ml, from Cappel) for two hours with gentle shaking and then transferred to fresh 
medium and returned to a 37°C incubator. Virus-containing supernatant was collected 72 
hours later, sterilised using a 0.45µm filter and stored in aliquots at -80°C. 
2.1.7 Reinfection of EBV-loss clones with recombinant EBV 
The critical cellular receptor for EBV binding and entry of B cells is CD21 [489] however, many 
BL cell lines are found to express only low levels of CD21 on the outer membrane [490]. EBV-
loss BL cells were transduced with CD21 lentivirus according to the spin-infection method as 
described in Section 2.1.5, then seeded into 6-well plates at 2x106 EBV-loss cells/well with EBV-
containing medium at >100 MOI (multiplicity of infection), in a total volume of 5mls. The cells 
were then infected according to the spin-infection method as described in Section 2.1.4, 
except that the cells were not washed following infection. Instead, the majority of the 
supernatant was gently removed and fresh medium added. After infection the cells were left 
to recover for 48 hours before selection of EBV-positive cells was begun by the addition of 
antibiotics to the cell culture medium. Cells infected with the Akata recombinant EBV (rEBV) 
were selected for G418 (Sigma) resistance (using 400, 700 or 1000µg/ml for clones of Kem, 
Akata or Mutu-BL, respectively), whereas reinfectants carrying the CpWp-KO virus were 
selected on the basis of hygromycin-B (Sigma) resistance (500µg/ml for all EBV-loss clones).  
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We and others has previously shown that reinfection of EBV-loss or EBV negative cell lines 
often results in a Latency III-pattern of viral gene expression [491, 492]. However, a 2011 
publication by the Sample group described Latency I reinfection being achieved only after an 
extended period in culture [493] and so, after subsequent correspondence with Professor 
Sample, we decided to screen our re-infected cells after a minimum of 8-weeks in culture in 
selection medium. Unlike in previous experiments, we found that we were now able to 
generate stable cell lines expressing only Latency I-associated genes. Some reinfected bulk 
cultures were found to express EBNA2 in a subpopulation of cells; such cultures were 
subjected to single cell cloning, as described in Section 2.1.3 in order to isolate Latency I 
expressing cells.  
 
2.2 Cell death, cell growth and cell survival assays 
2.2.1 Cell viability assays 
Routine cell viability assays were carried out prior to setting up all apoptosis assays by adding 
20µl of trypan blue (0.4% solution, from Sigma) to 20µl of thoroughly mixed cell suspension. 
This was then mixed by pipetting and 10µl applied to a cell counting slide and the percentage 
of viable cells was quantified using a TC-10 cell counter (Bio-Rad). A minimum of two separate 
counting chambers was measured per sample and the viability taken to be the mean of the 
recorded values. This method was also used to quantify cell viability during apoptosis time 
course experiments where cells were subsequently harvested for gene expression analysis.  
2.2.2 Proliferation assays 
Cells were initially plated at 9x104/cm2 in 10cm dishes in standard BL cell media, and 
thoroughly resuspended every 24 hours at which time 3 x 75μl aliquots were removed for 
counting. Each 75μl aliquot was then passed through the Accuri C6 Flow Cytometer (BD 
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Bioscience) to obtain absolute cell counts per unit volume. Counts were recorded and 
expressed relative to measurements taken immediately after seeding. The mean and standard 
deviation (SD) of triplicate measurements was calculated and plotted to compare the growth 
of different cell lines over time.  
2.2.3 Apoptosis assays 
For all assays, actively dividing cells (passaged 24 hours before apoptosis induction) were 
seeded at 9x104/cm2 and treated with various apoptosis-inducing stimuli or DMSO as a vehicle-
only control as listed in Table 2.2. For small scale assays, cells were seeded in 96-well plates 
with triplicate wells being set up for each treatment or control and each experiment being 
carried out on at least three occasions. For apoptosis assays where cells were harvested for 
gene expression studies, 10cm dishes were used and triplicate data were taken from three 
independent experiments.  
Sensitivity to apoptosis-inducing stimuli was determined using flow cytometry to differentiate 
between live, apoptotic and dead cells. The translocation of phosphatidylserine (PS), from the 
inner to the outer leaflet of the plasma membrane, is a well-defined marker of entry to 
apoptosis and so fluorescent conjugates of Annexin-V, which has a high affinity for PS, are 
widely used to detect cells in the early stages of cell death [494, 495]. Propidium iodide (PI) is 
excluded from live cells and cells in the early stages of apoptosis and is only able to enter cells 
which have lost outer membrane integrity when the cells are dead or in the late stages of 
apoptosis. The response of EBV-loss clones to different stimuli, compared to their EBV-positive 
counterparts, was characterised by dual staining of cells with Annexin-V and PI at 24-72 hours, 
depending on the stimulus used (see Table 2.2). In assays where cell lines were GFP-positive, 
Annexin-V was conjugated to Alexa-Fluor 647 (Life Technologies), and in other assays a FITC-
Annexin V conjugate was used (eBiosciences). In all assays a 2x mix of Annexin-V and PI was 
made up in 2x Annexin binding buffer (eBioscience), then 100µl of cell suspension from each 
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assay well was harvested and 100µl of the 2x Annexin V/PI mixture was added. The final 
concentration of both Annexin V and PI was 2.5µg/ml. Each tube was briefly mixed and then 
analysed immediately on an Accuri C6 or LSR I flow cytometer (both Becton Dickinson).  
Cells were first gated according to forward and side scatter profiles to eliminate debris (events 
with very low forward and side scatter) from the analysis, the selected events were then 
analysed on two-dimensional dot plots of Annexin-V vs PI to quantify the percentage of live, 
apoptotic and dead cells, respectively, as shown in Figure 2.1-A and 2.1-B. At the time-points 
chosen for our phenotypic assays we found that we rarely detected Annexin-positive/PI-
negative cells; all of the non-viable cells also stained for PI and so on some occasions PI 
staining alone was used to quantify cell death, as shown in Figure 2.1-C. As with the dual-
Table 2.2 Details of drugs used in apoptosis assays and length of assays. Where a range of 
concentrations has been used the exact concentration of drug used in individual 
experiments is stated in the Results text or Figure legend.  
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staining assays, a 2x dilution of PI was mixed with harvested cells 1:1 and samples were 
analysed on the Accuri C6 cytometer.  
2.2.4 Data analysis for apoptosis assays 
For each sample a minimum of 10,000 events was recorded and data were analysed using 
FlowJo software (Treestar) or Accuri C6 software (Becton Dickinson), depending on which 
instrument was used to process samples. Induced cell death was calculated as: (% total death 
in drug treated cells – mean % cell death in matched untreated cells)/mean % viable cells in 
untreated sample. Mean and standard deviation were calculated and the significance of any 
differences between cell lines was determined using a two-tailed Student’s T-test. Values of 
p<0.05 were considered significant.  
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Figure 2.1 Apoptosis assay gating strategies 
 
A Annexin-V-FITC/PI staining on untreated and ionomycin-treated Kem n1 EBV-loss cells  
B Example of Annexin-V-APC/PI staining on GFP-positive untreated and doxycycline-
induced BimS-wt-transduced Kem n1 EBV-loss cells  
C PI-only viability staining on untreated and ionomycin-treated Kem n1 EBV-loss cells 
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2.3 DNA analysis 
2.3.1 DNA preparation  
For analysis of viral genome load in single cell clones in preliminary screening assays, a small 
aliquot of cells was resuspended in 100µl lysis buffer comprised of; 1.5mM MgCl2, 50mM KCl 
10mM Tris-HCl, 1% Tween-20, and 40µg/ml Proteinase K (all Sigma), then incubated at 55°C for 
1 hour to lyse the cells, followed by 10 minutes at 95°C to inactivate the Proteinase K.  
For more accurate genome load or other DNA analysis, such as sequencing or for use in 
cloning, purified DNA was extracted from 5-10x106 cells using the GenElute Genomic DNA Kit 
(Sigma), according to the manufacturer’s instructions and eluted in 50µl diethylpyrocarbonate 
(DEPC) treated water. DNA concentration and purity was measured using a Nanodrop 1000 
spectrophotometer (Thermo Scientific). 
2.3.2 PCR quantitation of EBV genome load 
The copy number of EBV genomes per cell was determined using quantitative DNA-PCR for the 
EBV polymerase gene, BALF5, and normalised to the cellular gene, β-2-microglobulin (β2M) as 
previously described [496]. Briefly, assays were carried out in a total volume of 25µl in 96-well 
PCR plates (Geneflow). The reaction mix contained 1x Taqman Universal Master Mix II (Life 
Technologies) and BALF5 and β2M Taqman assays and samples consisted of 5µl of lysed cells, 
5µl lysed virus-containing supernatant (to measure the concentration of purified virus stocks), 
or 5µl of 2ng/µl purified DNA. Threshold values (Cts) were quantitated by comparison to a 
standard curve of DNA extracted from the Namalwa-BL cell line, which contains 2 integrated 
copies of the EBV genome per cell. Clones were deemed to be EBV negative where a well was 
found to be negative for BALF5, but positive for β2M. The EBV-positive clones selected for 
comparison were chosen for having a similar average viral genome to the parental BL cell line. 
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2.4 PCR amplification of DNA 
2.4.1 PCR amplification of viral and cellular genes 
Portions of cellular and viral genomic DNA were amplified for molecular cloning by end-point 
PCR. Primers consisted of 15-20 bases of complementary sequence to the 5’ end or reverse 
complement of the 3’ end of the target sequence with the addition of necessary restriction 
sites or spacers. G+C content, melting temperatures (Tm) were calculated and sequence 
specificity checked using Primer3 (NCBI). Details of genes and genomic fragments amplified 
can be found in Section 2.6. 
Typically, reactions were carried out in a total volume of 50µl containing; 300nM primers, 1x 
MgCl2-containing PCR buffer (Roche), 200-500ng of template DNA (EBV-positive Raji-BL), and 
200µM dNTPs (Roche). Tubes were heated to 96°C for 4 minutes and then the reaction was 
started by addition of 1µl of high fidelity DNA polymerase (Roche). Thermal cycling was carried 
out in a Techne TC-512 for 40 cycles comprised of: 15 seconds at 96°C, 15 seconds at 50-65°C 
(depending on Tm) and 30 seconds at 72°C per kb of sequence to amplify, followed by a 10 
minute final extension at 72°C. 
2.4.2 Agarose gel electrophoresis and purification of PCR products 
Following PCR amplification DNA fragments were separated by electrophoresis at 90V in 1x 
TBE buffer (90mM Tris-borate, 2mM EDTA) according to size on 1-2% agarose gels containing 
0.5µg/ml ethidium bromide. DNA samples and 1kb Plus DNA Ladder (Life Technologies) were 
mixed with FastDigest gel sample buffer (Thermo Scientific) prior to loading and once the 
yellow dye (corresponding to 10bp) had migrated the full length of the gel, electrophoresis was 
stopped and gels examined on a UV transilluminator.  
Bands containing the desired PCR products were excised from gels using a scalpel blade and 
then purified using the Qiaquick Gel Extraction kit (Qiagen) according to the manufacturer’s 
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instructions. DNA was then precipitated by the addition of 0.1 volumes of 0.3M sodium 
acetate, followed by 2 volumes of 100% ethanol. After overnight storage at -80°C DNA was 
pelleted, washed in 70% ethanol and resuspended in DEPC-treated water.  
2.4.3 Sequencing PCR 
DNA sequencing analysis of amplified DNA fragments, ligation products and plasmid DNA was 
carried out on an Applied Biosystems 3700 DNA Analyser operated by the University of 
Birmingham Functional Genomics department. Each reaction comprised of 200-500ng DNA 
and 3.2pmol of sequencing primer. 
 
2.5 Bacteriology 
Chemically competent Stbl3 E. coli cells were used for the preparation of concentrated plasmid 
DNA as these cells are able tolerate lentivirus constructs, which contain repeat regions that 
may be unstable in other strains [497]. Stocks of competent Stbl3s were made using the Inoue 
method [498]. 
Bacterial cell suspension cultures were grown in Lennox LB medium and bacterial colonies 
were propagated on LB-agar plates. Both agar and Lennox LB were from Sigma and were used 
as directed by the manufacturer. Bacterial work was carried out under sterile conditions and 
equipment and solutions were autoclaved before use if not pre-packed sterile. LB media and 
LB agar were supplemented with antibiotics before use where constructs contained selection 
cassettes for simplified screening.  
2.5.1 Transformation of Stbl3 E. Coli 
Aliquots (<100µl) of Stbl3 were thawed on ice and 10ng of plasmid DNA or <10µl of ligation 
mix was added and the mixture incubated on ice for 30 minutes. Tubes were then heat 
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shocked at 42°C for 90 seconds and then briefly returned to ice before adding 1ml LB medium 
and leaving to recover at 37°C in a shaking heat block for 1 hour. Cells were then spun for 1 
minute at 6500rpm (~4,000g) in a microcentrifuge and the pelleted cells spread onto agar 
plates and incubated at 37°C overnight.  
2.5.2 Isolation of plasmid DNA from bacterial cultures 
Single colonies were picked from plates following overnight incubation and used to inoculate 
3mls of LB medium. If the bacteria were transformed with the products of a ligation reaction 
multiple colonies (usually 12) were chosen for screening. Cultures were placed in a benchtop 
shaking incubator at 225rpm, 37°C, until confluent (around 8 hours) and then plasmid DNA 
was extracted using the QIAPrep Spin Miniprep kit (Qiagen) according to the manufacturer’s 
instructions.  
Where larger amounts or higher concentrations of pure plasmid DNA were required a 3ml 
culture was used to inoculate 200-400ml LB medium overnight and plasmid DNA was extracted 
using the Qiagen Plasmid Maxi kit as per the supplied protocol.  DNA purity and concentration 
was measured using the Nanodrop 1000 (Thermo Scientific) and plasmids were checked by 
restriction digest before use in cells.  
2.5.3 Restriction digestion and DNA ligation 
Restriction digests were carried out using FastDigest system (Thermo Scientific) according to 
the manufacturer’s instructions. Briefly, the products of a PCR reaction or <5µg DNA were 
digested in a 50µl volume containing 1x FastDigest Buffer and 1-2µl of the required enzyme(s) 
(up to 5µl total). Digests were incubated at 37°C for 15-30 minutes and a small amount of the 
reaction mix was checked on a gel to confirm complete cutting. Before use in cloning, digested 
DNA was purified using a HighPure PCR Purification kit (Roche).     
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Ligations were generally set up using 10-20ng of vector DNA and a vector:insert molar ratio of 
1:3 and 1:10 using the Rapid DNA Ligation kit (Roche) according to the manufacturer’s 
instructions. Reaction mixtures were incubated at 16°C overnight then transformed into 
competent bacteria.  
 
2.6 Molecular Cloning 
Lentivirus constructs were used to express EBV genes in this thesis in order to overcome 
limitations we have found with other systems such as; poor transfection efficiencies and poor 
maintenance of episomal vectors. Episomal vectors also rely on constitutive expression of 
EBNA1 to maintain them in cells, which complicates EBNA1 functional studies. All of our 
lentiviral constructs were derived from the FTUG vector [483], which can be used to express 
Pol II driven genes by cloning the gene of interest into the original FTUG vector immediately 
downstream of the tet-on Trex promoter and then the whole expression cassette subcloned 
into the FH1t-UTG vector in place of the PacI-flanked H1t-shINSR expression cassette (see 
Figure 2.2). Alternatively Pol III transcribed genes can be cloned into an intermediate vector 
downstream of the human H1 promoter and then the whole expression cassette subcloned 
into the FH1t-UTG vector in place of the PacI-flanked H1t-shINSR expression cassette. All 
constructs were sequence verified before use. 
2.6.1 Generation of EBNA1 lentivirus 
FTrex-EBNA1-FLAG-UTG, a gift from Dr Graham Taylor, which contained the full length EBNA1 
sequence subcloned from pRTS-CD2-EBNA1-FLAG [499], was modified to include an optimised 
Kozac sequence and a 3’ polyA signal as protein expression from the unmodified vector was 
found to be poor (Tracey Haigh, unpublished). A schematic is shown in Figure 2.2-A. 
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2.6.2 Generation of FH1t-EBER-UTG lentiviruses 
Each EBER was amplified from B95.8 genomic DNA using primers to generate fragments of 167 
and 172 nucleotides corresponding to positions 6629-6796 and 6956-7128 of the prototypic 
EBV genome sequence (Genbank record AJ507799), respectively. These fragments were then 
cloned into a small plasmid downstream of a tet-on human H1 promoter and the expression 
cassette consisting of the EBER sequence and the H1 promoter was then cloned into the F-UTG 
lentiviral vector backbone (see Figure 2.2-B), which also expresses a tet-repressor and eGFP 
separated by a T2A sequence from a constitutively active ubiquitin promoter.  
2.6.3 The pEKS10 EBER plasmid 
The pEKS10 plasmid was generated by the Takada laboratory [310] in the following manner. A 
fragment of the pcDNA3 vector (Life Technologies) containing the neomycin (G418) resistance 
cassette was ligated to the SacI-EcoRI subfragment of the EcoRI K fragment of the Akata strain 
of EBV (Genbank reference KC207813.1) to give rise to pEK, which contains one copy of each 
EBER. Linker sequences containing a BglII or BamHI restriction site were then added to both 
ends of the SacI-EcoRI subfragment to allow successive additions of SacI-EcoRI subfragments 
by concatenation in a directional fashion to generate pEKS10 which contains 10 tandem 
repeats of the EBERs and surrounding sequence (6,297-7,325bp of KC207813.1). A schematic 
of pEKS10 is shown in Figure 2.2-C. 
2.6.4 Generation of BART lentiviruses 
Genomic fragments encoding the two clusters of miR BARTs were amplified from Raji genomic 
DNA, cloned into the FUTG vector and then subcloned along with the Trex promoter into the 
FH1t-UTG vector (Figure 2.2-D). Cluster 1 consisted of nucleotides 138997 to 140144 whilst 
Cluster 2 was comprised of nucleotides 145770 to 149022 of the EBV reference genome 
(AJ507799) using an identical strategy to that used by Pratt et al. [171]. 
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Figure 2.2 Schematics of plasmids used in this thesis 
 
A  FTrex-EBNA1-FLAG-UTG 
 
B  FH1t-EBER1-UTG, identical to the construct used to express EBER2 except for the 
gene of interest  
 
C  pEKS10 plasmid 
 
D  FTrex-BARTs cluster 1-UTG, identical to the construct used to express BARTs cluster 
2 except for the gene of interest 
 
E  FH1t-miR BART 5-UTG 
 
The control vector for all lentivirus experiments contained all backbone elements of 
the FUTG lentivirus but containing no gene of interest expression cassette which was 
generated by excising the PacI-PacI fragment of FH1t-shINSR-UTG and re-ligating the 
vector.  
The control vector for pEKS10 experiments was pcDNA3 containing a neomycin 
resistance cassette but no EBV DNA.  
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Figure 2.2 
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An EBV genome fragment encoding pre-miR BART 5 was amplified from Raji DNA using 
identical primers to those published by Choy et al. [365], which amplify a fragment 
corresponding to nucleotides 946-1196 of the BamHI A region of C666.1 (Accession no. 
EF102892) and introduce a termination sequence (AAAAAA) at the 3’ end. This fragment was 
cloned downstream of a tet-regulated version of the human H1 promoter and then subcloned 
along with the promoter into the FH1t-UTG vector (see Figure 2.2-E). 
2.6.5 BimS lentiviruses 
The human BimS-derived BH3 variant-expressing lentiviruses were a kind gift from Dr Toru 
Okamotu who cloned the BimS variants into the FTrex-UTG system. The BimS variants 
themselves are described in Table 2.3 and were generated by Lin Chen (BimS-wt, -Noxa, -Bad 
and -4e) and Erinna Lee (BimS-2a) and colleagues at the Walter and Eliza Hall Institute (WEHI) 
[423, 500]. 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.3 Details of BimS variant constructs cloned into the FTrex-UTG 
lentivirus system for functional BH3-induced cell death assays. 
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2.6.6 FTrex-BHRF1-UTG lentivirus 
The FTrex-BHRF1-UTG lentivirus was a kind gift from Rachael Cartlidge. It contains the coding 
region of BHRF1 amplified from the pRTS-CD2-BHRF1 vector [89], cloned into FUTG lentiviral 
backbone downstream of the Trex promoter and subcloned along with the promoter to create 
FTrex-BHRF1-UTG 
2.6.7 Akata-GFP2 recombinant EBV BAC 
The Akata virus genome was isolated from the Akata-BL cell line by Takada and colleagues as 
described by Kanda et al. [488]. The wt virus genome was engineered to contain an F-plasmid 
for replication and maintenance within E. coli. The BAC then had GFP and a G418 selection 
marker inserted into the genome at the BamHI X locus to give rise to the Akata-GFP2 BAC 
plasmid. 
2.6.8 CpWp-KO recombinant EBV BAC 
 
The CpWp-KO virus is derived from the 2089 EBV BAC [486], but contains deletions to disrupt 
viral gene expression driven from the Wp and Cp promoters. The virus construct was made 
from the 0W BAC [493], which completely lacks the BamHI-W repeats where Wp resides, by Dr 
Rosemary Tierney for use in an unrelated project [485]. In addition to lacking Wp, the CpWp-
KO BAC also contains a deletion spanning the entire Cp promoter (coordinates 10799 to 12190 
of Genbank reference genome NC-007605). All constructs were checked by BamHI restriction 
digest analysis before being cloned into 293 virus producer cells.  
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2.7 RNA analysis  
2.7.1 Preparation of purified RNA  
For total RNA purification, including small RNAs, 1-5x106 cells were harvested during 
exponential growth phase (24 hours after last subculture) and processed according to 
manufacturer’s instructions using the miRVANA RNA Extraction Kit (Ambion). Samples were 
eluted in DEPC-treated water and purity and concentration then measured using the 
Nanodrop 1000 (Thermo Scientific). RNA was stored at -80°C and kept on ice during use to 
prevent sample degradation. Where downstream applications required the use of DNA-free 
RNA (low density array cards or q-PCR to detect unspliced/single exon transcripts) purified 
RNA was treated with recombinant DNAseI (Ambion) according to the manufacturer’s 
instructions.  
2.7.2 Synthesis of randomly-primed cDNA 
RNA was reverse transcribed using the qScript cDNA SuperMix (Quanta Biosciences) which is a 
5x master mix containing qScript MMLV-derived reverse transcriptase, dNTPs, MgCl2, an 
RNAse inhibitor, and oligonucleotide primers. Each 20μl reaction contained 4μl SuperMix cDNA 
synthesis mastermix and 0.5-1μg RNA template. Reaction tubes were then incubated at 25°C 
for 5 minutes, followed by 42°C for 30 mins and 5 minutes at 85°C as per the manufacturer’s 
instructions. For q-PCR cDNA was diluted in DEPC water to a concentration equivalent to 5ng 
template RNA per microliter. For Low Density TaqMan Array cards 500ng of RNA template was 
used for cDNA synthesis in a 20μl reaction and diluted to 300μl. 
2.7.3 Synthesis of stem loop-primed cDNA for the detection of miRNAs 
Reverse transcription of miRNAs was carried out using the TaqMan microRNA Reverse 
Transcription Kit according to the manufacturer’s instructions. Briefly, for each miRNA to be 
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amplified, a master mix was prepared containing 0.15μl dNTPs, 1μl Multiscribe MuLV-derived 
reverse transcriptase, 1.5μl buffer 0.19μl RNAse inhibitor, 4.16μl DEPC water and 3μl miR-
specific RT primer per sample (allowing for error). Primers specific for each microRNA were 
supplied with TaqMan miRNA q-PCR assays, all other reagents were included in the kit. For 
each sample 5μl of template RNA diluted to 2ng/μl (a total of 10ng) added to 10μl of master 
mix and transcription was performed by incubating samples at 16°C followed by 42°C for 30 
minutes each, then at 85°C for 5 minutes.  
2.7.4 TaqMan q-PCR for EBV and cellular genes 
Quantitative PCR assays were carried out using an Applied Biosystems 7500 real-time PCR 
system (Life Technologies) in 96-well optical plates (Geneflow). Each reaction well contained 
1x TaqMan q-PCR master mix (Life Technologies), gene-specific primers and probes, 
endogenous control primers and probes and 5μl diluted cDNA in a 25μl total volume. All 
samples were plated out in duplicate or triplicate and mean and standard deviation calculated 
for each sample. All data were analysed using the ΔΔCt method relative to a reference sample 
that was known to express the gene of interest [501]. 
 
 
 
 
 
 
 
 
 
 Table 2.4 Details of inventoried q-PCR assays 
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Cellular q-PCR assays were purchased from Applied Biosystems, details of which can be found 
in Table 2.4. EBV gene assays were designed by Dr A Bell and are published elsewhere [90, 
317], except for the BZLF1, BHRF1 total mRNA, BARTs cluster 1 mRNA, BARTs cluster 2 mRNA 
LF1, LF2 and LF3 gene assays which were developed for this study and are described in Table 
2.5. Primer and probe sequences were designed using the Applied Biosystems custom assay 
tool and validated in-house according to published guidelines [502]. For quality control the R2 
value was checked over a serial dilution, where a value of >0.98 was deemed acceptable and 
no template, no RT, and no DNase controls were also included for all assays. Validation of all 
EBV assays for both mRNAs and microRNAs has been published (Bell 2006, Pol paper, Amoroso 
2011). All probes were labelled with FAM with a TAMRA quencher except for the GAPDH probe 
which was labelled with VIC to allow it to be multiplexed with FAM-labelled probes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 Details of unpublished, custom made q-PCR assays. Used to detect EBV-encoded 
transcripts as indicated, all sequences are in the 5’-3’ orientation 
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2.7.5 TaqMan q-PCR for miRNAs 
Quantitative PCR assays for microRNAs were also carried out using an Applied Biosystems 7500 
real-time PCR system (Life Technologies) in 96-well optical plates (Geneflow). Each reaction 
well contained 1x TaqMan q-PCR master mix (Life Technologies), Taqman micro-RNA specific 
stem-loop primers and probes or endogenous control primers and probes and 1.33μl undiluted 
miR-specific cDNA in 20μl total volume. All samples were plated out in duplicate or triplicate 
and mean and standard deviation calculated for each sample. All data were analysed using the 
ΔΔCt method relative to a reference sample that was known to express the miRNA of interest 
[503]. Assays for miRNAs were purchased from Applied Biosystems, details of which can be 
found in Table 2.6. All probes, including the RNU48 endogenous control probe, were labelled 
with FAM as these assays were not multiplexed.  
 
 
 
 
 
 
 
 
 
 
 Table 2.6 Details of commercially available EBV miR q-PCR assays used in this study 
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2.7.6 TaqMan human apoptosis low density q-PCR arrays  
Low-density q-PCR arrays for apoptosis-related human genes were carried out using TaqMan 
Low Density Array (TLDA) cards which are pre-loaded with 93 q-PCR assays to detect a panel of 
genes that are known to be important in controlling apoptosis and are reported to be 
transcriptionally regulated, together with 3 endogenous control genes (Life Technologies, part 
number 4378701). TDLAs work on the same principle as standard q-PCR but using far smaller 
volumes of samples and allowing transcription of 96 genes in 4 samples to be assayed on a 
single card, increasing the efficiency and cost effectiveness of the workflow. Each cDNA sample 
was generated as described in Section 2.7.2 and checked for quality using conventional q-PCR; 
comparing DNA-free cDNA to cDNA made from untreated RNA and a no RT control. Once 
verified, 2 x 100μl aliquots of the cDNA were pipetted into 2 adjacent loading ports (each port 
fills 48 wells and so supplies sample to only half of the 96 genes) and a total of 200ng template 
RNA was used per sample. Samples were evenly distributed into wells by centrifugation as per 
the manufacturer’s guidelines, checked for even filling and sealed, before running on the 
Applied Biosystems 7900HT real time PCR system (Life Technologies). All apoptosis gene arrays 
were carried out on three EBV-positive and 3 EBV-loss clones and samples from all six clones in 
all three independent experiments were run in duplicate. 
Data were collected using SDS software v2.4.1 (Life Technologies) and analysed with DataAssist 
software v3.01 (Life Technologies) using the ΔΔCt relative quantitation method [501]. Gene 
expression data were normalised to the mean of GAPDH and ACTB, (the third endogenous 
control, 18S, was not used as it was expressed at levels far in excess of any other transcript in 
our samples) and the calibrator sample was untreated EBV-positive Kem clone P1 cells or the 
mean of the three untreated EBV-positive clones, depending on whether a grouped or 
individual analysis was being carried out. The fold-change cut off used for classifying a gene as 
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differentially regulated between two samples or groups was 2 and the significance cut off was 
p=0.05.  
2.7.7 Fluidigm viral gene expression q-PCR Arrays 
Rather than running a large number of individual assays for EBV gene expression in xenograft 
tumour samples and some cell lines, 48 EBV transcript-specific assays and endogenous controls 
were loaded onto Fluidigm Dynamic Array microfluidic chips. These chips can be used to 
quantitate expression of all 48 transcripts of interest in up to 48 samples simultaneously. In 
addition, we used a plasmid containing DNA amplicons complementary to all 48 assays to 
allow us to absolutely quantitate the number of each of the 48 transcripts present in each 
sample. The use of this method for high throughput analysis of EBV gene expression in a range 
of samples is described in detail elsewhere [175], but is essentially similar to conventional q-
PCR except that cDNA undergoes 14 rounds of pre-amplification in the presence of primers 
specific to each of the 48 assays loaded onto the card. Pre-amplification is necessary due to 
the very small amounts of template RNA used per sample. For each assay, linearity of control 
DNA over a range of dilutions was confirmed. 
2.7.8 Northern blotting 
RNA was isolated using Trizol reagent (Life Technologies) according to the manufacturer’s 
instructions and separated on 6% TBE-Urea pre-cast gels in TBE buffer (Life Technologies) 
followed by semi-dry blotting onto nylon membranes (Amersham). RNA loading was checked 
by UV-visualisation of ethidium bromide stained gels.  Radiolabelled DNA probes were 
generated by PCR amplification of the EcoRI-J fragment of the EBV   genome   using   forward    
primer    5′-TGCTAGGGAGGAGACGTGTGT   and   reverse   primer 
 3′-GAATCCTGACTTGCAAATGCTCTA in the presence of 32P labelled dCTP (Hartmann Analytic), 
followed by column purification and nick translation (Roche). Probe hybridisation and washes 
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were carried out using the XpressHyb system, (Clontech) according to the manufacturer’s 
instructions. Exposures were carried out at -80°C for 1-14 days. 
2.7.9 EBER in-situ hybridisation (ISH) 
EBER expression at the single cell level cells were analysed using a FITC-conjugated EBER probe 
which was hybridised to permeablised cells in solution and then analysed by flow cytometry. 
For each assay, 1x106 PFA-fixed cells were permeabilised by 15 minute incubation in 50µl of 
0.5% Tween 20 in phosphate-buffered saline (PBS), and then washed in 200µl formamide 
buffer (75µl formamide, 10mM NaCl, 5mM Na2EDTA and 50mM Tric-HCl, pH7.5) to maximise 
probe binding. Cells were then resuspended in 50µl EBER-PNA probe solution (Dako) and 
hybridised at 56°C for 1 hour. Following hybridisation, cells were washed twice for 10 minutes 
at 56°C in 1ml 0.5% Tween 20 in PBS to remove any unbound probe and then resuspended in 
1ml PBS supplemented with 2% FCS and 1mM EDTA, placed on ice and analysed immediately 
on an Accuri C6 flow cytometer (Becton Dickinson).  
For each sample a minimum of 5,000 events were recorded and analysis carried out using 
Accuri C6 software. Gating was set to exclude dead cells, debris and doublets and remaining 
events were plotted on a histogram compared to negative control samples (both control probe 
stained EBV-positive and EBV negative cells) to determine the percentage of EBER-expressing 
cells.    
 
2.8 Protein analysis 
2.8.1 Protein preparation 
For Western blot analysis, 5-10x106 cells were harvested, washed in PBS and then lysed in 9M 
urea buffered with 50mM Tris pH 7.5 on ice. Samples were then homogenised for 30 seconds 
each by sonication (QSonica, model CL-18) to shear DNA and cell debris. Samples were titrated 
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against bovine serum albumin (BSA) standards of known concentration and quantitated using 
a BioRad DC colorimetric assay kit according to the manufacturer’s instructions. Cell lysates 
were diluted to 0.5-2mg/ml in urea gel sample buffer (U-GSB) (5M Urea, 10% glycerol, 5% β-
mercaptoethanol, 4%  SDS, 62.5mM Tris pH6.8 and 0.01% bromophenol blue), denatured for 5 
minutes at 100°C, and stored at -20°C until needed.  
2.8.2 SDS-PAGE / Western Blotting 
Proteins were separated on pre-cast 4-12% Bis-Tris gels (Life Technologies) in MES buffer 
(comprising 50mM 2-[N-morpholino]-ethanesulphonic acid (MES), 50mM Tris base, 1mM EDTA 
and 0.1% (w/v) SDS, pH 7.3) at 100 volts until the dye front had migrated almost the whole 
length of the gel (around 100 minutes). Wells were loaded with 20µg of protein or 10µl of 
prestained size markers (SeeBlue 2.0 Plus, Life Technologies). Proteins were blotted onto 
methanol-activated PVDF membranes in an XCell blotting module (Life Technologies) filled 
with blotting buffer (25mM Tris base, 192mM glycine and 20% v/v methanol). The reservoir 
around the blotting module was filled with water to keep the apparatus cool during blotting, 
which was carried out for 100 minutes at 30 volts.  
After blotting, non-specific protein binding was blocked by incubating membranes in 5% non-
fat milk diluted in PBS containing 0.1% Tween-20 (PBS-T) for 1 hour at room temperature. 
Primary antibodies were diluted in blocking buffer and bound overnight at 4°C, except for the 
loading controls, β-actin and calregulin, which were incubated at room temperature for 1 
hour. All primary antibodies are described in Table 2.7, those specific to EBV proteins are 
described in the following publications; BHRF1 [504], EBNAs 1 and 2 [505], LMP1 [506]. 
Membranes were thoroughly washed (6 PBS-T washes over 1 hour) in PBS-T and then 
incubated with horseradish peroxidase-conjugated secondary antibodies, (all from Sigma) 
diluted 1/1000 in blocking buffer, for 1-2 hours at room temperature, and finally thoroughly 
washed again. 
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Table 2.7 Details of primary antibodies used for Western blotting 
*All determined empirically as antibody concentrations vary between 
preparations 
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Chemiluminescence was detected by applying Enhanced ECL solution (GE Healthcare) and 
exposing membranes to autoradiography film for 1-20 minutes or using the BioRad ChemiDoc 
MP imaging system, which was also used to carry out densitometry calculations. Since 
traditional films can also be imaged and processed on the ChemiDoc MP, it was also used to 
determine band sizes as details of the ladder being used can be programmed in and then 
protein sizes calculated using point-to-point (semi-log) regression. 
For total protein analysis gels were stained in 0.1% Coomassie Blue R250 in 50% methanol, 
40% ddH20 and 10% acetic acid for 60 minutes and then destained in 50% methanol, 40% 
ddH20 and 10% acetic acid over 3 hours with 3 changes of the solvent solution and then gels 
were photographed.  
2.8.3 Immunofluorescence (IF) staining 
Cells were harvested during log growth phase, washed in PBS, resuspended at 10x106/ml and 
spotted onto slides (SM011, Hendley-Essex). Slides were air dried, fixed in pre-cooled 1:1 
methanol:acetone for 10 minutes at -20°C, and then dried again before adding BZLF1 primary 
mouse monoclonal antibody [135], diluted to 0.2µg/ml in PBS containing 10% heat-inactivated 
goat serum (HINGS). Both primary and secondary incubations were carried out in a sealed, 
humidified atmosphere at 37°C for 1 hour. After primary antibody binding, cells were washed 
twice in PBS, air dried, and then Alexa Fluor 488-conjugated α-mouse secondary antibody (Life 
Technologies) was applied at 1/1000 in 10% HINGS PBS. Slides were incubated for a further 
hour, washed in PBS twice and air dried. Finally, a drop of 1,4-diazabicyclo[2.2.2]octane 
(DABCO) mounting medium was applied to each dot, and a cover slip placed over the stained 
cells. Slides were viewed and photographed using a Nikon E600 fluorescence microscope and 
each experiment included positive and negative control cells, including a positive control cell 
line incubated with secondary antibody only.  
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2.8.4 CD19 FACS Staining 
To detect the proportion of human cells in single cell suspensions of murine xenograft 
tumours, cells were stained for human CD19 and analysed by fluorescence-activated cell 
sorting (FACS).  Most samples were analysed immediately after harvesting, but a small number 
had previously been cultured for up to 24 hours. There was no detectable difference in the 
proportion of cells which stained positive for CD19 regardless of whether they were freshly 
isolated or previously cultured. Briefly, 1x106 cells were washed twice in PBS and resuspended 
at 10x106/ml in Fc block (BD Pharmingen) diluted 1/100 in FACS buffer (1xPBS, 2% FCS, 1mM 
EDTA) and incubated for 20 minutes on ice. Cells were then spun down for 5 minutes at 
1500rpm, then resuspended in FITC-conjugated CD19 antibody (clone HIB19, BD Pharmingen) 
diluted 1/20 in ice cold FACS buffer. Staining was carried out at room temperature for 30 
minutes in the dark. Finally, cells were washed twice in ice cold FACS buffer and resuspended 
in 100µl FACS buffer containing 1µg/ml PI and analysed immediately on an LSRI flow cytometer 
(Becton Dickinson). Cells were gated to exclude dead cells and debris (PI positive) and then the 
percentage of FITC-CD19 positive cells was determined on a histogram compared to unstained 
control cells. As an additional control murine B lymphoma cells were confirmed to be negative 
for human CD19 staining using this protocol. We recorded a minimum of 5,000 events per 
sample and data analysis was carried out using FlowJo software (Treestar).  
2.8.5 Cell sorting 
In order to generate cell lines in which every cell carries a vector or recombinant virus of 
interest cultures were sorted for GFP, which was constitutively expressed in the majority of the 
constructs used in this thesis (see Section 2.1.4). Cells were washed in PBS, resuspended at 
25x106/ml in sorting medium (2% FCS, 16µg/ml gentamycin in PBS) and passed through a 
50µm cell filter before being placed on ice and taken for processing to the cell sorting facility at 
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either the University of Birmingham or WEHI, depending on where the experiments were 
carried out. Cells transduced with lentiviruses required at least two rounds of sorting several 
days apart to enrich for cells expressing the highest possible levels of GFP, and related samples 
(i.e. empty control and gene of interest in the same background) had identical gates applied to 
them. The purity of the collected cells was generally found to be around 98% (+/-2%). 
 
2.9 Reporter assays 
For each assay, 1x107 EBNA1-transduced or control cells were transfected by electroporation 
at 270V, 950µF in 4mm cuvettes (Geneflow) with 10µg FR-tk-luciferase and 1µg Renilla vector 
in order to normalise for transfection efficiency in the presence of 1µg/ml DOX or DMSO as a 
control. Renilla-only controls were also included. At 24 hours after transfection cells were 
harvested, lysed and analysed for luciferase and Renilla expression using the Dual-Luciferase 
Reporter Assay System (Promega) according to the manufacturer’s instructions. Briefly, 1x106 
cells per experimental condition were lysed in passive lysis buffer for 15 minutes at room 
temperature with vigorous shaking before being transferred to 96 well plates. Stop and Glow 
reagents (50µl of each) were added to wells at 1 minute intervals by automated injectors and 
read on an Orion-L luminometer (Berthold). All transfections were carried out in triplicate.  
 
2.10 Animal Work 
2.10.1 Xenografts 
Mice used for xenografts were of the NOD.Cg-Prkdcscidil2rgtm1Wjl/SzJ strain (more commonly 
referred to as NOD/SCID/IL2RγKO or NSG) originally developed by the Jackson Lab [507, 508]. 
Single cell suspensions of 5x104-1x107 BL cells in a 200µl volume of PBS were injected into the 
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peritoneum of 8 week-old recipient NSG mice by trained animal technicians. Mice were then 
palpated to determine tumour growth 3-4 times weekly and were sacrificed when total 
tumour burden reached approximately 1cm3 in accordance with Walter and Eliza Hall Institute 
(WEHI) Animal Ethics Committee Guidelines. Monitoring continued for up to 250 days at which 
point any remaining mice were discarded.  
One animal developed lameness that was unrelated to the xenograft and so was sacrificed and 
excluded from the study and in an additional animal we found that viral gene expression had 
changed in vivo from Latency I to Latency III and therefore this animal was also excluded. 
Kaplan-Meier plots and log-rank tests to compare the survival of mice injected with different 
clones were carried out using Graphpad Prism™ 5.0 software. 
2.10.2 Histology 
Tumours, sternum, spine, heart, pancreas, kidneys, liver, lungs, spleen, and lymph nodes (if 
enlarged) were removed post-mortem and fixed in 10% Formalin. Preserved material was then 
sectioned, mounted on slides and H&E stained by the WEHI Histology Department. Analysis of 
H&E stained sections was carried out by haematologist Dr Brandon Aubrey at WEHI. Ki67 
staining was carried out by Dr Claudia Roberts in the Department of Cellular Pathology, Queen 
Elizabeth Hospital, Birmingham.   
2.10.3 Ex vivo cell culture 
Tumour samples were also harvested from mice for ex vivo characterisation; tissue was 
harvested into a small volume of ice cold medium, passed through a 100µm cell strainer 
(Falcon) and then filtered through a sterile cotton wool plug to create a single cell suspension. 
Several aliquots of these cells were immediately frozen and the remaining cells were washed 
in PBS, resuspended in fresh, warmed medium and placed into culture. Routine cell culture 
and cell freezing was carried out as described in Section 2.1.1.  
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3. Results Part I                                                                                       
ISOLATING AND CHARACTERISING EBV-LOSS CLONES 
3.1 Introduction 
In the 50 years since EBV was first associated with BL there have been many investigations into 
the role of the virus within the tumour cells. However, it is still not clear exactly how the virus 
contributes [509]. In 1994, the Takada group reported the spontaneous loss of EBV from EBV-
positive Akata-BL [309], allowing for comparison of isogenic tumour cells which either contain 
or have lost the virus. This model offers significant advantages over comparisons of EBV-
negative BLs to their EBV-infected counterparts because EBV-negative tumours may have 
cellular mutations that substitute for the presence of EBV compared to EBV-positive tumours. 
It is surprising then, that this phenomenon has only been reported in two additional BL cell 
lines, Mutu-BL and Awia-BL, to date [178, 341]. The Awia-BL cell line and its clones were 
generated from a panel of BL biopsies collected here in Birmingham during the 1980’s and 
1990’s from which a number of well-characterised BL cell lines have been generated (see 
Section 2.1.1). Therefore the Birmingham group initiated a project seeking to generate 
spontaneous EBV-loss clones from a panel of 12 EBV positive BL cell lines derived from our 
collection of biopsies. 
We also considered other approaches; treatment with hydroxyurea or a dominant negative 
EBNA1 (dnEBNA1) can expel the viral genome from EBV-positive BL cells [299, 311]. However,  
hydroxyurea is known to inhibit DNA synthesis and DNA damage repair [510], causing the 
accumulation of double strand breaks [511], and treating cells with dnEBNA1 or drugs to 
inhibit EBNA1 is highly toxic to BL cells [99, 182]. Therefore we were concerned that it would 
be difficult to isolate EBV-positive and EBV-loss clones from cultures undergoing high rates of 
apoptosis and that clones that were recovered might be phenotypically different to the 
parental BL. Consequently we chose to isolate EBV-loss clones by single cell cloning. 
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Figure 3.1 Workflow of experiments carried out to isolate and characterise BL clones 
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By comparing a panel of EBV-loss cells to their EBV-positive counterparts from the same 
patient we aimed to resolve conflicting reports in the literature about the possible anti-
apoptotic role(s) of EBV in BL and the mechanisms by which the virus may act [99, 323, 326, 
341, 512]. We were also interested to determine how widely the phenomenon of EBV-loss 
occurs, as this may provide insights into the pathogenesis and maintenance of BL tumours in 
vivo. The single cell cloning protocol used is detailed in Section 2.1.2 and the workflow of these 
experiments is depicted in Figure 3.1. Briefly, single cells from each BL cell line were expanded 
in 96-well plates and then a sample taken to analyse by q-PCR once cells from each clone had 
become numerous enough to determine the average viral genome load. Clones found to have 
no detectable EBV DNA were then selected for further expansion and analysis, as were a 
selection of EBV-positive clones which contained a similar viral load to the parental EBV-
positive line. In this study we have generated several hundred BL clones in addition to those 
generated by previous members of this research group, screened for EBV-loss and then 
characterised the viral gene expression and apoptosis phenotype of selected clones.  In order 
to gain a more detailed insight into the role of EBV in BL we have also studied the role of pro-
survival signals in the mechanism of EBV-loss from BL cells and compared the tumorigenicity of 
EBV-positive and loss clones in vivo. 
 
3.2 Single cell cloning of EBV-positive BL cell lines 
3.2.1 Generating EBV-loss clones from EBV-positive BL cell lines 
Our single cell cloning experiments showed that the average EBV genome load in single cell 
clones can vary greatly from zero to hundreds of copies per cell. Figure 3.2 shows the genome 
loads determined for clones of Kem-BL that were generated and tested as part of a single 
experiment. Interestingly, for the cell lines analysed in this study, the mean viral load of clones 
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generated in a single experiment was similar to the viral load of the parental cell line from 
which the clones were derived. For instance, in the example shown, the average viral load of 
the parental cell line, Kem-BL, is around 37 genomes per cell – shown as a blue dashed line on 
Figure 3.2-A, whilst the mean of all of the clones in this experiment was found to be 54, shown 
as an orange dashed line. This variation in viral load supports the theory that EBNA1 is not 
totally efficient at tethering viral genomes to sister chromatids evenly. Data to support this 
was first published by the Sugden group [295] and corroborated by a previous member of this 
group who found unequal numbers of genomes in sister cells undergoing mitosis by in situ 
hybridisation (Regina Feederle, unpublished). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Example of average viral loads in single cell clones of Kem-BL 
 
Whole cell lysates from single cell clones generated in a single experiment were 
subjected to DNA q-PCR as described in Section 2.3.2 
 
Blue dashed line – average viral load of parental cell line 
Orange dashed line – average viral load of clones in this experiment 
Kem-BL single cell clones 
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In total we have screened 1,820 single cell clones as part of this project, around 500 of which 
were generated as part of my thesis; a summary of all the single cell cloning experiments 
performed by myself and by previous members of the group (Drs Andrew Boyce and Gemma 
Kelly) is shown in Table 3.1. Overall, we found that EBV-loss was rare, only 3.4% of clones 
screened had lost the virus, and the vast majority of these were isolated from a single tumour 
background, Elijah-BL (Eli-BL). Although there was substantial variation in the rate of EBV-loss 
between individual cell lines, we did find that Akata-BL gave rise to EBV-loss clones at a similar 
rate to that reported by Takada et al. [310]. 
Three of the BL cell lines cloned (Avako-BL, Salina-BL and Oku-BL) exhibit Wp-restricted 
Latency, in which high levels of the anti-apoptotic viral Bcl-2 homologue, BHRF1, are expressed 
[89]. Of 365 Wp-restricted clones screened only a single clone of Avako-BL, which later died 
before a cell line could be established, had lost the virus, which may indicate that these BL cells 
are unable to tolerate EBV-loss. This may be due to addiction to BHRF1, similar to the addiction 
to cellular pro-survival oncogenes that has been described in a number of other tumours [513, 
514]. The parental Awia-BL cell line is also predominantly comprised of cells expressing Wp-
restricted Latency, but is unique in that the biopsy appeared to be heterogeneous for EBV 
antigen expression at the single cell level. Awia-BL gave rise to rare Latency I and 
EBNA2+ve/LMP1-ve clones in early passage in addition to 2 EBV-loss clones [178]. Of the 
remaining BLs, only Mutu-BL, which was cloned at passage 4, gave rise to EBV-loss clones 
during early or intermediate passage (<40 passages); Akata-BL, Kem-BL and Elijah-BL only 
yielded loss clones at very late passage (120-200 passages). These data suggest that retention 
of the virus is also highly selected for in Latency I BLs in the absence of a viral Bcl-2 homologue. 
3.2.2 Viral transcription in BL clones 
It is well documented that viral gene expression in EBV-positive Latency I BL cells can ‘drift’ to 
the growth transforming Latency III programme in culture [505] therefore, we screened our  
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single cell clones for expression levels of a number of viral transcripts by q-PCR. All EBV-
positive clones were profiled before further use and representative results from these 
experiments are shown in Figures 3.3 and 3.4. For each individual viral gene ΔCt values were 
normalised to the housekeeping gene GAPDH to control for variation in the amount of cDNA in 
the sample and then expressed relative to a reference cell line that is known to express the 
viral gene of interest. This means that if the gene is ‘on’ it will have a relative quantity close to 
or in excess of 1 and genes that are ‘off’ will have a relative quantity of close to zero. We 
wanted to determine how Latency I-like our EBV-positive clones were and so Qp-driven EBNA1 
transcripts were expressed relative to Kem-BL; a stable uncloned Latency I Burkitt, whilst 
Table 3.1 Compiled data from all BL single cell cloning carried out by this group  
 
 
Cell lines in shaded section express a Wp-restricted pattern of Latency  
EBV-loss frequencies are highlighted in red, except for the single loss clone of 
Avako-BL which was excluded because it did not survive  
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Latency III-associated genes (EBNA2, BHRF1 and LMP1) were expressed relative to X50-7, an 
LCL.  
EBERs are highly expressed in all BLs so they were also normalised to Kem-BL, but were not 
used to discriminate between Latency types. Whilst there was some variation in absolute 
expression levels between BL backgrounds and clones, the majority of EBV-positive clones 
derived from Latency I parental cell lines clearly expressed a Latency I genotype (Figure 3.3). 
The same was true of lytic transcripts; levels of BZLF1 in EBV-positive clones were compared to 
Kem-BL and 100% BZLF1-positive AKBM cells (Figure 3.4), showing that EBV-positive clones 
exhibited similar low levels of lytic activity to parental Latency I cells.  Occasionally clones of 
Mutu-BL did drift to Latency III, as shown in Figure 3.3-D, and these clones were removed from 
further analysis. As might be expected, the change in gene expression was accompanied by a 
change in phenotype, with the cells becoming lymphoblast-like in their size, shape and 
adherence to one another, so these clones were easy to detect. EBV-loss clones were also 
assayed for the presence of viral transcripts, both immediately after isolation and consistently 
showed no evidence of viral gene expression. 
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Figure 3.3 Transcription of viral gene products in EBV-positive BL clones 
 
All values were calculated using the ΔΔCt method, normalised to the housekeeping 
gene GAPDH, and the expressed relative to either Kem-BL (EBER1, EBER2, EBNA1 (Qp-
driven)) or X50-7 (EBNA2, BHRF1, LMP1). Using this system, a value of ~1 for EBNA1 
with very low or undetectable levels of  and would suggest the EBNA2, BHRF1 LMP1 
cells being analysed express a ‘typical’ Latency I gene expression pattern.  are EBERs
highly expressed in all BLs, but levels vary between cell lines so their expression is not 
an indicator of Latency type.  All q-PCR assays were carried out in duplicate.  
 
A EBV-positive clone of Akata-BL (Latency I) 
 
B EBV-positive clone of Kem-BL (Latency I) 
 
C EBV-positive clone of Mutu-BL (Latency I) 
 
D EBV-positive clone of Mutu-BL that has drifted and is expressing the Latency III-
associated genes, EBNA2, BHRF1 and LMP1 
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 Figure 3.3 
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3.2.3 Viral protein expression in BL clones 
Although q-PCR provides a quick, convenient and quantifiable method to determine the 
expression of a wide range of viral transcripts it can be difficult to interpret results where 
transcription of a gene is low but not absent, as the consequence of this for coding genes also 
depends upon how efficiently the message is translated and the half-life of the protein. 
Therefore we also characterised viral gene expression at the protein level in our EBV-positive 
clones. A Western blot of EBNA1 expression in EBV-positive and loss clones of 4 of the 5 BLs 
that yielded loss clones is shown in Figure 3.5-A, confirming that all cells found to be EBV 
negative by DNA q-PCR also contained no viral protein. To verify our q-PCR data we also 
blotted for EBNA2 and LMP1 proteins and found that both were undetectable in EBV-positive 
clones that exhibited a Latency I transcriptional profile. Example blots carried out on clones of 
Awia-BL are shown in Figure 3.5-B. 
Figure 3.4 BZLF1 transcription in EBV-positive BL clones 
 
Due to the magnitude of difference in BZLF1 expression between lytic and latent cells 
relative expression values are shown on a log2 scale relative to lytic AKBM cells that 
have been sorted for BZLF1 protein positivity and therefore are presumably 100% 
positive for BZLF1 transcript.  
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3.2.4 Viral RNA expression in single cells 
As we were interested in whether there was a difference in apoptosis protection between 
EBV-positive and loss cells we needed to be certain that all of our EBV-positive cell lines 
contained virus in every cell and were not a mixture of EBV-positive and loss cells, as this may 
Figure 3.5 Viral protein expression in BL clones 
 
A  EBNA1 blot confirming EBV-positive clones (P1-P2) of Akata-BL, Mutu-BL, Elijah-BL 
and Kem-BL express the viral maintenance protein EBNA1, whilst loss clones (n1-n2) 
are EBNA1 negative. EBNA1 Western blots were carried out on all clones used in this 
study 
 
B  Western blot of EBV protein expression in clones of Awia-BL confirming that EBV-
positive clones express a Latency I phenotype; i.e., EBNA1 in the absence of EBNA2 
and LMP1 
 
55kDa 
42kDa 
55kDa 
73kDa 
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69kDa 
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mask any EBV-associated phenotype. Therefore, we carried out fluorescence in situ 
hybridisation (F-ISH) on our BL cell lines using an EBER-specific synthetic peptide nucleic acid 
(PNA) probe to check for EBER expression at the single cell level. 
We found that EBV-positive clones of Akata-BL, Awia-BL, Elijah-BL, Kem-BL and Mutu-BL were 
>99% positive for EBER expression by FACS whilst EBV-loss clones were completely negative 
compared to cells that had never contained virus (Figure 3.6).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 EBER FACS in BL clones 
Examples of EBV-positive and loss clones of Akata-BL, Kem-BL and Mutu-BL stained with 
a FITC-conjugated EBER-PNA probe. BL cells that have never contained EBV (BL2 cell 
line) and EBV-positive cells stained with a negative control probe (control PNA probe) 
are shown as negative controls.  
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3.3 Investigating the response of BL clones to apoptosis inducers 
3.3.1 Etoposide and α-IgM: DNA damage response versus BCR crosslinking 
EBV has previously been shown to confer protection against α-IgM-induced apoptosis in 
Latency I clones of Awia-BL compared to EBV-loss clones [178] and so we wanted to 
investigate whether this finding held true for EBV-loss clones derived from other tumours. 
Since Akata-BL is surface IgM negative [130] we carried out apoptosis assays on α-IgM-treated 
clones of Kem-BL and Mutu-BL as well as Awia-BL (Figure 3.7-A). We found that EBV 
consistently provided protection to Latency I BL clones compared to their EBV-loss 
counterparts in all three tumour backgrounds. Although there was some variability between 
experiments, tumour backgrounds and clones in the precise amount of apoptosis induced, α-
IgM was generally found to cause around twice as much cell death in EBV-loss clones versus 
EBV-positive clones.  
Etoposide causes apoptosis by disrupting DNA replication leading to the accumulation of single 
and double strand breaks, leading to induction of the DNA-damage response [515]. It is also a 
commonly used chemotherapeutic agent which can be effective in treating non-Hodgkin’s 
lymphomas [516]. Therefore we were interested to determine whether EBV can protect 
Latency I BL clones from Etoposide-induced apoptosis. In Akata-BL clones Etoposide induced a 
similar amount of cell killing in all clones tested, whereas the amount of cell death induced 
varied between clones of Kem-BL and Mutu-BL (Figure 3.7-B). In all cases there was no 
discernible protection conferred by the presence of the virus, and in fact, EBV-loss clones of 
Kem-BL were less susceptible to cell death than were their EBV-positive counterparts.  
Crosslinking of surface IgM on resting B cells and lymphoma cell lines induces apoptosis via the 
hydrolysis of phosphoinositide and subsequent release of calcium from intracellular stores, 
leading to activation of Caspase-2 and -9, followed by the executioner protein Caspase-3 [517]. 
Anti-IgM treatment therefore induces apoptosis via the intrinsic apoptosis pathway. 
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Figure 3.7 Sensitivity of BL clones to α-IgM and Etoposide  
 
A  Example data of EBV-positive and loss clones of Awia-BL, Kem-BL and Mutu-BL 
treated with 10ng/ml α-IgM for 72 hours 
 
B Example data of EBV-positive and loss clones of Awia-BL, Kem-BL and Mutu-BL 
treated with Etoposide at two concentrations (25 or 50nM, as indicated on the X-axis) 
for 24 hours. 
 
Representative data from assays carried out in triplicate on three occasions. 
Appropriate drug doses were determined by titration of drugs onto cells which was 
carried out by Dr Gemma Kelly before this project was initiated [178] and unpublished 
data. Cell viability was determined by FACS staining for Annexin V-FITC and PI. 
Statistical comparisons were carried out using a Students T-test. 
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In contrast, Etoposide poisons the topoisomerase II enzyme, which can snip and unwind 
tangled DNA, causing a build-up of the enzyme on the DNA and an accumulation of strand 
breaks. When the cell then attempts to replicate and topoisomerase II is removed from DNA 
the genome is irreparably damaged and the cell dies via the DNA-damage response by 
induction of p53-signalling pathways [493, 518]. Given the difference in the mechanisms of 
action of these drugs and the knowledge that p53 function is abrogated in many BLs, including 
those included in this study [260], we hypothesised that EBV protects BL cells in a p53 
independent manner via the intrinsic apoptosis pathway.  
3.3.2 Ionomycin: a second calcium-dependent intrinsic apoptosis inducer 
Like IgM crosslinking, ionomycin-treatment of BLs and other immature B-cell derived cell lines 
induces intracellular calcium release and activation of several caspases including Caspase-9 
and -3 [519, 520]. Therefore we carried out experiments on ionomycin-treated, paired EBV-
positive and loss BL clones to see whether EBV could confer protection to a death inducer that 
is functionally similar to IgM crosslinking.  
We have also used ionomycin to induce apoptosis in previous studies where we examined the 
anti-apoptotic properties of BHRF1 in BL cells [178], which allowed us to infer the appropriate 
concentrations of drug to use. Our criteria were to use a dose at which the majority, but not 
all, of the EBV-loss cells underwent apoptosis in order to be able to clearly detect a difference 
between EBV-positive and loss cells.  
In the four BL backgrounds tested in this study (Akata-BL, Kem-BL, Mutu-BL and Awia-BL) we 
found that ionomycin consistently induced significantly less cell death in EBV-positive clones 
compared to those than had lost the virus (Figure 3.8). Although we saw some variation, and 
the difference was less marked at higher drug concentrations, we found that levels of 
apoptosis in EBV-loss cells were generally more than double that seen in corresponding EBV-
positive clones. 
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Figure 3.8 Sensitivity of BL clones to ionomycin 
 
A Akata-BL clones + 1μg/ml ionomycin    B Kem-BL clones + 1μg/ml ionomycin  
C Mutu-BL clones + 2μg/ml ionomycin   D Awia-BL clones + 0.75μg/ml ionomycin 
 
All ionomycin treated cells were harvested for analysis 48 hours after assay set up  
Representative data from assays carried out in triplicate on at least three occasions 
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3.3.3 Roscovitine and Staurosporine 
Roscovitine is a cyclin dependent kinase (CDK) inhibitor which disrupts the progression of the 
cell cycle therefore inducing cell death. In a number of tumour cell lines this has been shown 
to occur via the intrinsic apoptosis pathway [521]. The exact mechanism(s) of Roscovitine-
induced apoptosis are not yet clear, however it is clearly able to regulate the expression of a 
number of Bcl-2 family members [522, 523], and it has also been reported to directly inhibit 
EBNA-1 leading to EBV episome loss and apoptosis in BL cells [524]. We therefore compared 
the apoptosis phenotype of our BL clones after Roscovitine treatment and found that EBV-loss 
cells were consistently more susceptible to Roscovitine-induced apoptosis than were EBV-
positive cells (Figure 3.9-A). Interestingly, the difference between positive and loss clones was 
less pronounced than the α-IgM or ionomycin-induced phenotype, an observation that was 
found to hold true at two different concentrations of Roscovitine (data not shown).  
Staurosporine is a potent inhibitor of a wide variety of protein kinases and can induce 
apoptosis via both the extrinsic and intrinsic pathways [525]. Although the precise 
mechanism(s) of action are not yet clear Staurosporine has also been shown to regulate a 
number of Bcl-2 family members including Puma, Bcl-2, Bcl-XL and Noxa in a variety of cell 
types [445, 526, 527] including BLs [419]. Like Roscovitine, Staurosporine consistently induced 
more cell death in BL clones that had lost the virus than in EBV-positive cells, although again 
the phenotype was less pronounced than for α-IgM or ionomycin (Figure 3.9-B). 
3.3.4 Cell death inhibitors 
To further investigate our finding that Latency I EBV inhibits the intrinsic apoptosis pathway we 
compared the response of EBV-positive and loss clones to two different inhibitors of cell death 
after treatment with an apoptosis inducer. Ionomycin induced the greatest degree of cell 
death in EBV-loss clones compared to EBV-positive counterparts and so it was used to induce  
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cell death in these experiments. Q-VD.OPh is a broad-spectrum caspase inhibitor which can 
block the cleavage of executioner Caspases 3 and 7 as well as several of those upstream [528], 
whilst Necrostatin is an inhibitor of RIPK1 [529]. RIPK1 is a key signalling molecule that is able 
to initiate apoptosis as well as alternative forms of cell death including necrosis and 
necroptosis [530], which can also be induced by calcium activation of calpains [531, 532]. The 
drug concentrations used in these experiments were chosen from published work looking at 
Figure 3.9 Sensitivity of BL clones to Roscovitine and Staurosporine 
 
A  Example data of BL clones treated with 50μM Roscovitine for 48 hours 
B  Example data of BL clones treated with 250nM Staurosporine for 24 hours 
 
Representative data from assays carried out in triplicate on three occasions 
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the effect of these inhibitors in Hodgkin and Burkitt lymphoma cell lines respectively [301, 
533]. We found that whilst Q-VD.OPh was able to completely block ionomycin-induced cell 
death in Kem-BL clones Necrostatin had no discernable effect (Figure 3.10-A and 3.10-B), 
which supports our previous findings that BL cells are dying via caspase-mediated intrinsic 
apoptosis and allows us to rule out RIPK-1-dependent pathways to cell death as a target for 
EBV in BL cells. Consistent with our apoptosis data we were unable to detect cleavage of 
Caspase-3, -7 or -9 in cells treated with both Q-VD.OPh and ionomycin, whereas we did see 
cleavage of these proteins in cells treated with ionomycin only. Since we found no difference 
in the apoptosis phenotype of BL clones in the presence or absence of Necrostatin we did not 
confirm that RIPK1 was inhibited in these assays.  
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Figure 3.10 Ability of cell death inhibitors to block ionomycin-induced killing 
 
A  Example data of Kem-BL clones treated with 1μg/ml ionomycin and 25μM Q-VD-OPh for 48 
hours 
 
B  Example data of Kem-BL clones treated with 1μg/ml ionomycin and 30μM Necrostatin-1 
for 48 hours 
 
C Caspase-7 expression and cleavage in Kem-BL clones, clones used were P1 and n1, all cells 
were treated with 1μg/ml Ionomycin in the presence or absence of Q-VD.OPh for 48 hours  
 
Representative data from assays carried out in triplicate on three occasions. Drug 
concentrations used were chosen from published work [301, 509] 
Inhibitor-only and ionomycin-only controls were also included to check for activity of 
ionomycin and toxicity of inhibitors. 
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3.3.5 ABT-737 
Although our drug sensitivity assays implicate the cellular Bcl-2 family of proteins as likely 
targets for EBV in BL they do not provide direct evidence that this is the case. ABT-737 is a cell 
permeable BH3 domain mimic designed to selectively bind and inhibit anti-apoptotic Bcl-2 
family members Bcl-2, Bcl-XL and Bcl-w, but not Mcl-1 and A1 [534, 535]. We therefore 
hypothesised that, if EBV is able to change the dependency of BL cells on any or all of the pro-
survivals bound by ABT-737, then EBV-loss cells will exhibit enhanced sensitivity to ABT-737 
over their counterpart EBV-positive clones.  
We carried out titrations of ABT-737 onto clones of Akata-BL, Kem-BL and Mutu-BL and found 
that Latency I clones were relatively insensitive to ABT-737, possibly because BLs do not 
express Bcl-2. Interestingly, there was a difference between EBV-positive and EBV-loss clones 
and the 50% lethal dose was consistently higher for cells that contained the virus compared to 
EBV-loss clones (Figure 3.11). The variation between tumour backgrounds and clones from the 
same background suggests that the precise balance of pro- versus anti-apoptotic proteins may 
be heterogeneous at the single cell level in BL. 
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Figure 3.11 Sensitivity of BL clones to ABT-737  
 
A  Clones of Akata-BL exposed to serial dilutions of ABT-737 for 24 hours B  Clones of Kem-
BL exposed to serial dilutions of ABT-737 for 24 hours C  Clones of Mutu-BL exposed to 
serial dilutions of ABT-737 for 24 hours. Representative data from three independent 
experiments 
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3.4 Screening for cellular genes involved in the EBV-loss phenotype 
3.4.1 Microarrays 
After isolating a small number of EBV-loss clones from several BL tumour backgrounds, Dr 
Gemma Kelly and Dr Andrew Boyce went on to carry out microarray experiments on two EBV-
positive and two EBV-loss clones from each of three tumour backgrounds. Surprisingly, they 
found that there were no gene expression changes in common between the different 
backgrounds by rank product analysis (Figure 3.12-A), suggesting that different genes may be 
important in different patient backgrounds or that the mechanism by which EBV enhances cell 
survival is not transcriptionally controlled. Unfortunately, since we had expected to find 
consistent differences, the experiment only included 2 EBV-positive and 2 EBV-loss clones per 
tumour background. This meant that we were unable to look in more detail at gene expression 
changes that might be important in individual backgrounds as we would require at least three 
replicates in order to carry out appropriate statistical analyses.  
3.4.2 Protein expression studies 
Although some members of the intrinsic apoptosis signalling pathway are transcriptionally 
regulated, a number of apoptosis related genes are predominantly regulated at the post-
transcriptional level [536]. Therefore, we were also interested in looking at apoptosis-related 
gene expression in EBV-positive and loss cells at the protein level. As part of a previous study 
we carried out Western blots for selected regulators of apoptosis on EBV-positive and loss cells 
but were unable to find any consistent differences and so in this study we decided to carry out 
a more unbiased screen.  
Whole cell lysates of BL clones were separated by SDS-PAGE and then stained with Coomassie 
dye to visualise the total protein in each clone and screen for differences in banding between 
EBV-positive and EBV-loss cells. Any bands that were found to be considerably different 
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between clones containing or having lost the virus could then be excised and proteins 
contained therein could be identified using mass spectrometry.  
Unfortunately, we saw no clear differences between EBV-positive and loss clones in any 
tumour background (Figure 3.12-B). Although, it is important to note this approach would not 
identify proteins that had modifications that effect function but have little effect on protein 
expression level or size and that some highly expressed proteins will mask the expression of 
other proteins of a similar molecular weight.  
3.4.3 MYC 
We also considered that a very small change in expression of a large number of genes could be 
responsible for the EBV-loss phenotype. Recently it was reported that, rather than regulating a 
subset of genes by activation or repression, MYC is actually a global enhancer of Pol II 
transcription [251]. We therefore wondered whether c-myc levels remain constant between 
EBV-positive and loss cells; a change that was small in amplitude yet affecting many genes may 
explain why we saw no obvious differences in overall protein or transcription levels.  In clones 
of Akata-BL, Mutu-BL and Elijah-BL there was no evidence of a difference in MYC transcription 
between EBV-positive and loss clones (Figure 3.12-C). Awia-BL EBV-loss clones were found to 
express slightly higher levels of MYC than did their EBV-positive counterparts, which could 
presumably lead to increased apoptosis sensitivity in these cells.  However, if this difference in 
MYC expression were a direct consequence of EBV-loss we would expect to see it in every cell 
background which exhibits the EBV-loss phenotype. 
Overall these experiments to characterise differences in gene expression between EBV-
positive and loss clones did not explain the EBV-loss phenotype or directly indicate any cellular 
targets of EBV in BL, although we have good evidence that the Bcl-2 family play an important 
role, either directly or indirectly. There are several possible reasons for this; the pivotal 
player(s) may be regulated by subtle change in expression level, a post-translational  
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Figure 3.12 Screening BL clones for gene expression changes associated with EBV-loss 
  
A  Summary of data from Affymetrix U133 plus 2.0 microarrays carried out by Dr 
Andrew Boyce. Data were subjected to rank product analysis using Affymetrix 
GeneChip Operating Software (GCOS). Fold change cut off was FC>1.5 and the false 
positive probability threshold was set to 10%. Two EBV-positive and two EBV-loss 
clones were included for each of the three BL backgrounds included in this analysis 
(12 clones in total).  
 
B  Coomassie staining of whole cell lysates from BL clones separated by SDS-PAGE. 
Clones of Akata-BL, Mutu-BL and Awia-BL used match those included in the 
microarray experiments. 20μg of total protein was loaded per well.  
 
C Transcription of MYC in BL clones determined by q-PCR using the ΔΔCt relative 
quantitation method and expressed relative to Akata-BL clone P1. Data shown 
represent the mean and standard deviation of duplicate wells. GAPDH was used as an 
endogenous control for normalisation between wells 
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Figure 3.12 
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modification or a protein-protein interaction, which would not be identified by previous 
Western blotting, Coomassie staining of lysates or microarrays.  
It is also possible that we failed to see consistent differences because the study was carried out 
on unchallenged cells rather than after apoptosis induction when the EBV-loss phenotype 
becomes evident. Therefore we sought to take our studies further by investigating the factors 
affecting EBV-loss and characterising the effect of EBV-loss on BL cells in vivo to enable us to 
better understand the apoptosis sensitivity of EBV-loss clones. 
 
3.5 Investigating the effect of pro-survival signals on EBV-loss 
3.5.1 Mechanism of EBV-loss 
Although it is clear from the literature that EBV episomes are tethered to the cellular DNA by 
EBNA1 and segregated into daughter cells in a synchronous, largely symmetrical and non-
random manner [295, 296, 537], it is also clear from our work and that of several other groups 
that EBV-positive cell lines can give rise to spontaneous EBV-loss clones, albeit rarely [178, 309, 
538]. Sudgen et al. showed that in an LCL, which relies on EBV for proliferation as well as 
survival signals, EBV is faithfully maintained at a copy number that is apparently optimal for 
growth [295]. However, other studies looking at genome segregation have used small oriP 
plasmids in EBV negative cells [312, 318], which may behave differently to wild type virus in 
cells derived from an EBV-positive tumour. Interestingly, a number of the papers which 
support faithful partitioning of viral genomes also report instances in which they observed 
uneven segregation [295, 296].  
We therefore wondered whether survival signals within the cell are able to determine how 
faithfully the genome is passed to daughter cells: is retention of EBV only selected for where 
the virus provides a survival advantage, and conversely, if the cells obtain a survival advantage 
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by some other means will that alleviate the need to retain the virus? The EBV-encoded Bcl-2 
homologue, BHRF1, is able to robustly inhibit cell death in BL cells induced by various drugs 
[89, 419, 539] via binding to pro-apoptotic Bcl-2 family proteins [304, 305, 411]. Therefore, to 
test whether providing BHRF1 in trans would relieve the selection pressure for EBV in BLs, we 
generated EBV-positive Akata-BL and Kem-BL cell lines in which we were able to inducibly 
express BHRF1 prior to single cell cloning.  
3.5.2 Expressing BHRF1 in Latency I BLs 
We transduced the parental BL cell lines, Akata-BL and Kem-BL, that are >99% EBV positive by 
EBER-ISH, with the FTrex-BHRF1-UTG lentivirus, which contains inducible BHRF1 and a 
constitutive GFP marker (described in Section 2.6.6). Stable, GFP-positive cell lines were then 
generated by cell sorting. For each tumour background the highest 5% GFP expressers were 
selected and we also generated matched lines stably transduced with an empty vector control 
(Figure 3.13-A). Interestingly, the intensity of GFP is far higher in Akata-BL than in Kem-BL. 
Since the cells were transduced with the same batch of virus under the same conditions, this 
suggests that Akata-BL is able to take up and integrate lentivirus more efficiently than Kem-BL. 
When we looked at levels of BHRF1 expression from our construct we found good correlation 
between GFP and BHRF1; Kem-BL expressed far lower levels than Akata-BL, which expressed 
similar levels to a Wp-restricted BL and the X50-7 LCL. The highest levels were seen in the 
highly transducible 293 cells which also expressed very intense GFP (Figure 3.13-B, 3.13- C and 
data not shown). Unfortunately, we also noted from these experiments that our vector was 
not as tightly regulated as we had hoped, and we detected ‘leaky’ expression in uninduced 
cells at around 10% of the level seen in the doxycycline-treated cells by Western blot. We 
presume this leaky expression reflects incomplete silencing of the Trex PolII promoter by the 
tet repressor leading to low level expression of BHRF1 in all cells. Although since we did not 
carry out single cell analysis for BHRF1 by FACS we cannot rule out that this result instead 
reflects a small proportion of cells expressing high levels of BHRF1.  
Page | 110  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Expression of BHRF1 in Latency I BLs 
 
A   GFP expression in transduced Kem-BL and Akata-BL cells 
 
B Western blot for BHRF1 in transduced cells. The faint band seen in the Kem-BL + Empty 
vector lane is probably due to spill-over from the 293 + BHRF1 lane as this sample has been 
shown to be negative for BHRF1 by Western blot and PCR 
 
C Transcription of BHRF1 in transduced cell lines. Note that due to the range in expression 
levels between low and high expressers a log2 scale has been used. Values shown are the 
mean and standard deviation of duplicate wells. Data was analysed using the ΔΔCt relative 
quantitation method relative to Oku-BL and normalised to GAPDH. 
 
E = empty vector control, B= FTrex-BHRF1-UTG 
17kDa 
42kDa 
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3.5.3 Single cell cloning of BHRF1-expressing BLs 
Since BHRF1 has been shown to strongly inhibit apoptosis even when expressed at low levels 
[89, 539], we went on to look at whether this Bcl-2 homologue could have any effect on the 
outgrowth of single cell BL clones. Cells were grown in media supplemented with acyclovir to 
inhibit lytic viral replication and 1μg/ml doxycycline or DMSO as a vehicle-only control for 3 
weeks (9 passages) prior to cloning and were then plated out at 1 cell per well into 96-well 
plates. Interestingly, during the early stages of the experiment, the plates containing BHRF1-
expressing cells appeared to expand more quickly than the empty vector cells however, after 
three weeks, when cells were harvested, the number of outgrowing clones had become similar 
for each experimental group. The average viral load of each clone was enumerated by q-PCR 
and then the data for all conditions were compared. Wells in which no virus was detected 
were classified as EBV-loss clones, and the remaining clones were designated as having a high 
or low viral load if they were found to contain more than twice the number of genomes as the 
parental cells, or less than 10 genomes per cell, respectively. An example of average viral loads 
of BL clones across a single 96-well plate is shown in Figure 3.14.  
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Average viral loads in clones of BHRF1-expressing Akata-BL cells 
 
Average copy number of BALF5 DNA normalised to β2M (see Section 2.3.2) 
                  = 10;                      - viral load of parental BL;                     - EBV-loss (no EBV DNA) 
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The compiled data from our BHRF1 cloning experiments is presented in Table 3.2. Overall, the 
range and mean of viral loads detected was quite similar to that reported for the initial cloning 
experiments of the parental cell lines (see Table 3.1), although there did seem to be a slight 
tendency for BHRF1 expressing cells to have a higher viral load. In BHRF1-expressing Akata-BL, 
we noted that more clones had viral loads that were classified as very high or very low and 
that the frequency of EBV loss also increased slightly however, the numbers of clones analysed 
were insufficient to draw firm conclusions. Importantly, in Akata-BL, even the highest rate of 
genome loss was lower than in our initial cloning experiments and Kem-BL never gave rise to 
EBV-loss clones, even in the presence of BHRF1. Therefore, although the presence of a strong 
anti-apoptotic signal may slightly increase uneven genome segregation, its presence does not 
cause EBV to be lost from cells within the time frame of this experiment.   
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Compiled data from BHRF1 single cell cloning experiments 
 
Viral loads calculated using DNA q-PCR for EBV BALF5 and β2M as described in Section 2.3.2 
High viral load = >2x average viral load of parental (untransduced) cell line 
Low viral load = <10 genomes per cell 
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3.5.4 Apoptosis phenotype of BHRF1-expressing BL clones 
To confirm that BHRF1 was able to confer protection to Latency I BL cells, and to investigate 
whether the varying levels of expression in different cell lines affected apoptosis sensitivity, we 
carried out apoptosis assays on our stable cell lines that were used for single cell cloning 
experiments. All cell lines were induced with doxycycline for 48 hours prior to assay set up and 
assays were then carried out as described in Section 2.2.3. In both Akata-BL and Kem-BL it was 
clear that BHRF1 protects against ionomycin-induced apoptosis and the degree of protection 
correlates with the amount of BHRF1 in the cells (Figure 3.15). BHRF1-expressing Akata-BL was 
substantially protected from ionomycin-induced apoptosis, and uninduced cells were only 
slightly more sensitive to cell death induction than cells induced by Doxycycline treatment, 
supporting the notion that BHRF1 acts as a potent pro-survival signal even when present at a 
very low level compared to a Wp-BLs or LCLs. In Kem-BL the BHRF1 phenotype was less 
marked, in-keeping with the lower expression levels we observed in this cell line. However,  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Survival of BHRF1-expressing Latency I BL cells versus control cell lines 
 
All cells were treated with 1μg/ml ionomycin (+) or a vehicle-only control (-) for 48 hours, 
mean and SD of triplicate measurements are shown. Assays were carried out on three 
occasions. Statistical comparisons were made using a two-tailed Student’s T-test. 
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DOX-induced BHRF1-expressing Kem cells were still substantially protected from ionomycin 
induced apoptosis, although in this case uninduced cells were not significantly protected when 
compared to an empty vector control. 
 
3.6 Investigating the tumorigenicity of BL clones in vivo 
3.6.1 Design of in vivo studies 
The Takada group, which originally reported the spontaneous loss of EBV, also reported that 
the loss of EBV from Akata-BL rendered the cells non-tumorigenic in nude mice [309], a finding 
that was later supported by more detailed studies using SCID mice [310, 327]. Therefore, we 
were interested as to whether this held true for EBV-loss clones derived from other tumour 
backgrounds. Although both nude and SCID mice lack functional B and T cells and are thus 
severely immunodeficient, they also retain some mature lymphocytes, such as NK cells, which 
can cause xenotransplanted cells to be rejected. The NOD/SCID/IL2rγKO, or NSG mouse is the 
current breed of choice for xenotransplantation studies as it harbours a knock out of the IL2 
receptor common gamma chain in addition to the NOD/SCID mutations. This results in failure 
to produce several interleukins which are required for the proper functioning of NK cells, 
dendritic cells and macrophages. Therefore the functional immune repertoire of NSG mice is 
restricted to neutrophils and monocytes; B and T cells are absent and NK cells are crippled, 
whilst dendritic cells and macrophages are partially functional [507].  
Although other groups had injected BL cells subcutaneously (SC) into the flanks of mice we 
primarily chose to inject cells into the peritoneum (IP) to allow the tumour cells to diffuse and 
circulate within the animal. We also injected fewer cells (up to 2 x106 IP) into our mice than the 
Sample and Takada groups (107) on the advice of our colleagues at the WEHI, who routinely 
transplant lymphoid cells into NSG mice and because we felt that this would better reflect the 
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conditions of our in vitro experiments. Figure 3.16 shows a diagram of the set-up for our 
experiments using clones of Kem-BL and Mutu-BL. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Experimental workflow of in vivo experiments using EBV-positive 
and loss clones of Kem-BL and Mutu-BL 
 
Clones of Kem-BL and Mutu-BL were injected IP at two inoculums. For each cell 
line one positive and two loss clones were included. Mice were monitored for 
signs of tumour growth and sacrificed when tumour burden reached 
approximately 1cm3, in accordance with the Walter and Eliza Hall Institute 
Animal Ethics Committee guidelines.  
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3.7 Features of BL xenograft tumours in NSG Mice 
3.7.1 Sites of tumour formation 
Consistent with human BL, clones of Kem-BL and Mutu-BL gave rise to tumours at various sites, 
including the ovaries, pancreas, spleen and mammary tissue. However, we never saw ocular, 
maxillofacial or gastrointestinal tumours, which are also commonly affected sites in human 
endemic BL [540]. An example of a typical mouse with ovarian, pancreatic and mammary 
tumours is shown in Figure 3.17-A. Like the human form of BL, we also found that the thymus 
in BL xenotransplant mice was never affected, and lymph nodes were only involved in 2 cases 
where the tumour was attached to the mesenteric nodes. Table 3.3 summarises all of the 
tumours and the incidence with which each site was affected. The growth of BL xenotransplant 
tumours was also aggressive in NSG mice and the first mouse was sacrificed only 33 days after 
injection, in-keeping with the rapid growth of BL tumours in human patients and with BL cell 
line proliferation in vitro [541]. 
3.7.2 Histology – H&E stains 
Tumour tissue, major body cavity organs, and sections of sternum and spine from every mouse 
were fixed and embedded in paraffin for histology. Examples of H&E stained slides of various 
tumours are shown in Figure 3.17-B. Histological examination revealed that the tumours were 
largely homogeneous and displayed ‘starry sky’ patterning, the histological hallmark of BL. This 
is clearly visible in the ovarian, pancreatic and splenic sections in Figure 3.17-B. The tumours 
also destroyed the natural architecture of the organs and infiltrated into the bone marrow. 
Analysis of H&E stained sections was carried out by Dr Brandon Aubrey in Melbourne.  
We also carried out staining for the proliferation marker Ki67 on sections of ovarian tumours 
from mice injected with different BL clones to see whether there were any differences 
between tumours from EBV-positive and loss clones. In every case at least 95% of the cells 
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stained positive, in line with human BL, and no differences were evident between EBV-positive 
and EBV-loss tumours, suggesting that these cell lines proliferate similarly in vivo.  
 
 
 
 
  
Table 3.3 Summary of sites of BL xenograft tumour formation in NSG mice 
 
For each clone the frequency with which tumours occurred at each site is listed both 
as a percentage (i.e. where 4 of a group of 5 animals that all received cells of the 
same BL clone developed ovarian tumours the frequency of ovarian tumours in this 
group is listed as 80%) and as the absolute number of animals in the group. Totals are 
the total frequency and number of animals which had tumours at each site for each 
tumour background (data for all three clones pooled).  
 
LN – Lymph node involvement, SMFP – swollen mammary fat pad 
Page | 118  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Appearance of BL xenograft tumours in NSG mice 
 
A  Example of pancreatic, ovarian and mammary tumours in a single mouse showing 
starry-sky patterning and destruction of normal tissue 
 
B  Examples of H&E stained organs from BL xenotransplant mice showing starry-sky 
patterning, destruction of normal tissue, extra-medullary haemopoiesis (Spleen) and 
infiltration into bone marrow (Sternum) 
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3.7.3 Human CD19 FACS 
Although the histology and appearance of the tumours was consistent with human BL we 
wanted to confirm that the tumour cells were of human origin, so we carried out FACS staining 
for human CD19 on ex vivo cells. Tumour samples were passed through a cell strainer before 
staining and lymphoma cells from an Eμ-Myc mouse were included as a negative control whilst 
EBV-positive Mutu-BL cells that had not been passaged in vivo served as a positive control. 
Figure 3.18 shows staining of controls as well cells of an ovarian tumour from a mouse that 
was injected with an EBV-positive Mutu-BL clone. We also stained cells from mice injected 
with EBV-loss clones of Mutu as well as EBV-positive and loss clones of Kem and we included 
both ovarian and splenic tumours in our analysis. In line with the results shown, we found that 
virtually all of the ex vivo tumour cells were positive for human CD19. This finding is consistent 
with human BL where there is very little infiltration of non-tumour cells [107].  
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Example of CD19 FACS staining of ex vivo xenograft cells compared to 
controls. In each case unstained control cells are shown in red and the 
experimental sample listed below each panel is shown in blue.  
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3.8 Survival of BL xenotransplant mice 
To determine whether the presence of EBV affects the growth and progression of BL xenograft 
tumours in vivo we plotted the survival data for our two cohorts of Kem-BL injected mice and 
the single cohort of Mutu-BL injected mice using Kaplan-Meier plots and compared the survival 
of mice injected with different BL clones by conducting Logrank tests. Figure 3.19-A shows the 
compiled data for both cohorts of Kem-BL injected mice and Figure 3.19-B shows the data for 
Mutu-BL injected mice. EBV-loss clones of Kem-BL were significantly less tumorigenic in NSG 
mice than were EBV-positive cells; mice that received Kem-BL derived EBV-loss cells survived 
twice as long on average, than those that received EBV-positive cells. Two mice that received 
Kem n1 cells survived past 250 days, the endpoint of the experiment. Although the effect was 
less dramatic in mice injected with Mutu n2 than Mutu n1 we still found that EBV-loss clones 
of Mutu-BL were significantly less tumorigenic than was an EBV-positive clone from the same 
tumour. Overall, mice injected with EBV-loss clones of Mutu-BL survived at least twice as long 
as those injected with an EBV-positive counterpart. In this analysis, data for the two inoculums 
used are pooled however, we found that mice injected with fifty-thousand cells survived only 
slightly longer than those injected with two million cells (data not shown).  
This in vivo study is the first to compare the overall survival of mice injected with EBV- positive 
and loss clones on clones derived from two endemic BL patients and we have found convincing 
evidence for a role for the virus in an animal model. 
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Figure 3.19 Survival analysis of NSG mice injected with BL clones 
 
A Pooled data from two cohorts of mice which were injected with EBV positive Kem-
BL cells or one of two EBV-loss clones, Kem n1 and Kem n2 
 
B Data from a single cohort of mice which were injected with an EBV positive Mutu-BL 
clone, P1, or one of two EBV-loss clones, Mutu n1 and Mutu n2 
 
In each cohort, 3 mice per clone were injected with 5x104 cells, and 3 mice per clone 
received 2x106 cells. Kaplan-Meier curves were generated using GraphPad Prism 5 
software. From these survival curves median survival (Kd) was calculated and 
statistical comparisons were carried out. Curves were considered statistically different 
where the p-value was calculated to be <0.05 using a Log-rank (Mantel-Cox) test.   
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3.9 Analysis of EBV in xenotransplants 
To confirm that EBV retained the Latency I gene expression profile in vivo we profiled viral 
transcription in a range of EBV-positive BL xenotransplant tumour tissue samples derived from 
both Kem-BL and Mutu-BL. Transcriptional profiling was carried out using microfluidic cards to 
perform 48 simultaneous q-PCR assays for 45 EBV-encoded genes as well as three cellular 
controls on RNA extracted from ex vivo cells. Data were analysed using the ΔΔCt method, 
normalised to GAPDH, and expressed relative to a standard cell line, as described in Section 
3.2.2. Examples of the gene expression profiles we generated are shown in Figure 3.20. Of the 
sample we tested, the majority had Latency I-like gene expression profiles similar to that of 
xenografts 65 and 77. However, one Mutu-BL derived tumour; xenograft number 54, 
expressed high levels of Latency III transcripts and so was excluded from the study. We also 
checked that viral DNA was retained in vivo at a similar viral load to that of the matched EBV-
positive clone before transplantation (data not shown). 
3.10 Akata-BL xenotransplants 
All of the xenotransplant data in this thesis pertains to mice injected with clones of Kem-BL 
and Mutu-BL because, to our surprise, our clones of Akata-BL appear to be non-tumorigenic in 
NSG mice. The animals that were injected intraperitoneally were monitored for over 180 days 
before they were taken ill with an unrelated bacterial infection of the lungs. After this we tried 
injecting mice with a higher number of cells under the skin of the abdomen to more closely 
recapitulate previously published studies. Again we found that all of the animals were tumour-
free at six months and so were discarded. Since previous reports state that EBV-loss clones 
caused no tumours in nude and SCID mice and only EBV-positive cells were able to cause 
tumours we would not have expected to detect tumours in animals injected with EBV-loss  
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Figure 3.20 Quantitative PCR on xenotransplanted BL cells ex vivo  
 
Example data gene expression profiling of ex vivo tumour cells from xenotransplanted NSG 
mice. Xenografts 65 and 77 express Latency I-associated transcripts EBNA1 and EBERs, whilst 
Latency III-associated BHRF1, EBNA2 and LMPs are almost undetectable. Xenograft 54 
expresses BHRF1, EBNA2 and LMPs in addition to EBNA1 and EBERs, consistent with a 
Latency III gene expression programme. 
EBNA1 refers to spliced transcript originating from the Qp promoter that is only found in 
Latency I cells 
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clones, but we are still not able to understand why EBV-positive Akata-BL cells caused no 
tumours. However, it is interesting to note there are indications in the literature of there being 
significant phenotypic variability between clones of Akata-BL in other respects. For example; 
the efficiency of lytic cycle induction upon α-IgG treatment can vary from as little as 5% up to 
75%, depending on the particular batch of Akata-BL cells used [126, 542].  
Conclusions I 
Our large-scale single cell cloning of 12 well-characterised endemic BL cell lines is the most 
comprehensive study of spontaneous EBV-loss to date. We have confirmed both the rare 
occurrence of such loss, which indicates that the presence of the virus is highly selected for, 
and the consistently detrimental phenotype that EBV-loss confers, in agreement with the 
published findings of several groups [99, 178, 182, 298, 309, 310]. Whilst EBV-loss clones 
appear to be unhindered in their ability to survive under optimal culture conditions, they are 
significantly more sensitive to a range of apoptosis inducers compared to their EBV-positive 
Latency I counterparts. This is the first study to carry out a detailed analysis of multiple clones 
derived from a range of classical Latency I BLs. Consistent with the finding that p53 signalling is 
frequently abrogated in BL [260], we find that EBV-loss sensitises BL clones to agents that 
induce cell death in a p53-independent manner via the intrinsic apoptosis signalling pathway. 
Interestingly, the EBV-loss phenotype did not correlate with any consistent difference in 
transcription, global protein expression, or c-myc status in comparisons of healthy EBV-positive 
and loss clones.  
Additionally, the viral Bcl-2 homologue, BHRF1, strongly inhibits intrinsic apoptosis in BL cells 
[89, 178], yet its ectopic expression does not lead to an increase in the rate of EBV-loss over a 
number of passages. This suggests that EBV-loss is truly a rare occurrence, rather than a 
frequent occurrence that is rarely detected because EBV-loss clones are unable to survive the 
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process of single cell cloning. These experiments also imply that, whilst the segregation of EBV 
genomes to daughter cells is uneven [295], EBV is extremely efficient at ensuring that multiple 
copies of the virus are inherited by each cell during mitosis.  
We have also expanded on the very limited studies of the effect of EBV-loss from BL cells in 
vivo; confirming that the presence of EBV is associated with enhanced tumorigenicity and 
reduced survival in NSG mice injected with clones of Kem-BL and Mutu-BL. These new 
experiments clearly demonstrate that EBV is able to make an ongoing contribution to the 
aggressive phenotype of BL. Surprisingly, although we confirmed that EBV-loss clones of Akata-
BL are non-tumorigenic in immunocompromised mice, we were also unable to engraft EBV-
positive Akata-BL cells in contrast to the findings of the Takada and Sample groups [309, 310, 
327, 339, 340]. Although we noted that, in experiments carried out by the Takada group, mice 
were injected with pools of six different EBV-positive clones and that one of four mice included 
in one study and one of seven in a second study, failed to develop tumours [310, 339]. We 
have since found that NSG mice injected with very early passage Akata-BL cells can develop 
tumours, although these experiments are ongoing and we have not examined these mice in 
detail unlike those injected with clones of Kem-BL and Mutu-BL, and therefore those results 
are not included in this thesis.  
We conclude that EBV contributes to the pathogenesis of BL by inhibiting intrinsic apoptosis, 
thereby allowing c-myc to drive the aggressive growth of the tumour despite also activating 
pro-apoptotic signalling pathways. We therefore went on to investigate the precise 
mechanism by which EBV confers this phenotype by examining the anti-apoptotic potential of 
the Latency I-associated viral genes; EBNA1, the non-coding EBER RNAs and the BART 
microRNAs. 
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4. Results Part II                                                                          
INVESTIGATING THE ROLE OF LATENCY I                                                 
EBV-ENCODED GENES IN APOPTOSIS 
4.1 Outline of Latency I gene re-expression studies 
Having confirmed and built upon previous studies to show that loss of EBV from BL cell lines is 
rare and consistently detrimental to their survival, we went on to consider the possible role of 
each of the viral genes that are normally expressed within EBV-positive BLs. At least 85% of all 
BLs occurring in endemic areas are thought to express the Latency I pattern of gene expression 
in which only the EBNA1 protein, the EBER RNAs and the BART miRNAs are consistently 
expressed [156, 505]. In our next set of experiments we therefore re-expressed each in turn to 
test whether individual Latency I genes can restore apoptosis resistance to EBV-loss clones.  
To achieve this we used a lentiviral expression system, originally developed by Marco Herold, 
which can be used to express both coding and non-coding transcripts [483]. This allowed us to 
study gene expression in difficult to transfect cells and to select and enrich for transduced cells 
by FACS since these vectors constitutively express GFP. Additionally, once selected, the cell 
lines remain stable in long term culture as the lentiviral provirus particles integrate into the 
genome of the target cell [543].  
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Figure 4.1 Workflow for EBNA1 re-expression experiments.  
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4.2 EBNA1 
4.2.1 Expressing EBNA1 in EBV-loss BL clones 
EBNA1 is the only EBV-encoded protein expressed in all EBV-associated malignancies and has 
previously been reported to have anti-apoptotic properties [298, 320]; therefore we wanted to 
determine whether EBNA1 contributes to the EBV-loss phenotype.  
We used the FTrex-UTG lentivirus containing a full length EBNA1 sequence (fully described in 
Section 2.6.2) to inducibly express EBNA1 in 6 EBV-loss clones derived from 3 patient 
backgrounds; a workflow for these experiments is shown in Figure 4.1. Once stable cell lines 
had been generated, EBNA1 protein expression was measured by Western blot compared to 
EBV-positive cell lines. We did not examine the dose responsiveness of these vectors to 
doxycycline as we and others have previously found that they are maximally induced even in 
the presence of low doses (1-10ng/ml) of doxycycline [164, 483], although we did investigate 
whether extending induction times might cause EBNA1 to accumulate in EBV-loss cells.  
After sorting cells for high GFP expression we found that we were consistently able to achieve 
comparable levels to those seen in in the respective EBV-positive parental BL lines after 24 
hours of induction. There was no increase in levels of EBNA1 protein in cells that had been 
induced for 14 days; in fact found there appeared to be less EBNA1 in  Kem-BL cells that had 
been induced for longer (Figure 4.2-A & 4.2-B).  
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Figure 4.2 EBNA1 expression in FTrex-EBNA1-UTG transduced BL clones 
 
A Examples of EBNA1 expression in clones from different BL backgrounds. Cells 
containing the EBNA1 lentivirus or an empty control (C) were induced for 24 hours (+) 
or 14 days (++) and no vector (nv) and uninduced (-) controls were also included. 
 
B Example of EBNA1 expression in an alternative clone of Akata-BL 
 
Media was supplemented with 1μg/ml DOX or DMSO as a vehicle only control 
EBNA1 in the X50-7 sample was calculated to be 55kDa and β-actin 42kDa 
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4.2.2 EBNA1 Reporter Assays 
In order to confirm that our EBNA1 construct could not only express physiological levels of 
EBNA1 protein, but that this protein was also functional, we carried out reporter assays to 
measure the ability of EBNA1 to transactivate luciferase expression from an EBNA1-responsive 
reporter in EBV-loss BL cells. EBNA1 transactivation activity was determined using the FR-tk-
luciferase reporter construct [544], which contains the firefly luciferase under control of the 
Herpes simplex type I thymidine kinase promoter (HSV-I-tk) 2 kilobases upstream of the EBV 
oriP family of repeats (FR), which is comprised of 20 repeats of a 30bp EBNA1 binding site (a 
schematic of the system is shown in Figure 4.3). EBNA1 has previously been shown to increase 
expression from this promoter by >20-fold in a range of cell types including BLs [545].  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Schematic of EBNA1 FR-tk-reporter system 
 
Containing the HSV-I-tk promoter, TK(p), terminator, TK(t), family of repeats, EBV-FR, 
and firefly luciferase 
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As shown in Figure 4.4, EBNA1 was able to potently increase luciferase expression from the 
HSV-I-tk promoter in EBV-loss Akata by around 200-fold compared to DOX-induced cells 
transduced with an empty vector control lentivirus, suggesting that it is functional in these 
cells. Interestingly, there is also some transactivation of HSV-I-tk evident in the uninduced 
EBNA1 cells, which is in line with our other experiences of using this vector where low levels of 
the gene of interest were constitutively expressed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Luciferase reporter activation by EBNA1 in EBV-loss Akata cells 
 
Data plotted are mean and standard deviation of three separate transfections carried 
out in duplicate. Promega Dual-Luciferase reporter reagents were used according to 
the manufacturer’s instructions (see Section 2.9) and firefly luciferase activity was 
normalised to Renilla luciferase activity to allow us to control for variation in 
transfection efficiency 
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4.2.3 The apoptosis phenotype of EBNA1-expressing EBV-loss clones 
To determine whether EBNA1 could protect EBV-loss cells from cell death, EBNA1-expressing 
EBV loss cells were compared to empty vector transduced controls in apoptosis assays. All 
cultures were induced with doxycycline 24 hours prior to assay set up and experiments were 
carried out on three independent occasions, as described in Section 2.2.3. Apoptosis was 
induced using ionomycin in these assays as this gave the most robust and consistent results in 
our screen of responses to various apoptosis-inducing stimuli (see Section 3.3) and was 
quantified as percentage increase in PI-positive cells per sample compared to untreated 
controls.  
Figure 4.5-A-C shows representative data from experiments carried out on two EBV-loss cones 
derived from each of Akata-BL, Kem-BL and Mutu-BL, respectively. Although there was some 
variation between different EBV loss clones transduced with either FTrex-EBNA1-FLAG-UTG or 
the empty vector control, there was no consistent evidence that EBNA1 confers apoptosis 
protection across all 3 tumour backgrounds. Interestingly, there tended to be slightly less cell 
death in both EBNA1-expressing Akata clones than in matched controls and conversely, slightly 
more cell death in EBNA1-expressing Mutu clones than their matched controls. This difference 
was significant within replicates from a single experiment using a Student’s T-test, hinting that 
EBNA1 may contribute differently to different tumours. However, when data from 3 
independent experiments was pooled, the difference between EBNA1-expressing and control 
cells was not statistically significant (Figure 4.5-D). Therefore, we conclude that EBNA1 does 
not consistently confer apoptosis protection to BL cells and is therefore not solely responsible 
for the EBV-loss phenotype.  
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Figure 4.5 Apoptosis phenotype of FTrex-EBNA1-UTG transduced BL clones 
 
A Examples of apoptosis in EBNA1-expressing and control vector-transduced 
Akata-BL clones after treatment with 1μg/ml Ionomycin + 1μg/ml DOX for 48 
hours 
 
B Examples of apoptosis in EBNA1-expressing and control vector-transduced 
Kem-BL clones after treatment with 1μg/ml Ionomycin + 1μg/ml DOX for 48 
hours 
 
C Examples of apoptosis in EBNA1-expressing and control vector-transduced 
Mutu-BL clones after treatment with 2μg/ml Ionomycin + 1μg/ml DOX for 48 
hours 
 
A-C representative data from single experiments carried out in triplicate. In 
each case mean and standard deviation of triplicate measurements are shown  
 
D Comparison of apoptosis data from three independent experiments in 
EBNA1-transduced and control Akata EBV-loss clone n5 cells. Pooled data from 
three independent experiments (denoted 1, 2 and 3), mean and standard 
deviation of triplicate measurements are shown 
 
Cells were treated with a dose of Ionomycin at which the corresponding 
untransduced EBV-loss BL clone undergoes 60-80% apoptosis by the 
experimental end-point (48 hours), whilst their EBV-positive counterparts 
undergo around half as much apoptosis. Using a dose in which there is a clear 
and broad difference in the apoptosis phenotype of protected and 
unprotected cells should allow us to confidently identify small or subtle 
changes in apoptosis susceptibility between experimental groups.  
 
P-values were calculated using two-tailed Student’s T-tests 
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Figure 4.5  
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4.3 EBERs 
4.3.1 Expressing the EBER RNAs in EBV-loss BL clones 
The non-coding EBER RNAs are abundantly expressed in all EBV-associated malignancies and 
have previously been reported to have anti-apoptotic properties in B cells and T cells and to 
confer tumorigenicity to EBV-loss Akata cells in vivo [546]. Therefore we investigated whether 
they were able to confer apoptosis resistance to our panel of EBV loss clones. 
Initially, the EBERs were cloned individually into the same lentiviral backbone as was used to 
re-express EBNA1 in Section 4.2, except that a tet-responsive human H1 promoter was used 
instead of the Trex promoter because EBERs can be transcribed in vitro by RNA polymerase III 
(Pol III) but not Pol II [547] (construct described in detail in Section 2.6.2). Transduced cells 
were enriched for high GFP expression by cell sorting before being induced with doxycycline 
and RNA expression measured by quantitative PCR and Northern blot. Surprisingly, although 
the levels of EBER RNA expressed from these constructs looked to equal or exceed 
endogenous levels in EBV-infected cell lines by q-PCR (Figure 4.6-A) Northern blotting could 
only detect weak signals even in those lines expressing the highest levels of EBERs by q-PCR 
(Figure 4.6-B).  
Since there have previously been reports of poor termination of non-coding RNAs by Pol III 
[548, 549], we decided to test whether our transcripts were failing to terminate by carrying 
out q-PCR assays to compare the total numbers of EBER transcripts with transcripts that ran 
through the termination sequence.  For each EBER we designed an alternative reverse primer 
to be used with the conventional forward primer and probe in q-PCR; by comparing the 
conventional assay to the run through assay we could quantify the relative amount of 
appropriately terminated transcripts being generated. We found that the vast majority of our 
transcripts were running through the termination sequence (Figure 4.6-C), which explains why 
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Figure 4.6 Expression of EBER RNAs in FH1-EBER1/2-UTG transduced cells 
 
A EBER q-PCR measured in duplicate and expressed relative to the X50-7 LCL 
 
B Northern blot of EBER RNA in FH1-EBER1/2-UTG transduced 293s, nv = no vector control 
 
C ‘Read through’ q-PCR, samples were measured in duplicate relative to DNA plasmid 
standards. Total EBERs was measured using the standard EBER q-PCR assay [90] whereas 
read-through assays used an alternative reverse primer that bound the backbone of the 
FH1t-UTG plasmid immediately downstream of the EBER sequence (primer: 5’-
GAGGCCAGATCTGGAGCCGA-3’). Standard curve comparisons showed that the standard 
EBER and read-through assays amplified linearly over several orders of magnitude and with 
similar efficiency as indicated.  
 
Inductions were carried out using DOX at 1μg/ml  
C 
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the levels of EBER expression by Northern blot did not correlate with the high levels of 
transcripts detected by q-PCR. 
There are EBER homologues in other viruses which have more complex requirements for 
efficient termination than the 4 or 5 T tranche thought be sufficient for EBER termination. For 
example; the Adenovirus VAs, contain two termination sequences per RNA, which can give rise 
to VAs of alternative lengths [550, 551], and a distantly related Chicken virus (Chicken 
embryonic lethal orphan virus, CELO) also contains short RNAs with two termination 
sequences which give rise to different sized RNAs with different functions [552, 553]. Both the 
EBERs and CELO RNAs also contain runs of 4 or more T residues within their transcribed 
sequence which appear not to be sufficient for termination [551], so clearly termination 
requirements can be complex and varied for different Pol III transcripts.   
Interestingly, the EBV genome does indeed contain a second polyT after each conventional 
EBER termination sequence [547] (Figure 4.7). Unfortunately however, the close proximity of 
the ‘secondary’ termination sequences to the conventional termination sequences makes it 
impossible to distinguish between transcripts using q-PCR and the very strong signals given by 
Northern blots make it hard to be sure of the exact size of EBER transcripts being produced in 
EBV-infected cell lines  (Figure. 4.6-B). Additionally, it has been reported that tRNA transcripts, 
which fold similarly to EBERs, associate with ribonucleoproteins such as La, and in some cases, 
are encoded at loci where secondary termination sequences are present, can be processed by 
exonucleases which ‘nibble’ transcripts to the correct length [554, 555]. It would be technically 
complex and time consuming to determine whether any of these factors are important in the 
transcription of EBERs and then to generate vectors to efficiently express them individually in 
an inducible manner. For subsequent experiments therefore, we decided to use an alternative 
system which contains multiple copies of the EBERs in their endogenous sequence context.    
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The EKS10 vector was developed by the Takada group and has been shown to express near-
endogenous levels of EBER RNAs in a number of cell types [310, 556]. In this system both EBER 
RNAs are expressed constitutively from their respective endogenous promoters and stable cell 
lines are generated by drug-selection of transfected cells (see Section 2.6.3). We generated 
three pairs of EBER-expressing and empty vector control cell lines on each of three tumour 
backgrounds; 9 pairs in total.  
In each tumour background, two pairs of cell lines were made in a single EBV-loss clone as well 
as one pair in an alternative EBV-loss clone to allow us to control for variation between 
transfection and selection procedures and between different loss clones as well as between 
tumour backgrounds. In all the cell lines generated we could express reasonable amounts of 
EBER RNAs, approximately 20-60% of that seen in the parental EBV-positive BL cell lines (Figure 
4.8). Since EBERs are present at such high copy numbers in EBV-positive BLs, are variable 
between BL cell lines, and have been reported to be functional at this level of expression by 
other groups, we deemed this series of transfectants suitable to ascertain whether EBERs can 
restore the apoptosis protection phenotype to EBV-loss BLs. 
Figure 4.7 PolyT tracts in EBV and CELO virus compared to lentivirus constructs 
 
FH1t-EBER1/2-UTG both contain only a single polyT (pink highlight), corresponding to the 
published EBER termination sequences [524], however there are additional polyT 
sequences downstream of each EBER in the viral genome, similar to the short and long 
polyT sequences in CELO VA RNA, which are both required for termination. 
 
EBER DNA accession number J02078.1, CELO VA accession number M12738.1 
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Figure 4.8 EBER RNA expression in EKS10 transfected BL clones 
 
Northern blots carried out as described in Section 2.7.8. Control cells were transfected 
with pcDNA3 and drug selected under identical conditions to the EBER-encoding EKS10-
transfected cells.  
 
All lanes contained 20μg RNA, P32-labelled DNA was used as a probe, film cassettes were 
stored at -80°C for 14 days before developing and 28s RNA was used as a loading control.  
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4.3.2 The apoptosis phenotype of EBER-expressing EBV-loss clones 
Apoptosis assays on EBER-expressing cells and empty control cell lines were set up as 
described in Section 2.2.3 with all samples plated out in triplicate and all experiments carried 
out on three independent occasions. Cell death was induced by the addition of ionomycin and 
cells were harvested and analysed by FACS after 48 hours. In contrast to some reports from 
other groups we found that EBER-expression did not convincingly confer any protection to 
EBV-loss cells in the Akata, Kem, or Mutu BL backgrounds (Figure 4.9). Although the EBER-
expressing Mutu clone n2 cells were less susceptible to ionomycin-induced cell death than 
were the other EBER-expressing cell lines, the empty vector control line showed a similar 
phenotype; indicating that this result was due to clonal variation.  
 
4.3.3 Expression and function of human IL-10 in EBV-loss clones 
The Takada group reported that EBER-expressing EBV-loss Akata cells could be protected from 
IFNα and hypoxia-induced cell death [338, 339], and that the mechanism responsible for this 
was upregulation of cellular IL-10 via activation of RIG-I [342]. Therefore we carried out q-PCR 
to look at transcription levels of cellular IL-10 in our panel of EBV-positive and loss clones as 
well as in our EBER-expressing and control EBV-loss cell lines. The assays were carried out in 
technical and experimental duplicate using an inventoried TaqMan primer and probe set (see 
Section 2.7.4) that is able to detect human IL-10 mRNA (Genbank reference NM000572.2) and 
does not cross react with the EBV-encoded IL-10 homologue, BcRF1. Surprisingly, we found no 
evidence that IL-10 is more highly expressed in either EBV-positive or EBER-expressing EBV-loss 
BL cell lines compared to EBER-negative cells (Figure 4.10-A, 4.10-B and data not shown). We 
also found that, whilst the addition of exogenous IL-10 could modestly protect BL cells from 
ionomycin-induced cell death, it could not fully reverse the EBV-loss phenotype; irrespective of 
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Figure 4.9 Apoptosis phenotype of EKS10 transfected BL clones 
 
A Akata-BL-derived cell lines B Kem-BL-derived cell lines, both induced using 1μg/ml 
ionomycin   C Mutu-BL-derived cell lines, apoptosis induced using 2μg/ml ionomycin 
 
All data representative, assays carried out on three separate occasions.  
n1 (a) and (b) = two different transfectants made in the same EBV-loss clone (n1)  
n2 = transfectants made in a second EBV-loss clone, n2  
clone n1 nv = EBV-loss clone n1 cells, no vector control 
Akata/Kem/Mutu BL/P1 = EBV-positive control for the respective BL backgrounds 
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 EBER status (Figure 4.11-A and 4.11-B). We could also never induce any apoptosis in BL clones 
by addition of IFNα, even using ten times the amount that is used by the Takada group, nor 
enhance the effect of ionomycin treatment (data not shown) and so were unable to 
investigate whether EBERs can affect cell survival by modulating IFN signalling in BL cell lines.   
 
 
 
 
 
 
Figure 4.10 IL-10 mRNA expression in EBER-positive and negative BL cell lines 
A IL-10 mRNA in EKS10 transfectants of Kem EBV-loss clone n1 and controls, relative to 
X50-7 
B IL-10 mRNA in EKS10 transfectants of Akata EBV-loss clone n1 and Mutu EBV loss clone n1 
and controls, relative to X50-7.  
 
Data from one pair of transfectants is shown for each tumour background, but all 
transfectants generated were tested. Relative quantities were calculated using the ΔΔCt 
method, mean and standard deviation of duplicate measurements is shown 
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Figure 4.11 IL-10 function in BL clones 
 
A Effect of 0,50 or 500ng/ml IL-10 on ionomycin-treated Kem-BL-derived cell lines 
comparing EBV-positive parental cells (Kem-BL), and loss clone n1 either 
untransfected (nv), containing control vector (control) or expressing EBERs (EKS10). 
Mean and standard deviation of triplicate measurements is shown 
 
B Apoptosis in ionomycin-treated EBER expressing cells supplemented with IL-10 
comparing EBV-loss clones from different backgrounds, IL-10 added at 50ng/ml. Mean 
and standard deviation of triplicate measurements is shown 
 
All assays carried out in triplicate on 3 separate occasions  
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4.3.4 Further investigations into EBER function in BL cells 
In order to further explore possible reasons for the disparity between our findings and the 
reports of others we carried out a number of other tests on our EBER-expressing cell lines. 
EBER FACS using a commercially-available PNA probe (Figure 4.12) showed that the majority 
(60<75%) of EKS10-transfected cells stained positive for EBERs. This may suggest either that 
some cells in the culture were EBER negative, or that some cells express low levels, below the 
threshold of detection. Whilst we may expect either of these two possibilities to influence the 
apoptosis phenotype of the cells, we would still expect to see a difference between EBER-
expressing and control cells in apoptosis assays if the EBER RNAs were able to confer 
resistance to EBV-loss clones. 
Finally, to determine whether EBER RNAs were able to confer a growth advantage to EBV-loss 
BL cells which could have been masked in our apoptosis experiments we carried out 
proliferation assays on healthy EBER-expressing cells versus empty vector control cells. We 
found that our stably transfected cell lines grew identically in culture over a seven day period 
in all three tumour backgrounds tested, indicating that EBERs provide no growth advantage to 
BL clones in vitro (Figure 4.13).  
 
 
 
 
 
 
 
 
 
Figure 4.12 EBER FACS in EKS10 transfectants A EBER FACS comparing EKS10 and control 
transfectants of Akata n1 B EBER FACS comparing EKS10 and control transfectants of Kem n1 
EBV-positive and untransfected controls were also included. Each sample was prepared and 
analysed in duplicate. Cells were hybridised to an EBER-specific FITC-labelled PNA probe or a 
scrambled sequence negative control PNA-FITC probe 
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Figure 4.13 Proliferation in EBER-expressing EBV-loss clones  
 
Growth of EBER-expressing and empty-vector transfected control cells  
A Transfectants of Akata EBV-loss clone n1 B Transfectants of Kem EBV-loss clone n1 
C Transfectants of Mutu EBV-loss clone n1 
Population doublings calculated from absolute cell counts and calculated as cells/ml 
divided by cells/ml at time 0, all measurements were made in triplicate and assays 
were carried out on two occasions 
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4.4 BART microRNAs 
4.4.1 Expressing the BART mRNAs in EBV-loss clones 
Although the EBV BamHI A rightward transcript-derived microRNAs (EBV miR BARTs) were first 
identified in EBV-positive epithelial cells where they are very highly expressed [352], they are 
also expressed at tens to hundreds of copies each per cell in LCLs and BL cell lines [94, 168, 
171]. In silico binding predictions carried out by several groups using several different 
algorithms found likely seed sequence matches for miR BARTs in a large number of 3’ UTRs of 
apoptosis-related genes [99, 168, 365, 366, 371], suggesting that miR BARTs may modulate 
apoptosis in BL cells. Additionally, some recently published functional studies have suggested 
that miR BARTs can downregulate pro-apoptotic proteins in epithelial cells [365, 366], and may 
be able to partially rescue apoptosis in BL cells [99].  
After ruling out either the EBNA1 protein or EBER RNAs, we therefore considered that the miR 
BARTs may be responsible for the EBV-loss phenotype. The primary transcripts derived from 
the BamHI A locus are long and complex; the exons span over 22kb of the viral genome and a 
number of different splice variants have been described, only some of which are thought to 
give rise to the BART miRs [373]. The BART miRs reside in intronic regions arranged in two 
clusters, with the exception of miR BART 2 which is located several kilobases downstream of  
 
 
 
 
 
 
 
Figure 4.14 Schematic of organisation of BART miRNAs in EBV genome. Grey boxes 
denote BamHI A region exons and the position of the BARTs region relative to the 
B95.8/Raji-repaired EBV genome sequence (Accession number M80517.1) 
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the other miRs (Figure 4.14). Since cloning the entire BamA locus is beyond the capacity of any 
lentivirus system we opted to generate two separate lentiviruses, each encoding one cluster of 
the miRs and so two separate genomic fragments were inserted into the F-UTG lentiviral 
backbone, driven by the PolII Trex promoter (see Section 2.6.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 BARTs primary transcripts in FTrex-BARTs-UTG transduced BL cells 
 
A BARTs cluster 1 (exon 1-1a) mRNA in EBV-positive cell lines and transduced cells 
B BARTs cluster 2 (exon 2-3) mRNA in EBV-positive cell lines and transduced 293 and Kem 
n1 cells 
All transduced cells treated with 1μg/ml DOX for 48 hours 
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Once miR BARTs cluster 1 and cluster 2 transduced EBV-loss cell lines had been generated we 
measured expression of our inserts by q-PCR, using a primer/probe set directed within the 
exon 1-1a and 2-3 introns, respectively. Interestingly, we found high levels of both cluster 1 
and cluster 2 mRNA expression in EBV-loss BL cells, compared to their EBV-positive 
counterparts and 293 cells transduced with the same constructs (Figure 4.15-A and 4.15-B). 
This was surprising and could not be simply explained by differences in lentiviral transduction 
as 100% of cells expressed GFP after sorting and cells of the same clone transduced with 
different constructs expressed similar levels of GFP (Figure 4.16). This implies that the primary 
BARTs transcripts may not be processed correctly in BL cells; leading them to accumulate, but 
are more efficiently processed and therefore degraded in HEK 293 cells. Notably the Raab-
Traub laboratory has previously reported a disconnect between the level of primary miR BART 
transcripts and the mature microRNAs in a range of EBV-positive cell lines [373].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Expression of GFP in BART FT-UTG transduced cells 
No vector, BARTs cluster 1, miR BART 5 and cluster 2 transduced cells shown in purple are 
all in Kem clone n1 cells and had been sorted for GFP expression. 293 cells transduced with 
the BARTs cluster 1 vector (shown in pink) were not sorted as these cells efficiently take up 
and integrate high levels of lentivirus; this is reflected in the fluorescence intensity of GFP. 
Representative FACS data of experiments carried out on multiple occasions, all cell lines 
shown in this figure (except no vector control) were determined to be >99% GFP positive 
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4.4.2 Expressing the BART microRNAs in EBV-loss clones 
When we went on to look at expression of the mature miRs in EBV loss BLs using stem-loop    
q-PCR assays we found that although we could restore similar levels of miRs to that seen in 
Akata-BL, we could not restore levels similar to other BLs, such as Kem-BL, which express 
higher levels of miR BARTs than Akata-BL (Figure 4.17-A). To test whether this was a feature of 
the construct design, we also made a construct containing pre-miR BART 5 alone driven by a 
Pol III promoter (see Section 2.6.4), using an identical strategy to that of Choy and colleagues 
who had used their construct to show an anti-apoptotic function for miR BART 5 in epithelial 
cells [365]. We looked at miR BART 5 expression from this construct compared to the cluster 1 
vector and found that, whilst we could substantially increase mature miR expression, we were 
still unable to achieve levels comparable to that typically seen in of Latency I BLs, 
demonstrated here by comparison to Kem-BL (Figure 4.17-B). Interestingly, in 293 cells 
transduced with our miR BART expression vectors, we were able to achieve expression of 
mature BART miRs at levels comparable to, or in excess of, those seen in Latency I BLs (Figure 
4.18). This may be due to more efficient entry and integration of lentivirus particles and/or 
more efficient processing or primary transcripts to mature miRs in epithelial cells, although we 
have not investigated this further.  
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Figure 4.17 Expression of mature BART miRs in transduced BL cells by stem-loop q-PCR 
 
A Example miR BART expression in Akata loss clone n1 and Kem loss clone n2 transduced 
with either the cluster 1 or cluster 2 BARTs expression vectors compared to EBV-positive 
parental cell lines. Normalised to EBV-positive Kem-BL cells, Log2 scale has been used due 
to the variation in magnitude of difference in miR expression between individual miRs and 
between different cell lines 
 
B Comparison of miR BART 5 expression from either the cluster 1 construct or the miR BART 
5 only lentivirus in EBV-loss cells compared to Latency I cell lines. Normalised to Kem-BL 
 
N.B. A subset of BART miRNAs was measured because of the number of assays and 
therefore cost involved in measuring all of the miRNAs within our constructs. The assays 
chosen detect some of the more highly expressed miRs in our panel of Latency I BL cell lines  
All data shown are mean and standard deviation of duplicate measurements and analysis 
was carried out using the ΔΔCt relative quantification method 
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Figure 4.18 Expression of miR BARTs in lentivirus-transduced 293 cells by stem-loop q-PCR 
Each miR is expressed relative to Kem-BL, which expresses relatively high levels of miR 
BARTs compared to other EBV-positive BLs. Data are mean and standard deviation of 
duplicate measurements and analysis was carried out using the ΔΔCt relative 
quantification method 
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4.4.3 The apoptosis phenotype of miR BART-expressing BL clones 
Since we could achieve similar levels of expression of the EBV BART miRs to that seen in  
Akata-BL, which also exhibits sensitivity to apoptosis upon loss of the viral genome, we carried 
out apoptosis assays on miR BART lentivirus-transduced EBV-loss BL cell lines. Although there 
was some variation between individual experiments in all BL backgrounds tested (Figure 4.19-
A), we could never show a convincing or reproducible effect on ionomycin-induced cell death 
due to the expression of BART miRs in EBV-loss clones (Figure 4.19-B). In total, 5 sets of miR 
BART expressing cell lines were made and tested; two derived from EBV-loss clones of     
Akata-BL, two derived from Kem-BL and one in a loss clone of Mutu-BL. A set of cell lines 
consisted of cells stably transduced with each of the empty, BARTs cluster 1, miR BART 5 only 
and BARTs cluster 2 lentiviruses.  
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Figure 4.19 Effect of miR BARTs on the apoptosis phenotype of EBV-loss clones 
 
A Experimental variation in apoptosis assays carried out a set of BARTs transduced 
Akata clone n1 cell lines. Numbers 1,2 and 3 refer to the experiment number and nv 
denotes ‘no vector’ control EBV-loss BL clones 
 
B Representative data from apoptosis assays carried out on BART lentivirus 
transduced clones of Akata-BL and Kem-BL. Control cells contained the empty F-UTG 
lentivirus 
 
All assays were carried out in triplicate in at least three independent experiments, 
apoptosis was induced using 1μg/ml ionomycin and miR BART expression was 
induced using 1μg/ml DOX. Mean and standard deviation from triplicate 
measurements are plotted, cell lines were compared using a Student’s T-test, but 
since there were no statistically significant consistent differences p-values are not 
shown 
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Figure 4.19  
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4.4.4 Regulation of pro-apoptotic BH3-only proteins by miR BARTs 
Although we could show no effect of miR BART expression on the ionomycin-sensitivity of EBV-
loss BLs we sought to determine whether the viral miRs were able to modulate the expression 
of the pro-apoptotic proteins Bim and Puma as has previously been reported in epithelial cell 
models [365, 366]. In DOX-induced 293 cells, which express similar levels of miR BARTs to EBV-
positive cell lines, we were able to show that both miR BART 5 alone and the cluster 2 miRs 
were able to downregulate Puma protein levels (Figure 4.20-A). Despite this result being 
seemingly paradoxical since miR BART 5 is within the cluster 1 miRs, this finding does agree 
with the work of the Raab-Traub group, who reported the same finding in HK1 cells [366]. 
However, we were unable to show any downregulation in 293 cells of the Bim tumour 
suppressor protein, which was also reported by this group. In contrast to our finding in 293 
cells we found no evidence of downregulation of Puma by the miR BARTs in EBV-loss clones 
(Figure 4.20-B), which suggests that the targets for miR BARTs in may vary according to cell 
type, especially since this is coupled with our finding that miR BARTs-transduced BL cells are 
not protected from apoptosis.  
Interestingly, we found that total Puma transcription, using a q-PCR assay which is able to bind 
all verified Puma mRNAs, seemed to increase in BART-expressing 293 cells, which appears to 
be in direct discordance with protein expression levels (Figure 4.20-C). This is likely to be due 
to an increase in transcription of the β-isoform (Figure 4.20-D) that is predicted to be 8-9kDa 
smaller than Puma-α and did not appear to be detected by the antibody used for these 
Western blots. We also found that Puma transcription appeared to be unchanged in miR BART-
expressing EBV-loss cells compared to EBV-positive and untransduced controls (data not 
shown).  
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Figure 4.20 Regulation of pro-apoptotic BH3-only proteins by miR BARTs 
 
A Western blot of Puma-α and Bim-EL expression in miR BARTs-expressing 293s 
B Western blot of Puma-α expression in miR BARTs-expressing EBV-loss cells 
C Relative expression of total Puma mRNA in miR BARTs-expressing 293s 
D Relative expression of Puma-β mRNA in miR BARTs-expressing 293s 
 
All inductions carried out using 1μg/ml DOX for 48 hours 
23kDa 
24kDa 
42kDa 
23kDa 
42kDa 
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4.5 Reinfecting EBV-loss clones: the Akata virus 
4.5.1 Generating Latency I EBV-loss reinfectants with Akata strain rEBV 
Having found that re-expression of EBNA1, EBER RNAs or clusters of BART miRs individually 
cannot restore apoptosis protection to EBV-loss BLs, we went on to test whether reinfection 
with EBV could rescue the phenotype. The Takada group who first reported that loss of EBV 
from Akata-BL cells could sensitise them to apoptosis [309], also showed that reinfecting EBV-
loss Akata with an Akata virus BAC could restore protection to the cells [310, 338, 557], and so 
we set out to repeat this using the same virus strain in EBV-loss clones of Kem-BL and Mutu-BL 
as well as in Akata-BL.   
When our research group first attempted reinfection of EBV-loss clones with Akata strain 
recombinant EBV (rEBV) we found that, of cells that did take up the virus, the vast majority 
expressed Latency III-associated viral genes such as EBNA2 and LMP1, which are not expressed 
in the parental BL cell lines. Subsequently, Latency I reinfectants could only be isolated from 
one EBV-loss clone of Mutu-BL in these experiments, which was surprising given that Shimizu 
and colleagues had reported being able to easily generate EBNA1 positive, EBNA2/LMP1 
negative clones from re-infected EBV-loss Akata-BL cells [557].  
The Akata BAC carries both GFP and neomycin resistance as markers of infection and so 
reinfected cells were drug selected for several weeks, sorted for GFP and then screened by     
q-PCR for the presence of viral DNA. If the viral load was found to be similar to that of an EBV- 
positive BL (10-100 copies per cell on average) then the cell line was analysed for viral gene 
expression. However, if viral DNA was detectable at a low level (0.1-10 copies per cell on 
average) the cells were single cell cloned and then re-screened by q-PCR. At this stage, cell 
lines and clones that were carrying multiple copies of the EBV genome per cell were analysed 
by q-PCR, Western blot, FACS and IF to fully characterise viral gene expression. If the 
reinfected EBV-loss cells were found to have similar gene expression to their EBV-positive  
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Figure 4.21 Experimental workflow used for reinfection of EBV-loss clones with rEBV. Akata 
virus rEBV positive cells were selected for on the basis of neomycin resistance using G418 
conditioned media whereas 2089-derived rEBV infected cells were selected for on the basis 
of hygromycin (HYG) resistance  
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counterparts (i.e. Latency I) they were then used in apoptosis assays to determine whether 
reinfection had affected the sensitivity of the cells to ionomycin-induced apoptosis. The 
experimental protocol is depicted in Figure 4.21.  
 
4.5.2 Viral protein expression in Akata virus EBV-loss reinfectants 
After drug selection, all of the cultures that were reinfected with the Akata virus were found to 
be 100% positive for GFP by FACS, suggesting that every cell contained transcriptionally active 
virus (Figure 4.22-A). In agreement with the Takada group, every clone that was subsequently 
selected for gene expression studies expressed EBNA1 protein and the majority of the clones 
were negative for LMP1 and BHRF1 by Western blot (Figure 4.22-B).  
Unfortunately a number of the reinfected clones did express EBNA2 (Figure 4.22-B) and the 
propensity of reinfectants to express EBNA2 varied between EBV-loss clones. For example, we 
were never able to isolate Latency I cells from one of our Akata-BL EBV-loss clones, whereas 
others gave rise to Latency I cells after only a single attempt. Accordingly, some clones were 
subjected to several independent infection experiments in order to yield Latency I reinfectants 
which expressed only EBNA1 protein by Western blot. We also showed that our reinfectants 
had a similar amount of lytic activity to the parental cell lines, as only 1-2% of cells were BZLF1 
positive by IF (Figure 4.22-C). 
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Figure 4.22 Viral protein expression in Akata virus EBV-loss reinfectants 
 
A Example overlays of FACS plots showing EBV-encoded GFP expression in Akata virus 
reinfected  Akata n1 cells and Kem n1 cells  
B Example Western blots of Latency I-associated genes in Akata virus reinfectants from a 
single experiment. Clones that expressed only EBNA1 protein (eg Akata n2 and Mutu n2) 
were carried forward for use in apoptosis experiments and others were discarded.  
C Example BZLF1 immunofluorescence in Akata virus reinfected EBV-loss Mutu n2 cells 
55kDa 
17kDa 
73kDa 
69kDa 
55kDa 
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4.5.3 Viral transcription in Akata virus EBV-loss reinfectants 
We also profiled viral transcription in our reinfectants using a panel of 18 q-PCR assays 
encompassing Latency I, Latency III and lytic cycle-associated genes, in order to more fully 
characterise gene expression in these cell lines. The method used was identical to that 
described earlier in this thesis (see Figures 3.3 and 3.20), whereby we expressed the quantities 
of the individual transcripts relative to either Latency I Kem-BL, the X50-7 LCL, or 100% BZLF1-
positive AKBM cells to ascertain how similar the gene expression profiles were to Latency I, 
Latency III or lytic cells, respectively. In the representative results shown in Figure 4.23; Qp-
driven EBNA1 transcripts were expressed relative to Kem-BL; BHRF1, EBNA2, LMP1 and LMP2A 
were expressed relative to X50-7 and BZLF1 was expressed relative to lytic AKBM cells. 
Reassuringly, we found that all of the cell lines that were negative for EBNA2 by Western blot 
had Latency I-like transcriptional profiles. 
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Figure 4.23 Transcription of viral genes in Akata virus EBV-loss reinfectants by q-PCR 
 
A Transcription of Latency I and Latency III-associated genes in Akata clone n5 + Akata rEBV 
B Transcription of Latency I and Latency III-associated genes in Kem clone n3 + Akata rEBV 
A and B expressed relative to Kem-BL or X50-7 as indicated 
C BZLF1 expression from two representative reinfectant lines and Kem-BL, relative to 100% 
BZLF1-positive AKBM cells  
  
All assays carried out in duplicate, mean and standard deviation are plotted, relative 
quantitation was calculated using the ΔΔCt method          AkV = Akata virus 
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4.5.4 Expression of viral microRNAs in Akata virus EBV-loss reinfectants 
Since the BART miRs may play a role in the apoptosis phenotype of Latency I BL cells [99], we 
wanted to know whether they are expressed to levels similar to Latency I BLs in EBV-loss cells 
reinfected with rEBV. We therefore measured the expression of several miR BARTs by stem-
loop q-PCR. Representative data from two cell lines that were found to express comparatively 
high or low levels of miR BARTs, respectively, is shown in Figure 4.24. In general, we found that 
our reinfectant cell lines express relatively low levels of miR BARTs, around 5-20% of that seen 
in Kem-BL however, since the levels in reinfectants were still higher than those seen in     
Akata-BL, which also displays the EBV-loss phenotype we were not overly concerned about this 
finding. Interestingly, these levels were similar to levels of miR BARTs expressed in EBV-loss 
clones transduced with our miR BART lentiviruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24 Expression of BART miRNAs in Akata virus EBV-loss reinfectants by stem 
loop q-PCR 
 
Expressed relative to Kem-BL using the ΔΔCt method and plotted on a log2 scale due 
to the magnitude of difference in expression levels between different cell lines. All 
measurements were carried out in duplicate and mean and standard deviation of a 
representative experiment are shown. 
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4.5.5 The apoptosis phenotype of Akata virus EBV-loss reinfectants 
We successfully isolated Latency I reinfectants from three different EBV-loss clones each of 
Akata-BL, Kem-BL and Mutu-BL, numbering 9 reinfectant cell lines in total. In apoptosis assays 
we found, in agreement with the Takada and Sample groups, that reinfection with the Akata 
rEBV was able to completely and consistently rescue the EBV-loss phenotype, protecting the 
EBV-loss cells to a level that was indistinguishable from that of the parental BL cell lines (Figure 
4.25-A and 4.25-B). 
However, a full rescue of the EBV-loss phenotype only occurred in 6 of the 9 cell lines 
generated. In two of the three remaining cell lines (Akata n5 + Akata rEBV, and Kem n1 + Akata 
rEBV), we did see a substantial and significant amount of protection that was consistent in all 
assays, nevertheless the reinfectant cells were never protected to quite the same degree as 
EBV-positive parental cells (Figure 4.25-C). Surprisingly, the final cell line in this set, Akata n2 + 
Akata rEBV, could not be rescued by reinfection with the Akata virus and exhibited an identical 
phenotype to uninfected cells of the same loss clone (Figure 4.25-D), despite expressing 
EBNA1, EBERs and miR BARTs. Interestingly, we could find no correlation between the 
protection conferred by reinfection with Akata rEBV and viral gene expression. For example; 
the lowest miR BART-expressing reinfectant, Kem n2, was fully protected (see Figures 4.24 and 
4.25-B). Since we used the same panel of EBV-loss clones for all of our Latency I gene 
expression and reinfection assays, we conclude that the EBV-loss phenotype can be rescued by 
multiple, but not individual, Latency I-associated genes, although clonal variation between 
EBV-loss isolates also affects the apoptosis phenotype of BL cells.  
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Figure 4.25 Apoptosis phenotype of Akata virus EBV-loss reinfectants 
 
A Example of experimental variability in Kem clone n3 Akata rEBV reinfected cells. 
Data from three independent experiments carried out in triplicate 
 
B Representative apoptosis data from Akata rEBV reinfected EBV-loss cells in the 
Akata-BL, Kem-BL and Mutu-BL backgrounds.  
 
C Representative apoptosis data from Akata n5 + Akata virus, which was not fully 
rescued 
 
D Representative apoptosis data from Akata n2 + Akata virus, which was not 
protected 
 
All measurements were carried out in triplicate and mean and standard deviation of a 
representative experiment are shown for panels B, C and D. Statistical analysis was 
carried out using a two-tailed Students T-test 
AkV = Akata virus 
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Figure 4.25  
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4.6 Reinfecting EBV-loss clones: the B95.8 rEBV 
4.6.1 Generating Latency I EBV-loss reinfectants with CpWp-KO strain rEBV 
During primary infection of resting B cells, expression of the majority of the latent genes, (i.e., 
EBNAs 1, 2, 3A, 3B, 3C, LP and BHRF1), is initially driven by the Wp promoter and later from the 
Cp promoter, whilst LMP1 and LMP2 are transactivated by EBNA2 [85, 86]. We therefore 
theorised that knocking out the Wp Cp promoters would force the virus to consistently and 
permanently adopt a Latency I expression pattern, driving EBNA1 expression from the Qp 
promoter as it is in EBV-positive BLs. Such a virus (a C promoter and W promoter knock out; 
CpWp-KO) had already been generated by Dr Rose Tierney for use in another project [485] and 
so we carried out reinfections of EBV-loss BLs using the CpWp-KO 2089 rEBV. Like the Akata 
BAC, EBV-loss cells were drug selected for several weeks at which point clones carrying rEBV 
were screened for viral gene expression (see Figure 4.21). 
In comparison to the Akata virus fewer CpWp-KO infected cultures survived drug selection and 
viral loads in CpWp-KO reinfectants tended to be low (<10 genomes per cell) (data not shown). 
We also found in some cultures which were single cell cloned, that almost every clone had an 
average of 1-2 genomes per cell by q-PCR, suggesting that the EBV genome in these cells may 
have been integrated rather than episomal. Although generating reinfectants using the   
CpWp-KO virus was less efficient than we had hoped, we were able to isolate a total of six cell 
lines with a genome load of at least 8 genomes per cell; 3 in EBV-loss clones of Akata-BL, 2 in 
EBV-loss clones of Kem-BL and 1 from an EBV-loss clone of Mutu-BL.  
 
4.6.2 Viral protein expression in CpWp-KO virus reinfectants 
Figure 4.26-A shows Western blots carried out on a representative set of CpWp-KO 
reinfectants that were generated and screened at the same time. As expected, EBNA1 was 
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generally detectable in cells that were found to contain viral DNA, but we could never detect 
any EBNA2, BHRF1 or LMP1. In one reinfectant, Akata n3 + CpWp-KO virus, EBNA1 protein was 
not detectable however, we later showed that this cell line actually had a viral load of less than 
one copy per cell, and so may have contained a mixture of EBV-positive and EBV-loss cells 
(data not shown). This was not investigated further and the cell line was not used in apoptosis 
assays. As with the Akata virus, we found that only 1-2% of reinfected cells were BZLF positive 
by IF suggesting that these lines support a similar level of lytic viral gene expression to parental 
EBV positive BLs (Figure 4.26-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Protein expression in CpWp-KO reinfectants 
 
A Representative Western blots with calregulin as a loading control. Antibodies: 
EBNA1 – Human serum (AMo), BHRF1 – 5B11 mouse monoclonal, EBNA2 – PE2 
mouse monoclonal, LMP1 – CS1-4 mouse pooled clones  
B Representative immunofluorescence images showing nuclear staining (DAPI, blue) 
and a BZLF1 positive cell (red) surrounded by latent (BZLF1 negative) cells. Antibody 
was mouse monoclonal α-BZLF1 made by Martin Rowe as detailed in the methods 
section 
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4.6.3 EBER in situ hybridisation in CpWp-KO virus reinfectants 
Although the CpWp-KO virus carries a GFP marker, for reasons not fully understood it is not 
reliably expressed in B cells, therefore we measured EBER expression at the single cell level to 
ensure that every cell in CpWp-KO cell lines contained transcriptionally active virus. Reinfected 
cells and controls were hybridised to an EBER-specific fluorescently-labelled probe or a 
negative control probe in solution before being analysed by FACS. Of the six reinfectants that 
were used in apoptosis assays, at least 98% of cells were EBER positive in every case. 
Representative data from 2 of the 6 lines and uninfected controls is shown in Figure 4.27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 Representative EBER FACS in CpWp-KO reinfectants 
 = uninfected EBV-loss cells, Red  = CpWp-KO reinfectants purple
EBER RNA was detected using an EBER-specific, FITC-conjugated 
PNA probe. Cells of the relevant reinfectant hybridised to a 
scrambled control PNA-FITC probe and EBV-positive EBER-PNA-FITC 
stained cells were included as additional controls 
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4.6.4 Viral transcription in CpWp-KO virus EBV-loss reinfectants 
Viral transcription in the CpWp-KO reinfectants was measured using both standard q-PCR and 
microfluidic dynamic array chips, which can be used to run up to 48 different q-PCR assays on 
each of 48 different samples in a single run. Example data from two CpWp-KO reinfectants that 
were analysed on a microfluidic chip is shown in Figure 4.28-A. Using the same relative 
quantitation strategy as was used for the Akata virus reinfectants we found that CpWp-KO 
reinfectants exhibited a Latency I-like expression pattern and consistent with our Western 
blots, BHRF1, EBNA2 and LMP1 transcripts were low or undetectable in comparison to X50-7. 
We did detect a small number of LMP2A transcripts, suggesting that these cell lines contained 
intact terminal repeat regions, indicative of the presence of episomal virus particles [558]. 
Again, BZLF1 transcript levels indicated a similar amount of lytic activity to that found in the 
parental EBV-positive cells (Figure 4.28-B). 
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 Figure 4.28 Viral transcript expression in CpWp-KO reinfectants by microfluidic q-PCR 
 
A Transcription of Latency I and Latency III-associated genes in Akata clone n1  
B Transcription of Latency I and Latency III-associated genes in Kem clone n1 
A and B expressed relative to Kem-BL or X50-7 as indicated using ΔΔCt method  
C BZLF1 transcription in Akata n1 and Kem n1 compared to lytic Akata (AKBM) 
Data from microfluidic chip q-PCR carried out in duplicate 
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4.6.5 Expression of viral microRNAs in CpWp-KO EBV-loss reinfectants 
Since the CpWp-KO virus is a derivative of the B95.8 EBV strain it harbours a 12kb deletion in 
the BamHI A locus, and therefore only contains a small subset of the miR BARTs which lie 
outside the deletion [559, 560]. When we checked expression of those that remain in the virus 
(miR BARTs 3, 4, 1 and 15) we found that they were also expressed at low levels compared to 
Kem-BL (<5% of Kem-BL levels), but were still comparable to, or higher than, levels in Akata-BL 
(Figure 4.29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 Expression of BART miRNAs in CpWp-KO EBV-loss reinfectants 
 
Expressed relative to Kem-BL and plotted on a log2 scale due to magnitude of 
difference in expression levels between different cell lines. All measurements were 
carried out in duplicate and mean and standard deviation of a representative 
experiment are shown. 
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4.6.6 Phenotype of EBV-loss clones reinfected with CpWp-KO virus 
We next carried out apoptosis assays on the six CpWp-KO virus reinfected EBV-loss clones that 
had >8 viral genomes per cell and expressed Latency I. Although we found convincing evidence 
of apoptosis protection in 5 of the 6 strikingly, and in contrast to what was observed with the 
Akata-virus, we were unable to restore any of the 5 to their parental phenotype. Four of the 
reinfectants were considerably protected; their uninfected EBV-loss counterparts underwent 
more than twice the amount of cell death in response to identical stimulus. However, the 
reinfected cells were always noticeably and significantly less protected than their EBV-positive 
counterparts. This characteristic was found to be consistent between individual experiments 
(Figure 4.30-A) and across different tumour backgrounds (Figure 4.30-B). In the 5th CpWp-KO 
reinfectant that showed apoptosis protection the effect was further reduced; the Kem n1 
CpWp-KO reinfectant was only slightly protected from ionomycin-treatment compared to 
isogenic EBV-loss cells, though this difference was statistically significant (Figure 4.30-C). 
Interestingly, this was one of the same clones to which the Akata virus restored only partial 
apoptosis resistance (a CpWp-KO reinfectant was never isolated from the second clone which 
exhibited this phenotype).  
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In the sixth CpWp-KO reinfectant, Akata n2, the presence of the virus had no discernible effect 
and the cells were phenotypically identical to the uninfected EBV-loss clone (Figure 4.29-D). 
Intriguingly, Akata n2 is the same clone that could not be protected by reinfection with the 
Akata virus, suggesting that this clone is fundamentally different to the other EBV-loss clones, 
perhaps reflecting the acquisition of a cellular mutation in vitro. Clearly, although the      
CpWp-KO virus is able to confer apoptosis protection to EBV-loss BLs it is incapable of fully 
compensating for the loss of the endogenous virus from these cells.  
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Figure 4.30 Apoptosis data from CpWp-KO reinfected EBV-loss clones 
 
A Comparison of data from three independent experiments carried out in triplicate on 
CpWp-KO reinfected Akata n1 cells and controls to demonstrate consistency of 
phenotype  
 
B CpWp-KO reinfected Akata n3, Kem n2 and Mutu n1 cells in which the virus 
conferred partial protection 
 
C CpWp-KO reinfected Kem n1 cells in which the virus conferred only slight protection  
 
D CpWp-KO reinfected Akata n2 cells in which the virus conferred no protection 
 
All assays were carried out in triplicate on three occasions and data shown are the 
mean and standard deviation. Statistical analyses were carried out using a two-tailed  
Students T-test 
CW-KO = CpWp-KO virus, nv = no virus (uninfected)  
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Figure 4.30 
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4.6.7 Comparison of apoptosis in CpWp-KO and Akata rEBV reinfectants 
Figure 4.31-B is a graphical summary of all of the CpWp-KO and Akata virus reinfectants that 
were generated and used in apoptosis assays in this study. The relative amount of protection 
conferred to each clone by each virus is represented using a colour grading system (Figure 
4.31-A). Although we could not generate a complete set of reinfectants (derivatives of every 
EBV-loss clone reinfected with each of the two virus strains), this representation clearly 
demonstrates that reinfecting EBV-loss clones with the Akata virus tends to restore full or 
almost full protection from ionomycin-induced cell death, whereas the CpWp-KO virus is only 
ever able to restore partial protection at best. Interestingly, those clones which deviate from 
this general rule do so for both virus strains; most notably the Akata n2 EBV-loss clone could 
not be rescued by infection with either Akata or CpWp-KO rEBV. The Kem n1 clone could only 
be partially restored, although the differential amount of protection conferred by reinfection 
with Akata virus relative to CpWp-KO virus was evident. It is possible that this phenomenon is 
caused by these clones having acquired additional genetic mutations under conditions of 
cellular stress during single cell cloning, although we have not investigated this hypothesis.  
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Figure 4.31 Apoptosis phenotypes of CpWp-KO and Akata virus reinfectants 
 
A Key to colour chart:  
= statistically indistinguishable from uninfected EBV-loss cells  No protection 
 = statistically indistinguishable from parental EBV-positive cells  Full
 = small significant difference between EBV-positive and reinfected (more Substantial
than 70% protected) 
= intermediate phenotype between EBV-positive and loss (~50% protected) Partial 
 = small but significant difference between EBV-loss and reinfected (less than Minimal
30% protected) 
 
B Comparison table, ND = not done due to being unable to isolate a Latency I 
reinfectant in this clone 
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4.7 Loss of Akata rEBV from Akata clone n5 reinfected cells 
In one reinfectant cell line, Akata n5 + Akata rEBV, which was substantially, but never fully 
protected from ionomycin-induced apoptosis we wanted to determine the level of 
heterogeneity in viral gene expression between cells in the culture, as we hypothesised that 
this could explain the phenotype we had observed. First we re-cloned the cell line, and 
determined EBNA1 levels by Western blot. Interestingly, levels of EBNA1 protein did show 
some variability, although the protein was still clearly detectable in every clone (Figure 4.32-A).  
To test whether these varying levels of EBNA1 could affect the phenotype of the cells we 
carried out apoptosis assays on two clones which expressed high EBNA1 compared to two 
which expressed the lowest levels of EBNA1. We consistently found that one of the low 
EBNA1-expressing clones was more sensitive to ionomycin-treatment than the other clones, 
apparently supporting the idea that very low viral gene expression levels might be insufficient 
to protect EBV-loss clones from apoptosis (Figure 4.32-B). However, further investigation 
indicated that this interpretation is probably incorrect. During single cell cloning the media 
used for the cultures was not supplemented with G418 to select for retention of the rEBV 
genome and so it appeared that, whilst three of the four clones had retained the virus and 
were still >99% GFP positive, the fourth clone, which showed increased sensitivity to 
apoptosis, had lost the virus in the majority of the cells and was now only 20% GFP positive 
(Figure 4.32-C).  
Remarkably, loss of the virus had led directly to a loss in protection from apoptosis and so we 
found that we could directly reverse the EBV-associated apoptosis phenotype in cells that had 
been infected with and then lost EBV for a second time. Additionally, when we looked at GFP 
expression in the live population of cells from the sensitive clone after ionomycin treatment, 
almost all of the surviving cells were GFP-positive. Showing that even in a mixed population, 
only those cells that contained EBV were able to survive drug treatment, providing direct 
evidence that the presence of EBV really is responsible for the phenotype we see and is not a 
consequence of in vitro culture, single cell cloning or drug selection.  
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Figure 4.32 Effect of a second EBV-loss event on cell death in Akata n5 subclones 
A EBNA1 in subclones of Akata n5 + Akata rEBV, H = high EBNA1, L = low EBNA1. Blotted 
using AMo human serum which recognised EBV-EBNA1 
B Representative apoptosis assay data on Akata n5 + Akata rEBV subclones 
C GFP positivity of ionomycin-treated and untreated cell populations                     
Plus (+) and minus (-) denote ionomycin treated and untreated, respectively. Apoptosis 
assays were carried out in triplicate on three occasions and data shown are mean and 
standard deviation 
55kDa 
42kDa 
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4.8 Further investigation of viral transcription in Latency I BLs 
That the Akata virus strain could protect better than the CpWp-KO virus seemed a very 
surprising result considering that both ostensibly expressed only Latency I-associated genes. 
This left us with two hypotheses; that the CpWp-KO simply expressed levels of the Latency I 
genes that were too low to be effective, or that a factor encoded within the B95.8 deleted 
region, such as the BART miRs, may be necessary for full restoration of the apoptosis 
protection phenotype. However, since Latency I genes were expressed to variable levels in 
Akata virus reinfectants, and expression did not appear to correlate with the amount of 
apoptosis protection restored, we considered the second hypothesis to be more credible.  
We were also intrigued by a paper that had been published by the Flemington group [174], 
which reported that LF3, a lytic cycle-associated gene encoded on the opposite strand to the 
miR BARTs in the BamHI A region, is abundantly expressed in latent Mutu-BL and Akata-BL 
cells. In fact their analysis of polyadenylated transcripts from these cell lines by RNA 
sequencing showed that LF3 was present in latent BLs at copy numbers in excess of 98% of all 
cellular genes. In light of this we decided to examine by q-PCR, the expression of LF3 and its 
sister genes LF1 and LF2, which also reside within the BamHI A region, in EBV-infected cell lines 
(Figure 4.33).  
We assayed a large number of cell lines of various latency types and derived from a range of 
diseases and found detectable transcripts of LF1 LF2 and LF3 in every sample, including strictly 
latent cord blood-derived LCLs. Although expression of all three LFs did increase dramatically 
in AKBM cells induced into lytic cycle compared to uninduced AKBM cells, we also found that 
the Ct values obtained for LF3 in Latency I BLs were second only to EBER1 (data not shown). 
This suggested that LF3 may be present in numbers that would average many hundreds of 
copies per cell, making it unlikely that what we were measuring could be due to the presence 
of a small number of cells in lytic cycle. In order to absolutely quantify copy numbers of LFs in 
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EBV-infected cells, we used microfluidic chips to assay 45 EBV genes (including LFs) and 3 
endogenous controls simultaneously in a number of Latency I BLs compared to a plasmid DNA 
standard. The detailed viral gene expression profiling of a large number of EBV-infected cell 
lines will be published elsewhere [175], but data for the expression of Latency I-associated 
genes and LFs in a panel of Latency I BLs is shown in Figure 4.34.  
All EBV infected cells express EBNA1 as they are dependent upon its presence to maintain the 
viral genome, but due to the stability and long half-life of the EBNA1 protein it is only 
transcribed at very low levels [174]; less than 10 copies per cell by our estimates from absolute 
quantitation studies [175]. Although we see variation between Latency I BLs it is clear that 
transcripts of LF1, LF2 and LF3 are present in BL cells in at least equivalent abundance to 
EBNA1, and in some cases, at many times higher levels. Currently, we do not have functional 
data to support a role for these genes in Latency I BLs as our efforts to this end have been 
hampered by a lack of reagents. However, the new expression data do suggest that the 
accepted dogma of Latency I-associated genes may extend beyond the EBERs, EBNA1 protein 
and BART microRNAs.  
  
 
 
 
 
 
 
 
 
 
 
Figure 4.33 Position of LF genes in the BamHI A region of the EBV genome  
 
Schematic of the BamHI A locus showing the relative position of BamHI A exons (grey), 
miRNAs (red) and putative LF coding regions on the opposite DNA strand 
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Figure 4.34 Transcription of Latency I-associated and LF genes in BL cell lines using 
microfluidic chip q-PCR normalised to plasmid DNA standards in order to quantitate 
RNA copy number per microgram of total RNA as published in [175]. Values displayed 
on a Log2 scale due to the wide variation in copy number between different transcripts 
and cell lines.  
 
Absolute quantitation of EBV transcripts in 8 Latency I BL cell lines: Rael-BL, Ezema-BL, 
Sav-BL, Dante-BL, Akata-BL and EBV-positive clones of Kem-BL, Mutu-BL and Awia-BL 
 
NB the LF3 gene is mostly composed of repetitive sequences (known as the PstI 
repeats), downstream of a unique region. Our q-PCR assay is directed against a section 
of the unique region of the gene (primer/probe sequences and co-ordinates are listed 
in the Materials and Methods section of this thesis) so as to ensure that q-PCR values 
reflect number of whole LF3 transcripts, rather than the number of PstI repeats 
present. 
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Conclusions II 
We have shown that reinfection of EBV-loss clones with a wild-type, Akata-BL-derived 
recombinant EBV can fully restore the EBV-positive phenotype, thereby confirming that EBV is 
directly responsible for the difference in apoptosis sensitivity between EBV-positive and EBV-
loss BL clones. Furthermore, our finding that the loss of rEBV from reinfected cells reverses the 
phenotype and re-sensitises EBV-loss Akata-BL cells to apoptosis indicates that protection is 
mediated by EBV gene expression and reduces the possibility that this could be an unintended 
consequence of antibiotic selection.    
Consistent with the findings of other groups, we found that ectopic expression of EBNA1 
protein was unable to rescue the apoptosis phenotype of EBV-loss cells [327, 339]. 
Surprisingly, we also found that re-expression of the EBER RNAs or clusters of BART microRNAs 
did not confer any survival advantage to EBV-loss cells. In contrast, we found that a B95.8-
derived rEBV, which harbours a large genomic deletion in comparison to the Akata rEBV, could 
partially rescue the EBV-loss phenotype, but could not fully restore apoptosis protection unlike 
the Akata rEBV. We therefore hypothesise that the Latency I-associated genes function co-
operatively to inhibit apoptosis in BL and that viral genes encoded within the region of BamHI 
A locus that is deleted in B95.8 are partially responsible for the EBV-loss phenotype.  
We constructed lentiviruses to allow us to inducibly express individual EBERs in EBV-loss cells, 
but found that these vectors did not efficiently express RNAs of the correct length and thus, 
we could only restore EBER-expression to a fraction of the level seen in Latency I BL. 
Interestingly, we are aware that other groups have experienced similar difficulties with EBER-
expressing lentiviruses (Joan Steitz and Elizabeth Boulden, personal communications) and we 
hypothesise that this is due to poor transcription termination. We therefore used the pEKS10 
plasmid in our functional assays, as this vector contains the endogenous EBER regulatory 
regions and can restore EBER expression at comparable levels to Latency I BL cell lines [339].  
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Consistent with our hypothesis that the EBER RNAs may co-operate with other EBV gene 
products in order to protect BL cells from apoptosis, the two groups that have reported an 
anti-apoptotic role for EBV in BL found that ectopic expression of EBERs only partially restored 
tumorigenicity of EBV-loss clones of Akata-BL in SCID mice. Only around 50% of mice that were 
injected with EBER-expressing EBV-loss cells developed tumours, and EBER+/EBV- cells took 
significantly longer than an EBV-positive clone to give rise to tumours, suggesting that EBERs 
may be necessary, but are not entirely responsible for the EBV-loss phenotype [339, 340]. 
Additionally, the Sample group also reported that, whilst EBERs can contribute to 
tumorigenicity in vivo, they do not restore apoptosis protection to Akata-BL cells in vitro [340]. 
Unfortunately, since our in vivo experiments were carried out during a sabbatical visit to the 
Walter and Eliza Hall Institute, we have been unable to test whether our EBER+/EBV- cell lines 
are more tumorigenic than their EBV-loss counterparts in NSG mice. It is also important to 
note that the Sample group reported that 2 EBV-loss Akata-BL clones which stably express 
EBNA1 as well as EBERs were considerably more tumorigenic in vivo than the same clones 
expressing EBERs alone [340]. The authors attribute this finding to the increased level of EBER 
expression that they detect in the EBNA1+/EBER+/EBV- cells because cells expressing EBNA1 
alone are not tumorigenic, but another interpretation is that the presence of EBNA1 enhances 
the tumorigenicity of EBER-expressing cells by functional co-operation.  
It has been suggested that EBER RNAs might inhibit apoptosis in Akata-BL clones and EBV-
negative BJAB Burkitt-like lymphoma cells by upregulation of Bcl-2 and IL-10, or modulation of 
interferon signalling by inhibition of PKR [310, 339, 342, 561, 562]. However, these findings are 
contradicted by others [335], and we likewise find no evidence that EBERs are able to carry out 
these functions in our extensive panel of clones. We therefore infer that any anti-apoptotic 
function of the EBERs may occur by a previously undescribed mechanism. Alternatively, it is 
possible that EBER-mediated gene regulation is only evident after the induction of apoptosis in 
BL cells, and this is investigated in the following chapter. 
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Although EBV-loss has previously been described in three BL backgrounds, EBERs have only 
been shown to inhibit apoptosis in a small number of EBV-loss clones derived from the Akata-
BL background [327, 340, 341]. Our experiments carried out on nine pairs of EBER-expressing 
and empty-vector control cell lines derived from three different EBV-loss backgrounds is the 
most comprehensive study of EBER-function in BL to date. Therefore, we conclude that the 
EBERs are not solely responsible for the inhibition of apoptosis in Latency I BLs. However, we 
do suggest that the EBER RNAs are able to co-operate with EBNA1 and the BART microRNAs in 
protecting BL cells from apoptosis. 
This conclusion is further supported by a recent publication from the Sugden group, which 
showed that apoptosis induced by the forced eviction of EBV from Latency I BLs can be 
inhibited by the BART miRs [99]. Unfortunately, due to the nature of their experiment (i.e. not 
comparing BARTs-expressing EBV-loss cells to isogenic empty-vector controls), we are unable 
to determine whether the BART miRs are able to fully or only partially substitute for the 
presence of EBV from these data. Interestingly though, this paper did report considerable 
variation in the phenotype conferred by the BARTs miRs between two EBV-positive clones 
from two different Latency I BLs. In fact miR BARTs did not improve the survival of a Dante-BL 
clone as measured by population doublings until four weeks after the start of the experiment, 
whereas a clone of Sav-BL showed a difference between the control and BART-complemented 
cells after two weeks. It is likely that a very subtle phenotype such as this would not be 
detected in our 48 hour assays. We also carried out our experiments on multiple clones from 
three different tumour backgrounds to control for clonal variation and ascertain the generality 
of our findings, whereas the published study included only a single clone from each of two BL 
backgrounds.   
Although the BART miRs have been reported to downregulate Bim and Puma in epithelial cells 
[365, 366], we found, in-keeping with other groups, that these proteins are not regulated by 
miR BARTs in B cells [99, 168, 371]. However, it is possible that the microRNAs restrain the 
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expression of these proteins in BL cells rather than downregulating them, and therefore this 
phenotype would only be detected in assays comparing miR BART-positive and negative cells 
after apoptosis had been induced; a possibility which is investigated in the following chapter. 
We have also not investigated whether miR BARTs can regulate Puma and Bim or inhibit cell 
death when both microRNA clusters are expressed together, as we were unable to clone the 
entire BamHI A locus into a single vector. We postulate that sequence context may be an 
important requirement for efficient expression of miR BARTs as we were able to express 
endogenous levels of miR BART-5 from a lentivirus containing only its pri-miR sequence; we did 
not investigate this further due to the technical difficulties associated with transducing B cells 
with a different lentivirus to express each BART miR.  
Further to our hypothesis of co-operation between the viral genes, we also noted that the 
Takada and Sample groups both found that reinfected EBV-loss Akata-BL clones were less 
tumorigenic than their counterpart EBV-positive clones containing wild type virus [310, 340]. 
We interpret this as evidence for an anti-apoptotic role for the miR BARTs in this system as the 
recombinant Akata genome used contained an antibiotic resistance cassette and F-plasmid 
within the BamHI A locus. In contrast, our reinfection experiments used an Akata virus 
recombinant that was generated several years later and contains the selection cassette and    
F-plasmid within the BamHI X locus and consequently has an intact BamHI A locus [488]. 
Therefore, in order to further investigate our hypothesis of viral gene co-operation we are 
currently developing a new system for generating and modifying recombinant EBV genomes 
that will allow us to rapidly create viruses which are unable to express particular transcripts 
without disruption of other transcripts even within the same loci. This method uses two 
sequential rounds of temperature-regulated homologous recombination to create ‘scar free’ 
mutants that do not retain flip or lox sites. This approach has proven successful for generating 
mutant recombinant versions of a variety of viruses including KSHV and murine herpesvirus-
68, which are closely related to EBV [563-565].  
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Using this technology we plan to generate viral genomes that lack the ability to express EBERs 
or BARTs, although we will be unable to investigate the effect of knocking out EBNA1 due to its 
essential role in genome maintenance. In addition, we plan to make viruses that are knocked 
out for LF1, LF2, or LF3, in order to determine whether these transcripts, which appear to be 
abundantly expressed in BL [174], also contribute to apoptosis inhibition by EBV.  
Having shown that Latency I EBV can fully restore apoptosis protection to the majority, but not 
all, EBV-loss clones from three different tumour backgrounds we next went on to investigate 
the differences in apoptosis signalling between EBV-positive and loss clones. In these 
experiments, described in the next chapter, we aimed to identify targets of Latency I genes to 
further inform us about their possible mechanisms of action and determine whether any 
differences in apoptosis signalling between clones could explain why two clones were not 
phenotypically rescued by reinfection with a recombinant EBV. We also hoped to confirm our 
hypothesis that gene regulation by EBV would only be revealed when comparing EBV-positive 
and loss clones after apoptosis has been induced.  
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5. Results Part III                                                                                              
THE ROLE OF CELLULAR GENES IN THE APOPTOSIS-
PHENOTYPE OF EBV-LOSS CLONES 
5.1 Apoptosis-response of EBV-loss clones to BH3 ligands 
Whilst our attempts to identify precisely how EBV genes protect BL cells were hampered by 
apparent requirements of co-operation, we considered that there may be some consistent 
pattern to downstream effects on cellular genes. Our earlier experiments, in which we used a 
range of different drugs to induce apoptosis in BL cells, indicated that that the intrinsic Bcl-2 
family-mediated apoptosis pathway is important in the EBV-loss phenotype, so we focussed on 
determining which members of the Bcl-2 family are important in the response of BL cells to 
cytotoxic insults. Microarray studies comparing EBV-loss clones to their EBV-positive 
counterparts or EBV-positive and negative BLs from different patients have found few 
differences in transcription between cells which do or do not contain the virus, we therefore 
decided to use functional assays to investigate the role of the Bcl-2 family in BL clones [194, 
195, 566]. 
In 2007, a method was published by which cells could be ‘BH3 profiled’ that is, the ability of 
BH3-only proteins to initiate the apoptotic cascade in different cells could be determined 
[567]. Due to the specificity with which anti-apoptotic Bcl-2 homologues bind to different pro-
apoptotic BH3 only proteins, BH3 profiling can reveal which of the anti-apoptotic proteins is 
critical for the survival of the cells being profiled. This in turn has been shown to correlate 
directly with the sensitivity of cells with different BH3 profiles to cytotoxic insults [568-570]. 
We were keen to investigate whether EBV-loss clones might have an altered BH3 profile to 
their EBV-positive counterparts, which may in turn allow us to resolve the question of which 
Page | 191  
 
cellular apoptosis regulators EBV may target to inhibit apoptosis in BL and therefore the 
mechanism by which the virus achieves this.  
5.1.1 Expressing BimS-derived BH3 ligands in EBV-loss clones 
In the BH3 profiling technique published by Letai and colleagues [567], short BH3 peptides (20-
25 amino acids of the BH3 domain of the BH3-only protein of interest) are added to 
permeablised cells and the amount of mitochondrial membrane depolarisation caused is 
measured by FACS. However, another group has shown that BH3 peptides of less than 26 
amino acids may not bind pro-survival Bcl-2 proteins in the same way as the full length 
proteins [500]. It is also relatively expensive to have the full range of BH3 peptides synthesised 
and technically difficult to permeablise the plasma membrane of cells without affecting the 
inner cell membranes, including that of the mitochondria, which might impact the subcellular 
localisation or function of Bcl-2 family member proteins or other regulatory molecules.  
Our collaborators at the WEHI developed a similar method which uses whole BH3 variant 
proteins to induce apoptosis as opposed to BH3 peptides. The variant proteins are all derived 
from BimS, the smallest and most potent isoform of the pro-apoptotic BH3-only protein Bim 
[450]. In each BimS-derived BH3-variant the BH3 domain has been modified either by replacing 
the entire domain or by mutating specific residues to mimic the binding specificity and affinity 
of a range of BH3-only proteins. The binding selectivity of several endogenous pro and anti-
apoptotic Bcl-2 family members is depicted in Figure 5.1-A and the corresponding BimS-derived 
BH3 variants are shown in Figure 5.1-B. BimS-wt is the wild-type BimS protein, BimS-Bad and 
BimS-Noxa were made by replacing the entire BH3 domain (residues 51-76 of BimS-wt) with 
that of Bad or Noxa respectively, BimS-2a is an Mcl-1-specific 2 amino acid mutant of BimS-wt 
and BimS-4e is a 4 point mutant of BimS-wt which is unable to bind any of the pro-survival Bcl-2 
family and serves as a negative control (Table 2.3 contains a detailed description of BimS BH3 
ligands) [423, 500]. These BimS-derivatives have been shown to closely correlate in their  
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Figure 5.1 Binding specificity and affinity of BH3 proteins and mimetic ligands  
 
A Endogenous Bcl-2 family members B BH3 variant binding to Bcl-2 homologues 
 
C Affinity of BH3 peptide binding to pro-survival Bcl-2 proteins, all measurements in nM 
from Biacore solution competition assays carried out by Lin Chen, Erinna Lee and 
colleagues at WEHI [398, 472] 
Page | 193  
 
binding to Bcl-2 homologues with the full length proteins they mimic in both in vitro assays and 
in cells [500]. Therefore this method can be used to diagnose blocks in the Bcl-2 signalling 
pathway that can then be overcome using specific BH3 mimetics [301, 434, 571]. The relative 
binding affinities of each of the BH3 domains inserted into the BimS backbone for each of the 
pro-survival Bcl-2 proteins, as measured by groups who generated this system, are shown in 
Fig 5.1-C. 
5.1.2 Generating BimS variant-expressing cell lines 
Each of the BH3 variant proteins shown in Figure 5.1-B was cloned into the FTrex-UTG DOX-
inducible lentivirus system (as used in previous experiments to re-express viral genes) by Toru 
Okamoto and Marco Herold, and were kindly made available for my experiments. The BH3 
variant BimS lentiviruses were then individually transduced into a total of ten cell lines from 
three tumour backgrounds, comprising; one EBV-positive parental and three loss clones of 
Akata-BL; one EBV-positive and two EBV-loss clones of Kem-BL and one EBV-positive and two 
EBV-loss clones of Mutu-BL.  
Expression of all of the BH3 variants was similar in the Akata-BL derived cell lines, deviating by 
less than two-fold between the highest and lowest expressers (Figure 5.2-A). We also found 
similarly low levels of variation in BH3 variant expression levels in each of the three Akata-BL 
EBV-loss clones used in these experiments (data not shown). In the Kem-BL background, we 
found a greater degree of variation in expression of BH3 variants within the same clonal 
background, up to 8-fold in EBV-positive Kem-BL (Figure 5.2-B), and up to 4-fold variation 
between different variants in EBV-loss Kem cells (data not shown). In Mutu-BL derived BH3 
variant cell lines, we found that levels varied up to around three-fold in all of the clones used 
(Figure 5.2-C and data not shown). 
As mentioned earlier in this thesis, we and others have found that GFP intensity in lentivirus 
transduced cell lines closely mirrors the level of expression of the gene of interest [484]. 
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Figure 5.2 BimS-variant expression in BL clones  
 
A Akata-BL-derived BH3 variant cell lines B Kem-BL-derived BH3 variant cell lines 
C Mutu-P1-derived BH3 variant cell lines 
 
Representative data, Bim expression was blotted and relative expression quantified in all 
ten sets of cell lines used for apoptosis experiments using BioRab ImageLab and 
normalised to β-actin expression  
Induced cells (+) treated with DOX and caspase inhibitor, Q-VD.OPh, for 24 hours 
Uninduced controls (-) were treated with Q-VD.OPh alone. Bim antibody (CST #2918, 
1/1000) used recognises endogenous BimEL and BimL isoforms as well as BimS.  
24kDa 
42kDa 
24kDa 
42kDa 
42kDa 
24kDa 
13kDa 
13kDa 
13kDa 
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Figure 5.3 GFP intensity in BL clones after successive rounds of GFP sorting 
 
Intensity of GFP expression was quantified by FACS in all ten sets of cell lines used for 
apoptosis experiments. In this figure GFP profile overlays are shown for BimS-variant 
transduced EBV-positive cells of Akata-BL, Kem-BL and Mutu P1 as an example 
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Therefore, to remedy the disparity between different BH3 variant cell lines, we enriched the 
Kem and Mutu-derived cell lines for high GFP expression as described in Section 2.1.4 using 
identical gating for all cell lines from the same family. After the second round of sorting we 
found that the intensity of GFP expression in our BimS-variant cell lines was almost identical, as 
shown in Figure 5.3, and so we went on to look at the functional consequence of expressing 
BH3 variants in BL clones. Unfortunately it was not possible to carry out detailed examination 
of BimS expression in the cells that had undergone a second round of sorting as these 
experiments were carried out during a short sabbatical visit to the Walter and Eliza Hall 
Institute (WEHI), as previously noted. However, it has been demonstrated in this thesis and 
elsewhere that GFP expression closely correlates with that of the gene of interest in this 
system. 
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5.1.3 The apoptosis phenotype of BimS variant expressing cell lines 
In Akata-BL derived cell lines we found that EBV-positive parental cells were protected against 
BimS-Bad, -2a and -Noxa compared to their EBV-loss counterparts, although protection 
conferred by EBV was most striking in BimS-Noxa expressing cells (Figure 5.4-A). Interestingly, 
EBV-positive Akata-BL cells were sensitive to BimS-wt, undergoing similar amounts of cell death 
to Akata EBV-loss clones expressing the same variant. Although there was a small amount of 
variation between individual assays this pattern of responses was consistent, suggesting that 
Akata-BL cells are not solely dependent on any one of the anti-apoptotic Bcl-2 family members 
being investigated. Instead it appears that, whilst ligation of any one of the pro-survival Bcl-2 
proteins by BH3 domains is sufficient to induce cell death in EBV-loss Akata cells, EBV-positive 
Akata cells are generally more resistant to BH3 and can only be killed when all pro-survival   
Bcl-2 proteins are depleted by BH3 binding.  
In Kem-BL derived cell lines we again found that the EBV-positive parental cells were relatively 
resistant to BimS variant expression compared to two EBV-loss Kem clones (Figure 5.4-B). In 
contrast to Akata-BL however, we found that Kem-BL and loss clone n2 were completely 
resistant to BimS-Bad expression, whereas loss clone n1 was sensitive. This suggests that 
whilst survival in parental Kem and n2 cells is Bcl-w, Bcl-XL or Bcl-2 independent, loss of EBV 
from clone n1 has caused the cells to become dependent on one or more of these 
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Figure 5.4 The apoptosis phenotype of BimS-variant expressing BL clones  
 
A Akata-BL-derived BH3 variant cell lines B Kem-BL-derived BH3 variant cell lines 
C Mutu-BL-derived BH3 variant cell lines 
Cells were treated with 1μg/ml DOX for 72 hours and data shown are mean and 
standard deviation of triplicate assay wells  
 
Representative data, all assays carried out in triplicate on three separate occasions.  
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anti-apoptotics in order to compensate. All of the Kem-BL derived cell lines show sensitivity to 
BimS-2a, BimS-Noxa and BimS-wt, although to a lesser extent in the EBV-positive cells, 
indicating that Mcl-1 and A1 are important for the survival of Kem-derived cells. The difference 
in response between EBV-positive and loss cells again implies some sort of general protective 
effect of EBV on Bcl-2-family signalling. 
The EBV-positive Mutu clone P1 showed a gradual increase in sensitivity to BH3 variant 
expression with a similar hierarchy to that seen in Akata-BL suggesting a modest dependence 
on Mcl-1, A1 and Bcl-XL (Figure 5.4-C). Mutu EBV-loss clone n1 exhibited a similar profile, 
except that it was resistant to BimS-Bad and so does not appear to be dependent on Bcl-XL, 
Bcl-2 or Bcl-w, but conversely displayed increased sensitivity to BimS-Noxa and BimS-wt 
indicating a greater and more profound dependence on A1 in this clone. EBV-loss Mutu clone 
n2 showed a marked and surprising resistance to both BimS-2a and Noxa, but retained 
sensitivity to BimS-wt, possibly indicating that this clone has also partially adapted to 
compensate for the loss of EBV, but is still unable to survive strong apoptotic signals as well as 
EBV-infected Mutu cells.  
 
5.1.4 Summary of BH3 variant re-expression studies 
Using BimS proteins with variant BH3 domains we were able to demonstrate the ability of EBV 
to protect BL clones against intrinsic apoptosis signals in all three of the BL backgrounds tested 
however, there was considerable heterogeneity in responses to individual BH3 variants in 
different clones. Figure 5.5 is a graphical summary of the data obtained from all of the BimS 
variant induced apoptosis assays carried out in this study, in which each clone/BH3 variant 
response has been graded and then colour coded according to the average amount of cell 
death induced across three independent experiments (Figure 5.5-A). Expressing the data in this 
way clearly shows that, rather than selectively targeting any one member of the Bcl-2 family, 
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Figure 5.5 Summary of BH3 variant expression studies in BL clones  
 
A Legend showing grading of induced cell death and corresponding colour code B 
Akata-BL-derived cell lines C Kem-BL-derived cell lines  
D Mutu-BL-derived cell lines     All values refer to the mean of three experiments 
 
 
 
Representative data, all assays carried out in triplicate on three separate occasions.  
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EBV appears to inhibit apoptosis by a general dampening of signalling through the intrinsic 
apoptosis pathway (Figure 5.5-B, C & D).  
The Bcl-2 family are dynamic and highly sensitive to changes within the cell [391, 392], which 
makes them robust enough to control cell death effectively, but also difficult to subvert. Thus, 
a mechanism of global repression of Bcl-2 signalling allows EBV to affect a consistent outcome 
despite diversity in gene expression between individuals, between cells within one individual, 
and under different conditions, which may be critical for the virus to persist in vivo. This 
hypothesis also accounts for the finding that EBV-positive cells are not entirely resistant to 
BH3-induced killing; apoptosis signalling in these cells is diminished, but not crippled. 
 
5.2 The cellular apoptosis response in BL clones: preliminary data 
5.2.1 Assay design and validation 
Although these functional assays provided us with a direct way of measuring the relative 
importance of individual proteins in Bcl-2 family regulated apoptosis we were still unable to 
decipher the exact mechanism by which EBV inhibits this pathway in BL clones. Since we had 
already carried out microarray studies on BL clones from 4 patient backgrounds we thought 
that the phenotype was unlikely to be explained by transcriptional differences between EBV-
positive and loss clones however, total protein staining of BL clones and previous Western 
blotting studies had also suggested there are very few differences in protein expression 
profiles between clones from the same background (see Section 3.4). This led us to reconsider 
our initial microarray and protein expression studies and speculate that, rather than eliciting a 
permanent change in protein or transcript expression, perhaps EBV induces gene expression 
changes only under circumstances of cellular stress. We therefore decided to investigate 
transcriptional and protein expression changes in EBV-positive and loss BL clones that had  
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been induced to undergo apoptosis, to investigate our hypothesis that genotypic changes 
which would explain the phenotypic difference would be evident upon intrinsic apoptosis 
induction in these cells.  
First we carried out a small pilot study to ascertain whether this approach was likely to be 
successful and to determine the most appropriate experimental parameters as the assay had 
to be scaled up for RNA and protein analysis. Since we found the clearest difference between 
Figure 5.6 Cell death in Kem-BL and loss clone n1 after apoptosis induction by 1μg/ml 
ionomycin in the presence or absence of 25μM Q-VD.OPh  
 
A Representative cell viability assay data 
B Expression of PARP protein, PARP cleavage is a defining characteristic of apoptosis  
 
Representative data, assays carried out on three occasions. QVD = Q-VD.OPh 
89kDa 
55kDa 
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EBV-positive Kem-BL and loss clone n1 in our functional assays these cell lines were used in 
these initial experiments. Although our aim was to profile gene expression changes in response 
to the initiation of cell death, we also wanted to minimise the number of dead cells in our 
samples as this could give misleading results. Earlier in this study we showed that the pan-
caspase inhibitor, Q-VD.OPh, can completely block ionomycin induced cell death in BL clones 
and so we carried out apoptosis time courses on cells treated with ionomycin alone or in the 
presence of Q-VD.OPh to establish the kinetics of apoptosis in these cells, an example of which 
is shown in Figure 5.6-A. 
The cells remained >90% viable up to 6 hours after apoptosis induction regardless of EBV-
status and in the absence of Q-VD.OPh. However, at 24 hours post induction, whilst the          
Q-VD.OPh treated cells remained viable, cells with no caspase-inhibition had undergone a 
considerable amount of apoptosis, though EBV-positive cells characteristically less so than the 
EBV-loss clone (Figure 5.6-A). We then carried out Western blotting for PARP on these samples 
and found that PARP expression did not increase in any of the Q-VD.OPh-treated cells, 
confirming that QVD is able to completely block caspase activation in this system. In cells 
treated with ionomycin only, PARP upregulation and cleavage was evident at 24 hours, as 
expected, and occurred to a greater degree in EBV-loss cells (Figure 5.6-B).  
We also examined the expression of the EBV lytic genes in EBV-positive Kem cells as it has 
been reported in the literature that ionomycin-treatment can induce lytic reactivation in BLs 
[572]. We found that all 3 of the lytic cycle-associated genes that were assayed (BZLF1, BHRF1 
and LF3), were upregulated after ionomycin addition, but not at early time points (<6 hours) 
and not in Q-VD.OPh treated cells. This suggests that lytic cycle is only triggered after the cell is 
already committed to programmed cell death (Figure 5.7). Therefore we decided to only 
include cells that had been treated with Q-VD.OPh in subsequent experiments, to rule out any 
complications of viral lytic gene expression and to minimise indirect cellular gene expression 
changes associated with either lytic cycle or late stage apoptosis. 
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5.2.2 Bcl-2 family expression in drug-treated EBV-loss clones 
Next, we looked for changes in expression of Bcl-2 family genes by q-PCR and Western blot and 
although many of the proteins and transcripts that we investigated were unaffected by 
ionomycin-treatment, we did observe several interesting responses. At the protein level, the 
alpha isoform of Puma was gradually upregulated in EBV-loss Kem n1 cells over time, but was 
unchanged in EBV-positive Kem-BL. Conversely, Mcl-1L was expressed at low levels and the s-
isoform was gradually degraded over time in the n1 clone compared to Kem-BL cells (Figure 
5.8). It is interesting that healthy Kem-BL and Kem n1 cells express both the long (L) and short 
(S) isoforms of Mcl-1 because Mcl-1S has been shown to bind and antagonise the action of 
Mcl-1L and is therefore pro-apoptotic [573, 574]. Although the disappearance of Mcl-1 in the 
EBV-loss Kem n1 cells may be responsible for the apoptosis phenotype it is also possible that it 
does not affect the fate of the cells since both the long (pro-survival) and short (pro-apoptotic) 
Figure 5.7 Lytic gene expression in Kem-BL after apoptosis induction with 1μg/ml 
ionomycin in the presence or absence of 25μM Q-VD.OPh, quantified by q-PCR 
relative to baseline expression levels of each transcript in Ionomycin-only treated cells 
(-) at time 0 measurements carried out in duplicate and quantified using the ΔΔCt 
method, mean and SD shown 
QVD = Q-VD.OPh 
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isoforms are both degraded in Kem n1 cells in response to apoptosis induction. If this finding 
were to be confirmed in a wider panel of EBV-loss versus EBV-positive clones it would be 
important to examine the relative contributions of the different isoforms of Mcl-1 to the 
apoptosis phenotype of the cells.  
In accordance with the Western blot data Puma transcripts were also clearly upregulated in 
Kem n1, but were relatively unchanged in Kem BL (Figure 5.9-A). Mcl-1 expression did not 
change at the mRNA level, suggesting that its disappearance in ionomycin-treated Kem n1 cells 
may be due to degradation (Figure 5.9-B). Interestingly, Noxa transcripts were upregulated in 
both EBV-positive and loss Kem cells, showing around a 4-fold increase in both cell lines after 3 
hours, although transcript levels continued to rise only  in the EBV-loss cells, reaching an 8-fold 
increase compared to time 0 by 24 hours (Figure 5.9-C). Unfortunately, our Noxa antibody 
gave poor results in Western blot and so we were unable to conclude whether or not there 
was a concomitant change at the protein level (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Time course of Puma-α and Mcl-1 protein expression in Kem-BL and Kem 
n1 cells after treatment with 1μg/ml ionomycin and 25μM Q-VD.OPh 
 
Representative data, assays carried out on three occasions. Hours = hours since 
addition of ionomycin + Q-VD.OPh 
L denotes Mcl-1 long isoform (40kDa) and S denotes the short isoform (32kDa) 
23kDa 
55kDa 
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Figure 5.9 Time course of Puma, Mcl-1 and Noxa transcription in Kem-BL cells after 
treatment with 1μg/ml ionomycin and 25μM Q-VD.OPh 
 
Representative q-PCR data, assays carried out on three occasions. Mean and standard 
deviation of duplicate measurements is shown. Data analysed using the ΔΔCt method 
and expressed relative to expression levels in Kem-BL at time 0.   
TaqMan assays used are able to detect all known protein coding isoforms  
Page | 207  
 
5.3 The cellular apoptosis response in BL clones: q-PCR arrays 
5.3.1 Experimental set-up 
As we had hypothesised, our preliminary data identified genes that were expressed differently 
between treated EBV positive and loss cells that would have been missed by looking only at 
untreated cells. Interestingly, only a minority of the Bcl-2 family members assayed changed in 
their expression over the time points we looked at and the changes we did find; possible 
degradation of one isoform and almost total lack of a second isoform of Mcl-1, and 
upregulation of two BH3-only Bcl-2 homologues, suggest that the underlying mechanism may 
be complex, involving multiple interacting components of the same pathway.  
To investigate whether these changes were consistent between clones and to determine the 
impact of EBV on the orchestration of cell death in BL cells we carried out scaled up apoptosis 
assays on 6 clones of Kem-BL. As depicted in Figure 5.10, Kem-BL clones (three EBV-positive 
and three EBV-loss) were induced with ionomycin in the presence of Q-VD.OPh in three 
separate time course experiments and cells were harvested at 0, 6 and 48 hours. The final time 
point was changed from 24 hours to 48 hours after further optimisation because we saw the 
clearest difference in viability between EBV-positive and loss cells in ionomycin-only controls 
(i.e. without QVD) at this time point. We also omitted the 3 hour time point used in 
preliminary experiments to minimise sample number since changes in gene expression were 
more pronounced at 6 hours and there was very little difference in cell viability between 0 and 
6 hours in ionomycin-only controls.  
To analyse transcription in these samples we used commercially available microfluidic q-PCR 
cards pre-loaded with 93-apoptosis-related mRNA targets and 3 endogenous control genes. 
This allowed us to cost-effectively measure a large number of targets simultaneously, which 
have all previously been shown to regulate apoptosis and can be transcriptionally regulated. 
Expression of apoptosis-related proteins in these samples was then further investigated using 
Western blot and FACS. 
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Figure 5.10 Workflow used for experiments to investigate cellular gene changes in 
response to apoptotic stimulus in clones of Kem-BL  
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5.3.2 Apoptosis response of Kem-BL clones in scaled-up assays 
Before we ran samples on microfluidics cards we wanted to check that all of the clones 
behaved similarly in scaled up apoptosis assays to our small scale and preliminary experiments. 
Figure 5.11 shows the viability of the cells harvested for q-PCR arrays as well as ionomycin-only 
treated controls over three independent experiments. As in the small scale assays, there is a 
clear difference in viability between the EBV-positive and EBV-loss clones, although there is 
some variability between different clones for example; clone P1 is always the most protected 
and clone n3 is always the most sensitive, followed by clone n1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Viability of EBV-positive and loss clones of Kem-BL in scaled-up 
apoptosis assays  
 
Viability of cells was assessed using trypan blue staining in duplicate, mean 
and standard deviation from three independent experiments is shown  
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We also checked that Q-VD.OPh still completely blocked late stage apoptosis in all six clones of 
Kem-BL. Cells were treated with either ionomycin alone as a positive control (Figure 5.12-A), or 
ionomycin and Q-VD.OPh (Figure 5.12-B), for 48 hours and were then harvested for Western 
blot analysis. Blots were probed using an antibody against PARP which recognises both the full 
length protein and its cleavage products. PARP can be cleaved by a number of proteases as a 
consequence of cell stress and therefore PARP cleavage is considered a hallmark of apoptosis 
[575, 576]. In agreement with our preliminary experiments, QVD-treatment completely 
blocked PARP cleavage and PARP expression was similar in all Kem-BL clones in the presence of 
caspase inhibition. As expected, EBV-loss cells treated with ionomycin in the absence of          
Q-VD.OPh exhibited far more PARP cleavage than their EBV-positive counterparts. 
Interestingly, individual EBV loss clones appeared to show distinctive PARP cleavage patterns, 
which may be indicative of variation in the proteases responsible for cleaving PARP in different 
clones [577]. We also included treated or untreated Jurkat cells as controls, as many 
commercial antibodies, including our PARP antibody, have data available for Jurkat. Jurkat cells 
were harvested after 5 hours of treatment with either vehicle only, Etoposide and Q-VD.OPh 
as control for caspase inhibition or Etoposide alone as a positive control for apoptosis.  
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Figure 5.12 Western blots of PARP expression and cleavage in Kem-BL clones treated 
with ionomycin only (A) or ionomycin and Q-VD.OPh (B) for 48 hours showing that 
PARP cleavage is completely inhibited in Q-VD.OPh treated cells and that EBV-loss 
clones undergo a greater degree of PARP cleavage than their EBV-positive 
counterparts. Jurkat cells are included as controls for healthy cells (lane 7), and 
apoptosis induction in the presence (lane 8) or absence of Q-VD.OPh (lane 9)  
 
QVD = Q-VD.OPh, CALR = calregulin loading control FL = full length 
55kDa 
55kDa 
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5.3.3 Analysis of similarity between clones of Kem-BL in q-PCR arrays 
Since the assays on q-PCR array cards are run simultaneously on a single batch of sample 
material we were able to globally compare the ΔCt values (gene of interest – endogenous 
controls) for all of the targets loaded on the cards between different members of the same 
experimental group. This allows us to assess the overall similarity of one clone to another in 
terms of its apoptosis-related gene expression. We would expect all clones of one type (EBV-
positive or EBV-loss) to respond in the same way to apoptotic stimuli, and therefore have an 
almost linear relationship to one another. By plotting the ΔCt values of one clone against 
another on a scatter graph and then performing linear regression, a value describing the 
similarity of the two clones, known as the signal correlation coefficient, can be calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Global gene expression comparisons from q-PCR arrays 
Example plots of ΔCt values for each individual assay present on the microfluidic card in 
one sample (Kem P1) versus another sample (Kem P2) 
 
A EBV-positive clones P1 and P2 at 6 hours (in this example the correlation efficient is the 
highest between two samples and therefore they are most similar)  
B EBV-loss clones n1 and n2 at 48 hours (in this example the correlation efficient is one of 
the lowest between two samples and therefore they are less more divergent from one 
another in their gene expression pattern, although the relatively hight coefficient of 0.82 
reflects that overall these two genetically related clones are still highly similar) 
  
 A  B 
           Correlation coefficient: 0.98                                         Correlation coefficient 0.82 
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Examples of global signal comparisons between two pairs of Kem-BL clones are shown in 
Figure 5.13. EBV-positive clones P1 and P2 after 6 hours of ionomycin-treatment, were almost 
identical in their gene expression (correlation coefficient of 0.98) (Figure 5.13-A), whereas a 
comparison of gene expression in EBV-loss clones n1 and n2 after 48 hours of treatment 
showed less similarity (correlation coefficient of 0.82) (Figure 5.13-B). A summary of the 
similarity in all possible pairings of each of the three clones in each experimental group is 
shown in Figure 5.14. On the whole, the samples show a high level of similarity to one another 
(89% similarity overall) as would be expected in cells derived from a single individual. However, 
it is noticeable that the EBV-loss clones are less similar to one another compared to the EBV-
positive clones; 84.9% and 93.1% overall similarity, respectively. It is also interesting that the 
gene expression profiles of all Kem-BL clones tended to increase in their similarity after drug 
treatment compared to time 0. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Summary of similarity between pairs of EBV-positive and EBV-loss clones of 
Kem-BL based on signal correlation coefficients.  
 
Signal correlation values (in white) were also colour graded for clarity, as per the key 
(below the table) 
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5.3.4 Grouped pairwise analyses 
To assess the impact of EBV on apoptosis response on clones of Kem-BL, we grouped our 
samples according to EBV-status and then carried out pairwise analyses between the grouped 
data sets. Changes in gene expression were considered significant if the fold change was 
greater than 2 and the significance calculated to be less than p=0.05. Pairwise comparisons 
were plotted as a function of fold change (x-axis) versus significance of change (y-axis), known 
as a volcano plot. This allows for quick identification of genes that change significantly 
between two samples and to what magnitude, and also gives an overall view of the proportion 
of the genes that are differentially expressed between two samples.  
All gene expression data were normalised to an average of ACTB and GAPDH. 18S was also 
included as an endogenous control but we found that it was expressed at very different levels 
to the other targets so it was excluded from the analyses (average Ct values: 18S – 12, 
endogenous controls - 20, targets - 24). Importantly, expression of the two endogenous 
control genes used did not change in response to drug treatment and varied by less than 2Cts 
between all of the samples analysed. 
We created volcano plots for every possible pairing of the 6 groups of samples (EBV-positive 
and EBV-loss at each of 0, 6 and 48 hours) to look for changes which might explain the EBV-loss 
phenotype. Figure 5.15-A shows an example volcano plot comparing EBV-loss clones at 6 hours 
to the same cells at time 0. Up and downregulated genes are shown on either side of the 
parallel black lines; green dots on the left-hand side signify genes that are more than 2-fold 
downregulated, and red dots on the right-hand side are upregulated more than 2-fold, whilst 
the blue line marks the cut off for significance (P<0.05). Although 31 genes are changed across 
all three EBV-loss clones after 6 hours of drug treatment only RELB is changed significantly. In 
EBV-loss clones at 48 hours the vast majority of the genes change in their expression and of 
those, 15 change significantly (Figure 5.15-B|). Carrying out the same comparison on the  
Page | 215  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Magnitude and significance of gene expression changes in Kem-BL 
derived EBV-loss clones after treatment with ionomycin and Q-VD.OPh  
 
A  EBV-loss clones, 6 hours vs 0 hours B EBV-loss clones, 48 hours vs 0 hours 
Assays were carried out in technical and experimental triplicate and analysed 
using DataAssist software from Applied Biosystems. Cut-offs used were: Fold 
Change ≥ 2 and p-value in a two-tailed Students T-test ≤ 0.05 
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Figure 5.16 Magnitude and significance of gene expression changes in Kem-BL derived 
EBV-positive clones after treatment with ionomycin and Q-VD.OPh  
 
A  EBV-positive clones, 6 hours vs 0 hours B EBV-positive clones, 48 hours vs 0 hours 
Assays were carried out in technical and experimental triplicate and analysed using 
DataAssist software from Applied Biosystems. Cut-offs used were: Fold Change ≥ 2 and 
p-value in a two-tailed Students T-test ≤ 0.05 
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Figure 5.17 Magnitude and significance of gene expression changes in Kem-BL derived 
EBV-positive and loss clones after treatment with ionomycin and Q-VD.OPh  
 
A  EBV-loss versus EBV-positive clones at time 0 (comparison of baseline gene 
expression profiles) B EBV-loss versus EBV-positive clones at 48 hours post induction 
Assays were carried out in technical and experimental triplicate and analysed using 
DataAssist software from Applied Biosystems. Cut-offs used were: Fold Change ≥ 2 and 
p-value in a two-tailed Students T-test ≤ 0.05 
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EBV-positive clones shows that only 18 genes are changed >2-fold, 40% fewer than in EBV-loss 
clones, and of those only BIRC7, TNF, BCL3 and PMAIP1 (Noxa) are changed significantly at 6 
hours (Figure 5.16-A). Again, more genes are changed in their regulation at 48 after apoptosis 
induction, but in the EBV-positive cells only BBC3 (Puma) and CARD6 are significantly different 
(Figure 5.16-B).  
Figure 5.17 shows gene expression change comparisons between EBV-positive and loss clones 
at time 0 and 48 hours after apoptosis induction. As might be expected, only a only a single 
gene, BIRC7 (c-IAP2), varies in its expression between EBV-positive and loss cells at time 0 
(Figure 5.17-A), but surprisingly there are only two significant changes in gene expression 
between EBV-positive and loss cells after 48 hours (Figure 5.17-B). Interestingly, the same two 
genes, DEDD2 and CASP8AP2, were also significantly upregulated in EBV-loss clones at 48 
hours as well as when compared to their untreated counterparts.  
A summary of all the significant changes identified by grouped pairwise comparisons is shown 
in Table 5.1, which also lists commonly used aliases of the shortlisted genes. Many of the gene 
expression changes are quite moderate, less than 5-fold, although there must be consistency 
across different clones within the group as levels of significance in some cases are very high. To 
identify exactly how many of the gene changes were consistent across every clone within a 
particular group we next carried out pairwise analyses of individual clones. 
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Table 5.1 Summary of gene expression changes from grouped pairwise analyses 
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5.3.5 Pairwise analyses of individual clones 
All possible pairwise analyses of all 6 clones at 3 time points was carried out and shortlists 
made of all transcripts that changed >2-fold. These lists of differentially regulated genes were 
then compared to one another to identify common changes. Figure 5.18-A shows the number 
of genes that had changed by 2-fold or more in each EBV-positive clone at 6 hours (left) or 48 
hours (right), compared to time 0. At 6 hours 14, 33 and 21 genes had changed at least 2-fold 
in clones P1, P2 and P3, respectively, whereas at 48 hours 61, 34, and 57 genes had changed in 
P1, P2 and P3, respectively. This relatively large number of changes in apoptosis-related gene 
expression was surprising as the grouped analyses had suggested there were relatively few 
changes in EBV-positive clones. Interestingly, the vast majority of changes were common to at 
least 2 of the three clones at both 6 and 48 hours, although intriguingly, the number of genes 
that increased in their expression between 6 and 48 hours was very different for each clone, 
ranging from an increase of 1 to 47 changed genes.  
Figure 5.18-B shows the same comparisons at 6 hours (left) and 48 hours (right) for EBV-loss 
clones. More genes were changed in all of the EBV-loss clones at both 6 and 48 hours than in 
EBV-positive clones at the same time points. At 6 hours 19, 38 and 56 genes had changed in 
clones n1, n2 and n3, respectively, and by 48 hours 83, 78 and 81 genes had changed in n1, n2 
and n3, respectively. This finding is consistent with the EBV-loss phenotype, but we were still 
surprised that so many genes (83-89% of all targets on the card) had changed more than 2-
fold.  
As in the analysis of EBV-positive clones, the majority of changes were common to at least two 
of the loss clones at both time points, with 67 changes being common to all three clones at 48 
hours. Interestingly, clone n3 looked quite different to the other two clones at 6 hours and this 
clone was also consistently the least viable of the clones at 48 hours (see Figure 5.11-A). 
Therefore this clone is likely to be further along the apoptosis pathway in comparison to the 
other clones at 6 hours and by 48 hours the other clones have ‘caught up’. 
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With this in mind, we decided to pool the data and compare all changes that were common to 
all three positive clones at 48 hours to the 67 genes that were changed in all of the loss clones 
(Figure 5.18-C). We found that almost every gene that had changed in the positive clones had 
also changed in the loss clones. This further suggests that all BL clones undergo the same 
changes during the commitment to programmed cell death, but with slower kinetics in those 
clones that contain EBV. The two genes that were changed in all three EBV-positive clones but 
not all three EBV-loss clones, were also changed in two of the three EBV-loss clones, indicating 
that one loss clone was an outlier in this response.  
 Collectively, our transcriptional data suggest that many of the changes we have seen may 
reflect the degree to which each of the cell lines has committed to apoptosis, rather than being 
the specific triggers of apoptosis in BL clones however, the data from our q-PCR arrays alone 
are insufficient to prove this hypothesis. We therefore went on to further investigate the 
significant changes from the grouped analyses in order to look more closely at the kinetics of 
gene expression change in EBV-positive and loss clones, and to identify whether the changes 
we had seen at the transcriptional level are also evident at the protein level. 
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Figure 5.18 Overlap in gene expression changes of 2-fold or more in individual clones of Kem-BL   
A concordance between gene expression changes in 3 EBV-positive clones at 6 (left) or 48 
hours (right) after apoptosis induction 
B concordance between gene expression changes in 3 EBV-loss clones at 6 (left) or 48 hours 
(right) after apoptosis induction 
C concordance between gene expression changes in 3 EBV-positive clones versus EBV-loss 
clones 48 hours after apoptosis induction 
Made using VENNY software (Oliveros, J.C. (2007) VENNY. An interactive tool for comparing 
lists with Venn Diagrams http://bioinfogp.cnb.csic.es/tools/venny/index.html) 
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5.3.6 Relative quantitation  
By carrying out q-PCR arrays rather than traditional microarrays, we were also able to calculate 
with greater accuracy the relative quantities of all of the targets at every time point compared 
to a reference sample. We therefore plotted the mean of the three EBV-positive and three 
EBV-loss clones at each time point, for all of the 21 significantly differentially regulated targets 
identified by the grouped pairwise analyses (Table 5.1), using Kem clone P1 at 0 hours as the 
reference sample.  
Caspase-7 (CASP7), in conjunction with the other ‘executioner’ Caspases; -3 and -6, is 
responsible for the majority of the proteolytic destruction of cell substrates during apoptosis 
[384, 578]. In our screen, Caspase-7 was upregulated over 4-fold in EBV-loss clones after 
treatment with ionomycin however, it was also upregulated in some of the EBV-positive 
clones, although not significantly (Figure 5.19-A). Given the critical and important role of 
Caspase-7 in apoptosis it is not surprising that many viruses encode caspase inhibitors 
(reviewed in [579]), although no caspase inhibitor has been described so far for EBV. Our data 
imply that EBV may block transcription of Caspase-7 rather than inhibiting its proteolytic 
function.  
BIRC2 (c-IAP1) is part of the IAP family of apoptosis regulators which bind to and inhibit 
cleavage of caspases [580]. We found that BIRC2 was significantly upregulated over 7-fold in 
EBV-loss cells following ionomycin treatment, which may suggest that its NF-κB signalling 
capacity, rather than its ability to inhibit apoptosis is important in this context (Figure 5.19-B) 
[581]. Similarly to Caspase-7, BIRC2 was only significantly upregulated at the 48 hour time 
point and we again also saw a response in the EBV-positive cells, albeit more variable and of a 
lesser magnitude.  
CFLAR, also known as c-FLIP, a master regulator of apoptosis, was upregulated 18.6-fold in 
ionomycin-treated EBV-loss cells at 48 hours compared to time 0 (Figure 5.19-C). FLIP proteins 
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are known to be targeted by many viruses, and some, such as KSHV, a close relative of EBV, 
encode viral homologues of FLIP (v-FLIPs), [582, 583], although EBV itself does not. FLIP 
proteins, like IAPs, block the activation of the caspase cascade [584], providing a second 
example of EBV-loss clones upregulating a gene with known anti-apoptotic functions after 
ionomycin treatment. 
Overall, this pattern of gene expression, where the target of interest was only significantly 
changed in EBV-loss cells at the 48 hour time point and was also upregulated, albeit more 
Figure 5.19 CASP7, c-IAP1 and CFLAR transcription measured by q-PCR using the 
ΔΔCt method  
A Caspase-7 B Cellular inhibitor of apoptosis 1 C CFLAR, also known as c-FLIP 
Data expressed as relative quantitation with Kem-BL, 0 hours as the reference 
sample. Mean and SD from 3 different clones in 3 independent experiments. 
Statistical comparisons carried out using a two-tailed Student’s T-test 
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variably and to a lesser degree, in the EBV-positive group, was also evident in many of the 
other genes (both pro- and anti-apoptotic) that we had shortlisted (data not shown). This is 
consistent with our hypothesis that the majority of the changes identified by these arrays may 
be downstream effects of cell death initiation, even in the absence of PARP cleavage or loss of 
viability. Therefore, although these gene expression changes provide important clues to the 
signalling mechanisms by which BL cells commit to cell death, they are probably not the 
initiators of the response, and are therefore unlikely to be direct targets for EBV in this setting.   
In our preliminary assays, Puma (BBC3) was significantly upregulated in EBV-loss clone n1 
versus EBV-positive Kem-BL after ionomycin treatment (Figure 5.8 and 5.9-A) yet, in our q-PCR 
arrays Puma was identified as being significantly upregulated in EBV-positive cells at 48 hours, 
but not EBV-loss clones.  Consistent with many of our other shortlisted genes, relative 
quantitation data showed that Puma is upregulated in both EBV-positive and loss cells, but to a 
greater extent in EBV-loss clones. In this case however, the response in the EBV-loss clones is 
more variable than in EBV-positive cells and so the differential regulation is classed as 
significant only in the EBV-positive group (Figure 5.20).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 Relative quantitation of Puma expression transcription measured by q-PCR 
using the ΔΔCt method  
Data expressed as relative quantitation with Kem-BL, 0 hours as the reference sample. 
Mean and SD from 3 different clones in 3 independent experiments. Statistical 
comparisons carried out using a two-tailed Student’s T-test 
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DEDD2, also known as FLAME3, was one of only two genes found to be significantly changed in 
EBV-loss clones at 48 hours versus both untreated cells and treated EBV-positive clones. 
DEDD2 was upregulated 4.6-fold in treated EBV-loss cells whilst there was almost no change in 
EBV-positive cells (Figure 5.21-A). Little is known about the function of DEDD2, although its 
role in cell death is thought to occur via binding to FLIP proteins, [585, 586] and Caspases-8 
and -10 [587].  
CASP8AP2 (FLASH) was the second of two genes found to be significantly upregulated in EBV-
loss clones at 48 hours versus both untreated cells and EBV-positive clones at 48 hours post 
induction (Figure 5.21-B). Unlike many other genes identified in this screen, upregulation of 
FLASH appeared to begin early after apoptosis induction and, by 48 hours shows a more than 
5-fold increase over time 0 and an almost 30-fold increase over EBV-positive cells at the same 
time point. Interestingly, although there seems to be some early activation of FLASH in EBV 
positive cells this appears to be reversed by 48 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21 Relative quantitation of DEDD2 and FLASH measured by q-PCR using 
the ΔΔCt method  
A DEDD2 B CASP8AP2 more commonly referred to as FLASH 
Data expressed as relative quantitation with Kem-BL, 0 hours as the reference 
sample. Mean and SD from 3 different clones in 3 independent experiments. 
Statistical comparisons carried out using a two-tailed Student’s T-test 
 
Page | 227  
 
Our q-PCR arrays showed that, even in viable cells in the absence of caspase cleavage, a large 
number of apoptosis-related genes change in their expression in response to apoptosis 
initiation, and that many of the changes may be common between all BL cells regardless of 
EBV status. Of the shortlisted genes, only DEDD2 and CASP8AP2 appeared to change 
specifically in EBV-loss cells and not EBV-positives. Additionally, EBV-loss cells consistently 
underwent more rapid and dramatic apoptosis activation than their EBV-positive counterparts, 
suggesting that, as well as possibly transcriptionally regulating DEDD2 and CASP8AP2, EBV may 
have a role in targeting some upstream cell fate-determining ‘master switch’ and / or that the 
target(s) of the virus are not transcriptional. We therefore went on to characterise expression 
of a variety of apoptosis-related proteins in treated and untreated Kem-BL clones by Western 
blot.  
 
5.4 Apoptosis-related changes in clones of Kem-BL at the protein level 
5.4.1 Western blotting experimental set up 
Western blotting allows us to gain qualitative, and to some degree, quantitative data about 
gene expression and may be used to detect increases in protein synthesis or accumulation due 
to stabilisation, decreases due to a block in synthesis, degradation, cleavage events and in 
some cases, protein modifications indicated by a shift in protein size. Other technologies, such 
as antibody arrays or proteomics were considered for this study as this would allow us to look 
at a greater number of proteins, and in the case of proteomics, would be totally unbiased, but 
the number of samples required to draw reliable conclusions would make both techniques 
prohibitively expensive. The alternative option of running only a few samples may give 
misleading results, as we would have to sacrifice the number of clones included, the number of 
time points or the number of experimental replicates.  
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Every antibody used in his study has either been previously validated on other samples by us, 
or been used in publications from at least two different research groups. Details of antibodies 
used can be found in Section 2.8.2. Since small changes in expression are difficult to quantify 
by Western blot, we screened Kem-BL clones at 48 hours after apoptosis induction to look for 
changes that were consistent in all three clones of one group and were specific to either EBV-
positive or EBV-loss cells. Jurkat samples were included on every blot to allow for 
normalisation between different blots and to act as controls for healthy, apoptotic and pre-
apoptotic (caspase-inhibitor treated) cells. All changes in protein expression were normalised 
to calregulin levels as it was found to be expressed at similar levels at every time point in 
preliminary experiments, whereas β-actin levels clearly decreased in response to apoptosis 
induction (data not shown). Protein quantitation and normalisation was carried out using the 
BioRad ImageLab software. Densitometry data was normalised to the loading control 
calregulin and expressed relative to expression levels of the protein of interest in healthy 
(untreated) Jurkat cells or untreated Kem P1 cells in cases where the protein of interest was 
not expressed/undetectable in untreated Jurkat cells.  
 
5.4.2 Caspases 
Caspases are activated when they are cleaved from their full length, inactive form, whereupon 
their destructive proteolytic activity is unleashed. Our q-PCR arrays identified Caspase-7 and 
Caspase-8 as being more highly upregulated in EBV loss clones than their EBV-positive 
counterparts upon treatment with ionomycin in the presence of Q-VD.OPh. The Q-VD.OPh 
peptide is able to bind and inhibit cleavage of initiator Caspases-4, -8, -9, -10 and -12, as well 
as executioner Caspases-3, -6 and -7, although its activity varies depending on the 
experimental system used [588-590]. As previously mentioned, a number of viruses inhibit 
caspase expression and/or function, and a recent publication showed that EBV-encoded miR  
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35kDa 
Figure 5.22 Caspase-3, -7 and -9 Western blots on EBV-positive and loss Kem-BL 
clones 48 hours after apoptosis induction 
A Kem-BL clones treated with 1μg/ml ionomycin to induce apoptosis and 25μM Q-
VD.OPh to block caspase cleavage  
B Kem-BL clones treated with ionomycin only  
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BARTs can inhibit Caspase-3 promoter activity in BL cells [99]. Since Q-VD.OPh does not affect 
caspase transcription, we examined the expression and activation of several caspases in our 
panel of BL clones in order to further investigate whether EBV regulated caspase expression in 
BL clones. 
In Q-VD.OPh-treated cells Caspases 3, 7 and 9 remained in their inactive, full length forms and 
we found no significant difference in protein expression levels between EBV-positive and loss 
clones, suggesting that EBV does not inhibit transcription of Caspases 3, 7 or 9 in Kem-BL 
(Figure 5.22-A). Unfortunately, we were unable to determine levels of Caspase-8 expression by 
Western blot as our antibody gave very poor and inconsistent results, and so we were unable 
to validate our transcriptional data in this case.  
Cleavage of Caspases 3, 7 and 9 was evident in EBV-loss clones in the absence of Q-VD.OPh, 
but to a lesser extent or not at all in EBV-positive Kem-BL clones (Figure 5.22-B). Whilst this is 
supportive of a hypothesis of caspase inhibition by EBV, this is also consistent with the fact 
that there is simply more apoptosis occurring in the EBV-loss cells. Therefore we think that this 
is likely to be a downstream effect of cell death rather than directly related to presence or 
absence of EBV; a hypothesis that is corroborated by the fact that we see a similar effect in all 
three of the caspases investigated. Interestingly, and similarly to our PARP blots, we saw 
differences in the patterns of caspase cleavage products individual in different clones, 
indicating that there may be variation in which upstream proteases are responsible for 
cleaving and activating caspases in different clones.   
 
5.4.3 Targets from q-PCR arrays 
DEDD2, CFLAR, CARD6 and CASP8AP2 were all significantly upregulated in EBV-loss clones 
following ionomycin treatment in our q-PCR array experiments, we therefore examined 
whether levels of the corresponding proteins correlated with our transcriptional findings  
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Figure 5.23 Protein expression of targets identified by q-PCR array 
A Kem-BL clones treated with 1μg/ml ionomycin to induce apoptosis and 
25μM Q-VD.OPh to block caspase cleavage 48 hours 
B Kem-BL clones at 0 hours 
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(Figure 5.23). The FLAME3 protein, encoded by DEDD2, appeared to be more highly expressed 
in EBV-positive clones than those that had lost the virus after apoptosis induction, which is in 
direct contradiction to the change in DEDD2 transcription seen in our arrays (Figure 5.23-A). 
Surprisingly, there was also no evidence that CFLAR or CARD6 were more highly expressed in 
EBV-loss clones overall, although both were abundant in loss clone n1. Unfortunately, we were 
unable to obtain satisfactory staining with our FLASH antibody; the FLASH protein is predicted 
to run at around 200kDa however, the only clear bands on our blots ran at 70kDa or 97kDa in 
Kem or Jurkat, respectively [591]. We are unclear how to interpret this blot data, but we noted 
that, FLASH, encoded by CASP8AP2, is  thought to induce apoptosis via downregulation of  
Mcl-1 and CFLAR [592], which we similarly see no evidence of in our EBV-loss clones (Figure 
5.23-A & 5.25). 
BIRC7, which encodes Livin, was significantly lower in EBV-loss clones at time 0 compared to 
EBV-positives at the same time point at the transcript level, but this was not evident at the 
protein level (Figure 5.23-B). CARD6 was transcribed at significantly higher levels in EBV-
positive cells at 48 hours versus time 0 and DEDD2 (FLAME3) was specifically upregulated in 
EBV-loss clones at 48 hours versus time 0. However, when we compared our staining for these 
proteins in our untreated samples to ionomycin-treated cells, using the Jurkat controls as a 
reference point, we could see no evidence that these findings held true at the protein level 
(Figure 5.23-A & 5.23-B).  
Whilst it was disappointing that we could not corroborate our transcriptional data with levels 
of protein expression we are still able to draw useful conclusions from these experiments. It is 
interesting that there appear to be widespread transcriptional changes in BL clones following 
apoptosis induction that occur in the absence of caspase or PARP activation and do not 
necessarily lead to changes in protein expression. This robust and complex response to stress 
signals, in-keeping with our BimS mutant assays, suggests that the mechanism by which EBV 
acts is to a generally slow or dampen the progression of the apoptotic cascade. These findings 
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indicate that a more specific mechanism, whereby the virus inhibits or activates one particular 
entity within a pathway would surely not be sufficient to effectively subvert this wide-ranging 
response. 
 
5.4.4 The IAP family 
The inhibitor of apoptosis family of proteins (IAPs) were first identified as inhibitors of 
apoptosis, although it is now know they also play a role in the innate immune response via   
NF-κB and ubiquitin signalling [581]. These proteins are frequently deregulated in 
haematological malignancies and it is hoped that therapies that target IAPs may be useful to 
treat a number of cancers, we therefore examined the expression of several IAP proteins by 
Western blot (Figure 5.24) [593]. BIRC2 (c-IAP1) was significantly upregulated in EBV-loss 
clones in our q-PCR arrays compared to EBV-positives however, we could find no difference 
between EBV-positive and loss clones in c-IAP1 protein expression. We also found no 
correlation between XIAP, Livin (BIRC7) or Survivin protein expression and EBV status in     
Kem-BL clones after apoptosis induction. Therefore, although EBV has previously been 
reported to regulate IAPs in other systems [321, 594, 595], we find no convincing evidence that 
EBV regulates IAP protein expression in BL clones in this system. 
 
 
 
 
 
 
 
 
Page | 234  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24 Expression of IAP family member proteins in Kem-BL clones 
 c-IAP1 is predicted to run at 62kDa, corresponding to the upper band on this blot 
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5.4.5 The Bcl-2 family 
Our initial apoptosis assays using a variety of apoptosis inducers indicated that EBV protects BL 
cells from apoptosis via the intrinsic, or mitochondrial signalling pathway. We therefore 
examined differences in expression of the Bcl-2 family members, which coordinate the intrinsic 
apoptosis response. Rather than looking for changes in expression between untreated and 
treated cells we opted to screen for differences between ionomycin and Q-VD.OPh treated 
EBV-positive and loss clones. Of the anti-apoptotic Bcl-2 family members we looked at, Bcl-2 
itself was undetectable and Bcl-XL was expressed at very low levels in 5 of the 6 clones. 
Interestingly however, both Bcl-2 and Bcl-XL were expressed in EBV-loss clone n1 (Figure 5.25) 
the same clone that showed evidence of being Bcl-2 or Bcl-XL dependent in BimS variant 
studies and could not be fully rescued by reinfection (see Figures 4.29-B & 5.5-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Expression of pro-survival Bcl-2 proteins in Kem-BL clones after 
treatment with ionomycin and Q-VD.OPh 
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Figure 5.26 Expression of pro-apoptotic Bcl-2 homologues in Kem-BL clones after 
treatment with ionomycin and Q-VD.OPh 
A BH3 only proteins Bim, Puma-α, and Noxa 
B BH3-only proteins Bad and Bid and multi-domain effector proteins Bak and Bax 
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In addition, Mcl-1 was expressed at stable levels in all of the clones except clone n1, in which 
the L-isoform was barely detectable, in agreement with our earlier findings (Figure 5.8), which 
further suggests that this clone may have adapted to survive the loss of EBV. Unfortunately, 
we were unable to find a suitable antibody against A1. 
Of the pro-apoptotic BH3 proteins, Bim, Puma and Noxa have all previously been reported to 
play an important role in apoptosis in BL cells [267, 419, 596]. Both Bim and Puma appeared to 
be expressed more highly in all of the ionomycin-treated EBV-loss clones versus their EBV-
positive counterparts (Figure 5.26-A), confirming our Puma transcriptional data. Paradoxically, 
since it is a pro-apoptotic protein, Noxa appeared to be less abundant in two of the three EBV-
loss clones than EBV-positive clones. The exception to this being clone n1, which as 
mentioned, also stands out from the other EBV-loss clones in terms of its gene expression and 
response to challenge with BH3 variant proteins. Bid Bak and Bax were also expressed at 
higher levels in EBV-loss clones n2 and n3, but not n1 (Figure 5.26-B), although these 
differences were not significant when quantified (Table 5.2) so we would need to confirm this 
in additional EBV-loss clones. Bad protein was undetectable in clones of Kem-BL. 
 
5.4.6 Summary of Western blotting for apoptosis related proteins 
Table 5.2 is a summary of all of the Western blotting we carried out to compare protein 
expression in EBV-positive and loss clones after treatment with ionomycin and Q-VD.OPh. All 
quantitation was carried out using ImageLab software from Bio-Rad, relative to untreated 
Jurkat cells (or untreated Kem-BL if the protein of interest was not expressed in Jurkat) and 
data were normalised to Calregulin. This analysis identified 7 proteins (highlighted in red) as 
being upregulated more than 2-fold in EBV-loss clones compared to EBV-positives following 
apoptosis induction although, due to variation in expression levels between individual cells 
only 2, Bim and Puma, were deemed significant (P<0.05) using a Student’s T-test. If EBV-loss  
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Table 5.2 Summary of apoptosis-related protein expression in Western 
blots. Data normalised to calregulin loading control and expressed relative 
to untreated Jurkat cells. Fold change is calculated as the mean of the 
expression value in the three loss clones divided by the mean expression in 
the EBV-positive clones at 48 hours after apoptosis induction. P-values 
were calculated using a two-tailed Student’s T-test 
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clone n1 is excluded from this analysis Mcl-1, Noxa, Bid, Bak, Bax, Survivin and CARD6 would 
also vary more than two-fold between EBV-positive and EBV-loss clones however, none of 
these changes is reaches significance due to the lack of replicates.  
Compared to the huge number of proteins known to be involved in apoptosis we only looked 
at a relatively small subset, although we were able to include many key regulators of the 
intrinsic apoptosis pathway as well as targets identified by our q-PCR arrays. Given the large 
number of transcriptional changes in Kem-BL clones we were surprised that so few of the 
proteins we investigated changed in their expression and to fairly modest degrees. 
Interestingly however, Bim and Puma, which were both significantly differentially expressed 
between EBV-positive and loss clones, are known to be potent inducers of apoptosis [444, 
450], and as previously mentioned, have both previously been reported to be targets of EBV. 
Additionally, Bim, Puma and Noxa have been shown to play an important and likely                 
co-operative role in MYC-driven lymphomagenesis in vivo [274]. Therefore we considered that 
co-operation between Bim and Puma may be responsible for the EBV-loss phenotype.  
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5.5 FACS analysis of protein expression changes in Kem-BL clones 
Western blotting provided a convenient and effective way to screen for differences in protein 
expression between EBV-positive and loss clones at late time points after ionomycin and        
Q-VD.OPh treatment. We had expected to see a number of dramatic differences which would 
help to illuminate the mechanism of apoptosis inhibition by EBV. Had this been the case we 
could have then dissected the kinetics and orchestration of apoptosis initiation in these clones 
in order to better understand the role of the virus in subverting this response. Therefore, 
although we found consistent and convincing changes in the expression of the Bim and Puma 
proteins, due to the small number of targets and the modest fold changes we saw, we decided 
to further investigate their role in the EBV-loss phenotype using a more sensitive technique.  
FACS staining offered a number of advantages over Western blotting in these experiments; we 
were able to quantify both the number of cells expressing our gene of interest and with what 
intensity, allowing us to quantitate differences even where changes were relatively small. 
Additionally, although we carried out our initial screen on cells that had been treated for 48 
hours, we considered that any specific changes related to the presence or absence of EBV, 
rather than as a downstream consequence of the widespread activation of apoptosis 
regulating pathways (as we had seen in our q-PCR screens), would be evident soon after drug 
treatment. Consequently, and in line with our preliminary experiments where we saw changes 
in gene expression within a few hours of drug treatment, we decided to look at Bim and Puma 
expression at 6 hours post induction compared to cells harvested at the beginning of the 
experiment (0 hours). We also looked at Noxa expression in these cells as Bim, Puma and Noxa 
have been shown to exhibit synergy in lymphomagenesis [274], and because Noxa has 
previously been reported to be important in the EBV-loss phenotype [419]. Yet our Western 
blots, using the same antibody against Noxa showed weak staining that did not corroborate 
this finding (Figure 5.26-A). 
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5.5.1 Bim 
 We found that >90% of cells in every sample analysed stained positive for Bim expression and 
stained cells were clearly distinguishable from a negative control sample. Additionally, we saw 
good evidence of upregulation of Bim after 6 hours of ionomycin and Q-VD.OPh treatment 
(Figure 5.27-A). Overall, although the number of Bim positive cells and intensity of staining was 
found to be highest in drug treated EBV-loss cells compared to other sample groups, the 
difference between EBV-positive and loss cells after treatment was not found to be significant 
(Figure 5.27-B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.27 FACS analysis of Bim protein expression in Kem-BL clones 
A Example staining of untreated EBV-loss clone n1 at time 0 versus isotype control (left) or 
treated clone n1 cells at 6 hours (right) 
B Average mean fluorescence intensity (MFI) of Bim positive cells in each experimental 
group  
Representative data from assays carried out in triplicate on three occasions using three 
different EBV-positive Kem-BL clones and three different EBV-loss Kem-BL clones. Statistical 
comparisons were made using a two-tailed Student’s T test 
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5.5.2 Noxa 
The Noxa antibody worked well in FACS staining with clear separation between stained 
samples and negative controls. Surprisingly, we found evidence of Noxa upregulation in EBV-
loss cells in response to apoptosis induction (Figure 5.28-A). Although this disagrees with our 
48 hour blot data it is consistent with the findings of the Allday group (though their 
experiments were carried out at 24 hours after apoptosis induction) [419]. This suggests that 
the low levels of Noxa seen in EBV-loss clones n2 and n3 in Western blots may be due to 
degradation of the protein as Noxa has been shown to undergo rapid turnover, being 
degraded by the proteasome without the need for ubiquitin labelling [597, 598]. This finding 
highlights the importance of shifting our focus to look for more subtle changes than could be 
distinguished by Western blot that occur early after apoptosis induction. 
As we found for Bim, the majority of the cells in our samples stained positively for Noxa and 
the highest numbers of Noxa positive cells were in the treated EBV-loss cells, although the 
differences between the groups were again not significant (not shown). The intensity of Noxa 
staining was also highest in drug treated EBV-loss cells, though again this did not reach 
statistical significance (Figure 5.2B-B). Although this data suggests that Noxa may also be an 
important target for EBV in Latency I BL cells and is in-keeping with the published findings of 
another group [419] it is possible that this antibody may be binding something other than 
Noxa. Therefore, in order to be confident that Noxa is a target of EBV we would need 
additional data to corroborate these FACS experiments.  
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Figure 5.28 Noxa protein expression in Kem-BL clones  
A Example FACS staining of untreated EBV-loss clone n2 at time 0 versus isotype control 
(left) or treated clone n1 cells at 6 hours (right) 
B Average mean fluorescence intensity (MFI) of Noxa positive cells in each experimental 
group  
Representative data from assays carried out in triplicate on three occasions using three 
different EBV-positive Kem-BL clones and three different EBV-loss Kem-BL clones. Statistical 
comparisons were made using a two-tailed Student’s T test 
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5.5.3 Puma 
Unlike Bim and Noxa, Puma staining in Kem-BL clones was weak compared to negative 
controls, although we did still see clear shifts in Puma expression in response to treatment 
with ionomycin and Q-VD.OPh  (Figure 5.29-A). The low intensity of the staining may be due to 
the antibody used, although we did also get similar results with an alternative antibody (data 
not shown). More likely then, since Puma is a potent pro-apoptotic and still gives a single peak 
in staining, rather than a positive and a negative peak, is that Puma expression is generally low 
in Kem-BL cells, although we do not have enough data to be certain that this is the reason for 
this finding.  
Like Bim and Noxa, the largest proportion of Puma positive cells were found in the drug 
treated EBV-loss group, but due to variation between clones and experiments, the difference 
was only significant when compared to untreated EBV-positive clones (Figure 5.29-B). 
Similarly, Puma staining was also most intense in this group, though not significantly different 
to untreated EBV-loss cells or drug-treated EBV-positive cells (Figure 5.29-C).    
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Figure 5.29 Puma protein expression in Kem-BL clones  
A Example staining of untreated EBV-loss clone n2 at time 0 versus isotype control (left) or 
treated clone n1 cells at 6 hours (right) 
B Proportion of cells stained Puma positive in each group  
C Average mean fluorescence intensity (MFI) of Puma positive cells in each experimental 
group  
Representative data from assays carried out in triplicate on three occasions using three 
different EBV-positive Kem-BL clones and three different EBV-loss Kem-BL clones. 
Statistical comparisons were made using a two-tailed Student’s T test 
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5.5.4 Summary of FACS data  
In order to better visualise our FACS staining results, we expressed the all of the data in colour 
coded tables, organised by experiment (Figure 5.30). For each gene both the fluorescence 
intensity and the proportion of cells that stained positive were calculated compared to the 
reference group (EBV-positive cells at 0 hours) and fold-changes were then ranked by 
magnitude, as per the key in Figure 5.30-A. 
For Noxa and Bim (Figures 5.30-B & 5.30-C, respectively) the overall number of stained cells 
changed very little but the mean fluorescence intensity increased in the drug treated EBV-loss 
cells compared to the other groups in every experiment. For Puma, both the percentage of 
cells stained and the intensity of staining were increased in drug-treated EBV-loss cells 
compared to other groups (Figure 5.30-D).  
These data, in conjunction with our q-PCR arrays and Western blot data, show that EBV-loss 
clones of Kem-BL consistently upregulate pro-apoptotic BH3-only proteins in response to 
apoptosis induction to a greater degree than their EBV-positive counterparts, even at early 
time points. That we see this effect in several BH3-only proteins at once suggests that it is     
co-operation between these proteins which gives rise to the EBV-loss phenotype. This 
hypothesis fits neatly with our reinfection and ectopic expression studies which suggest that 
EBV genes work co-operatively to supress apoptotic signalling in EBV-positive cells. This theory 
also explains how it is that a virus that is apparently expressing so few genes exerts a 
consistent phenotype in cells from genetically different individuals and is able to mitigate the 
barrage of pro-apoptotic signals imposed by the translocation of MYC. 
Currently we have no clear indication as to what mechanism(s) EBV might be employing to   
co-ordinately exert control over the expression of multiple BH3-only proteins. However, it is 
our hope that more sophisticated viral gene expression systems as well as additional studies to 
look at possible mechanisms of apoptosis regulation outside of transcription and gross protein 
expression levels will allow us to finally begin to unravel the subtle, yet important survival 
advantage EBV affords to BL cells.   
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Figure 5.30 Summary of Noxa, Bim and Puma expression in Kem-BL clones 
at 6 hours post apoptosis induction versus time 0   
A Key to grading and colour coding of data, B Noxa, C Bim, D Puma, 
All data from three independent experiments carried out in triplicate 
Expt = experiment number 
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Conclusions III 
This is the first study to our knowledge to have profiled a large number of cellular targets in 
isogenic EBV-positive and loss clones in response to apoptosis induction, both functionally and 
by measuring changes in gene expression. This has allowed us to elucidate that EBV functions 
to supress apoptosis induction via the Bcl-2 family of intrinsic apoptosis regulators in Latency I 
BL. This is consistent with the findings of others that subversion of the intrinsic apoptosis 
pathway is able to synergise with c-myc during lymphomagenesis [266-269, 274]. 
Our functional assays using BimS-variant ligands to induce cell death showed that EBV-loss 
clones from three tumour backgrounds are increased in their sensitivity to BH3-ligands 
compared to their EBV-counterparts. Interestingly, these data indicated that no individual pro-
survival Bcl-2 protein is activated or inhibited by EBV; instead EBV-positive cells are generally 
more resistant to induction of the BH3 sensitiser proteins. Although we did observe some 
variation between different clones, this correlates with our earlier findings that there is some 
variation in the degree of sensitivity to apoptosis inducing agents, including the BH3 mimetic 
ABT-737, between different clones. We therefore went on to look in detail at the expression of 
a range of apoptosis-related genes in response to apoptosis induction, in order to uncover the 
underlying mechanism at work.  
Our detailed analysis of apoptosis-related gene regulation in multiple clones of Kem-BL 
unexpectedly revealed that EBV suppresses the Bcl-2 signalling pathway by co-ordinately 
targeting the pro-apoptotic BH3-only proteins Bim, Puma and Noxa. Whilst we were initially 
surprised by this finding, the reason for such a strategy is clear since the BH3-only proteins 
exhibit considerable functional overlap and redundancy [599]. Consequently, inhibition of 
multiple BH3-only proteins allows EBV to subvert apoptotic signalling initiated by any or all of 
the three apoptosis ‘sensor’ BH3-only proteins; allowing it to protect against a wide range of 
stimuli. Additionally, this mechanism of protection allows EBV to inhibit apoptosis even when 
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multiple BH3-only proteins are activated. If only one of the BH3-only proteins were inhibited 
by the virus this inhibition could be overcome by other BH3 only proteins either alone or 
synergistically, as has been shown to occur in BH3-only protein knock-out Eμ-myc mice [266, 
274].   
It is important to note at this point that although we chose to screen our clones at the 
transcriptional and protein level these techniques have limitations and it is possible that we 
may have overlooked other important differences between EBV-positive and loss clones that 
will help to reveal the molecular mechanism of apoptosis protection by EBV in BL. For 
example, some genes may not change in their total expression, but may translocate or change 
in activation status between experimental groups. We are particularly interested to know 
whether there is any difference in surface immunoglobulin expression between EBV-positive 
and loss cells (either in the presence or absence of an apoptosis-inducer) as this could explain 
the difference in sensitivity to α-IgM in EBV-positive or loss clones of Mutu-BL, Kem-BL and 
Awia-BL.  
Our investigations into apoptosis-related changes in gene expression also showed that there 
are widespread changes in a large number of genes during apoptosis initiation, even in viable 
cells that are unable to activate caspases. This underlines the importance of including multiple 
clones, carrying out unbiased screening and validating changes at the protein level at both 
early and late time points. These observations may also explain reports in the literature which 
identify other apoptosis-related genes as targets for EBV in BL as these studies were carried 
out in a limited number of clones, only looked at a small number of targets or included non-
viable cells in their analysis [99, 313, 419, 600]. Reassuringly however, we note that all of these 
studies identified individual components of the intrinsic apoptosis signalling pathway as 
targets for EBV.  
Consistent with our findings, data from the Allday and Clybouw groups suggest a role for Bim 
or Noxa directly, whilst the Takada group postulates a role for Bcl-2 and the Sugden group 
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instead points to Caspase-3 as a target of EBV. We therefore posit that Noxa and Bim (as well 
as Puma) are bona fide targets of EBV in BL, whilst upregulation of Bcl-2 in some clones of 
Akata-BL and upregulation of Caspase-3 in Sav-BL clone 1.1 may be indirect consequences of 
apoptosis induction in these cells. For example, our data show that many NF-κB family 
transcripts are deregulated following apoptosis-inhibition in BL cells, several of which are able 
to upregulate Bcl-2 [601-604], and Caspase-3 is a downstream target of multiple apoptosis-
related proteins that can be activated by a plethora of mechanisms [605, 606]. The Sugden 
group did consider a direct role for Puma and Bim however, since their retroviruses did not 
appreciably express miR BART-5, no investigation of Puma expression was carried out. 
Western blots for Bim were carried out and quantitation does show slightly higher expression 
of Bim in Sav-BL after dnEBNA1 treatment, which is then reduced in miR BART-complemented 
cells, although these changes are not significant. Interestingly we note that the levels of BART 
miRs expressed from the retrovirus constructs used in their study are many times lower than 
those endogenously expressed in Sav-BL as we find that early passage cells from this cell line 
express hundreds to thousands of copies of BART miRs per picogram of RNA [94], whilst these 
vectors express only tens to hundreds of copies per 10 picograms of RNA [99]. As mentioned 
previously, we and others have also found difficulty in expressing miR BARTs to endogenous 
levels in BL cells, and the low expression of BART microRNAs may explain why the subtle 
difference in apoptosis phenotype reported by this group between miR BART-complemented 
and un-complemented cells is primarily detected in Caspase-3; a downstream target of Bim, 
Puma and Noxa. In summary, although we cannot exclude a direct role for the BART 
microRNAs in targeting Caspase-3 as we also find differences between Caspase-3 expression in 
EBV-positive and EBV-loss clones, (but not in healthy cells), we propose that this is a 
consequence of subtle deregulation of BH3-only protein signalling.  
Although we have shown that Bim, Puma and Noxa are all upregulated in EBV-loss clones in 
response to apoptosis induction, we are currently uncertain of the mechanism by which the 
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virus controls their expression. Regulation of the BH3-only proteins is known to occur by a 
diverse and complex range of processes including post-translational modification, 
sequestration, degradation, and targeting by microRNAs, as well as transcriptional activation 
or inhibition [434, 443, 444, 447, 449-451, 458, 460-462]. Therefore further investigations are 
required to determine the precise nature of BH3-protein regulation by EBV. Additionally, 
because we hypothesise that the Latency I EBV genes co-operate in order to carry out this 
function, we expect to find that more than one molecular mechanism is responsible for this 
effect.  
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6. Discussion and future work 
Whilst individual viral genes are able to imitate the functions of multiple cellular genes, it is 
also established that multiple viral genes can co-operate in order to subvert particular 
signalling pathways within the cells of their host. In the case of EBV; the EBNA3A, B and C 
genes that are expressed in Wp-BLs as well as LCLs co-operatively regulate a variety of cellular 
genes [607]. Whilst it is unsurprising that individual EBNA3s are functionally homologous since 
they arose from the duplication of a single ancestor EBNA3 gene [608], they must co-operate 
in a non-redundant manner to carry out some of their essential functions. The most notable 
examples of this are the epigenetic regulation of Bim and p16INK4a by EBNA3A and C [181, 306, 
609]. Interestingly, and like the genes that regulate them, Bim and p16INK4a also show 
functional overlap, since p16INK4a upregulates the BH3-only protein Puma, whilst 
downregulating anti-apoptotic Mcl-1 and Bcl-2 [610]. Wp-BLs also express high levels of the 
Bcl-2 homologue, BHRF1, which strongly inhibits intrinsic apoptosis via binding to BH3-only 
proteins [89, 304, 411]. Therefore, EBV inhibits Bcl-2 family signalling in Wp-BL via a tripartite 
mechanism involving the epigenetic silencing of Bim and p16INK4a as well as direct BH3-only 
protein inhibition by BHRF1.  
The growth transformation of B cells by EBV also requires co-operation between viral genes, 
and this co-operation exhibits an all-or-nothing phenotype. That is; if any one of the essential 
genes is lacking, the virus is completely inert in transformation assays [107]. Although the 
essential growth transforming genes of EBV are known to have a range of targets, they also  
co-ordinately deregulate the Bcl-2 family. LMP1 upregulates the Bcl-2 homologues, Bcl-2,   
Mcl-1, Bfl-1 and A1 [611-614], and as mentioned, the EBNA3s downregulate Bim and Puma (via 
p16INK4a), whilst EBNA2 downregulates Bik [615]. Additionally, the EBV-encoded Bcl-2 
homologues themselves, (BHRF1 and BALF1) are also essential to transformation in 
combination [88]. There is clearly a precedent for the combinatorial targeting of the Bcl-2 
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family by multiple EBV-encoded genes in EBV-infected B cells and we therefore propose that 
subversion of the Bcl-2 pathway by a combination of Latency I genes is also necessary for the 
development and maintenance of Latency I BLs.  
In this study we find that the Latency I genes of EBV are able to inhibit the intrinsic apoptosis 
pathway in BL by co-operation and do so by targeting three of the BH3-only proteins. These 
findings reconcile some of the conflicting data that has been published on this topic and also 
explain why retention of EBV is highly selected for in BL cells in vitro and in vivo. Whilst this 
study includes the most detailed and comprehensive analysis of EBV-loss to date, we are also 
aware that we have been unable as yet to elucidate the precise mechanisms by which each of 
the Latency I genes contribute to the inhibition of Bim, Puma and Noxa, respectively.  
Since re-expressing individual genes from lentiviruses has proven technically challenging, we 
are hoping to advance this work using novel recombinant EBV constructs that have been 
engineered to lack individual transcripts of interest without disturbing the expression of 
nearby, overlapping or opposite strand transcripts. Although recombinant EBV technology has 
been available for a number of years, a system by which totally scar-less modified genomes 
can be made has only recently been developed [563, 564]. By carrying out careful modification 
of an EBV-BAC containing an intact BamHI A region we aim to create a number of BACs that 
are mutated for each of the known Latency I genes (except EBNA1), as well as the LF1, 2 and 3 
transcripts. We predict that a virus lacking a single Latency I gene, but retaining the rest, will 
show an apoptosis phenotype intermediate between that of EBV-positive and loss cells, which 
will enable us to directly prove a contribution for each gene. We will then be able to carry out 
more detailed investigations into the expression and regulation of Bim, Puma and Noxa in our 
novel reinfectants in order to unravel the underlying mechanisms by which EBV subverts BH3-
only protein signalling in Latency I BL. 
As well as genetic co-operation, our studies have also highlighted another important concept 
in cancer research; that of clonal heterogeneity. It is impossible for us to determine whether 
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the two EBV-loss clones that could not be phenotypically rescued by Akata rEBV acquired 
additional mutations in vitro. Neither can we know to what degree the tumours from which 
they are derived exhibited clonal variation in vivo or earlier during in vitro passage. Equally, we 
cannot determine the degree of clonal heterogeneity in BLs from the currently published 
whole genome sequencing studies as SNPs that are present in a minority of cells in the global 
population would not be identified using these techniques [277-279]. However, we have found 
that BL biopsy samples can exhibit heterogeneity in viral gene expression at the single cell level 
([178] and Rosemary Tierney, unpublished data); and subsequently we infer that there may 
also be clonal variation in cellular gene expression in vivo.  
Intratumoral genomic heterogeneity can now be detected using single cell sequencing on 
biopsy material and variations in gene expression can be detected using single cell q-PCR [616, 
617]; therefore we are keen to carry out such studies on fresh BL biopsies. In addition to 
further investigation of the occurrence and phenotypic consequences of heterogeneity within 
BLs, genetic studies on new tumour biopsies will also enable us to determine the frequency of 
cellular mutations in the Bcl-2 family. In these experiments it would be especially interesting to 
compare EBV-positive and negative tumours as we might expect EBV-negative tumours to 
necessarily acquire mutations to inactivate Bcl-2 signalling, whereas we would expect EBV-
positive tumours, in which the virus inhibits this family, to carry wild type sequences.  
Although the recent global analyses of the genetic landscape in BL tell us little about 
intratumoral heterogeneity, they do underscore the necessity for BLs to overcome Bcl-2-
mediated regulation of apoptosis. Three independent studies found that the most common 
recurrent cellular gene mutations in BL are found in ID3, CCND3 (cyclin D3) and TCF3 (E2A); all 
of which converge on the PI3 Kinase signalling pathway in order to carry out their functions in 
promoting cell survival and proliferation [277-279]. PI3 Kinase (PI3K) acts as a signalling hub for 
cell fate decisions and is consequently able to cross-talk with the Bcl-2 family [618]. Primarily 
this has been shown through activation of the extrinsic/intrinsic apoptosis mediator, Bad, by 
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phosphorylation at serine 136 [619, 620]. However, there is also evidence that PI3K and its 
signalling partner Akt, can also regulate Bax, and Mcl-1 as well as Puma and Bim via the 
transcription factor FoxO3a independently of any effect on Bad [447, 621-623]. We found that 
phosphorylation of Bad at serine 136 was undetectable in our EBV-positive and loss clones, 
either in resting cells or those induced into apoptosis (data not shown), but we are yet to 
investigate a role for PI3K in the upregulation of Bim and Puma in these cell lines. Notably, the 
NGS studies found that mutations in ID3, TCF3 and CCND3 were more common in sBL versus 
eBL, further implicating EBV as a substitute for the survival advantage conferred by these 
cellular mutations. 
In addition to studies on human cells we would also like to carry out more detailed analyses on 
the pathogenesis of BL in mouse models. Currently, in vivo studies of EBV in mice use NSG 
mice with humanised immune systems, in which the lymphoid compartments have been 
reconstituted via the engraftment of human CD34+ stem cells [624]. However, the introduction 
of CRISPR-Cas9 gene editing techniques has made it possible to rapidly create new mouse 
strains which carry several different specific mutations in the mouse genome, in order to 
investigate the complex interplay between common mutations in cancer [625]. Therefore, it 
may soon be possible to create a mouse which carries modified receptors; rendering it 
permissive to infection with EBV, as well as specific mutations in Bcl-2 family member genes. 
Although it should be noted that our understanding of exactly which receptors would need to 
be adapted is still lacking as mice carrying a humanised version of the CD21 ‘EBV receptor’ 
remain refractory to infection ([626] and Martin Rowe, personal communication). However, if 
this could be overcome, and in combination with novel recombinant viruses, these 
technologies make it possible to consider elegant models with which to illuminate the 
extremely complex interplay between cellular and microbial genomics in virus-driven cancers 
as well as to better understand tumorigenesis more generally.  
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Thus, after 50 years of paradigm-shifting, investigations into the role of EBV in BL may still help 
us to better understand the subtleties and complexities of cancer. Ultimately this will inform 
clinicians and lead to improvements in the treatment of BL, which remains woefully 
unsuccessful in some patient groups and settings. One example that leads directly from this 
project is that of specific BH3 mimetics. Several BH3 mimetics are being developed and 
selected for specific binding profiles, enabling them to overcome particular apoptotic ‘road 
blocks’. This method of using BH3 mimetics that are specific to the tumour, for example using 
ABT-199 to resensitise cells that are over-expressing Bcl-2, leads to apoptosis in the tumour 
cells, but also alleviates side effects, such as the destruction of platelets, which are common in 
patients treated with less specific BH3 mimetics, such as ABT-737 [434, 535, 627]. If multiple 
Bcl-2 family blockades must be overcome to successfully treat BL, this may mean that 
sophisticated strategies and combinations of chemotherapeutics will be required to improve 
outcomes in the cohorts of patients for whom BL is currently rapidly fatal.  
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